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ABSTRACT
Kaposi’s sarcoma-associated herpesvirus (KSHV) is causally related to Kaposi’s
sarcoma (KS), the most common malignancy in individuals with untreated
HIV/AIDS. Several lines of evidence indicate that KS oncogenesis is associated
with loss of T cell-mediated control of KSHV-infected cells. However, the adaptive
CD8 and CD4 T-cell responses against KSHV have not been fully characterised.
Neither the antigenic repertoire nor the immunodominant targets of CD8 and CD4
KSHV-specific T cells are fully understood, and the phenotypes and functions of
these cells remain largely unexplored.
To investigate the targets of the CD8 and CD4 T-cell responses against KSHV, a
novel approach for a large-scale screen of KSHV antigens was proposed that used
lentiviral-transduced monocyte-derived dendritic cells (moDCs) expressing a panel
of KSHV open reading frames (ORFs). Transduced moDCs naturally process the
KSHV gene products and present the resulting antigenic peptides in the context of
MHC class I and II. Transduced moDCs were cultured with autologous T cells and
the CD8 and CD4 proliferative responses to each KSHV ORF (or pool of ORFs)
were assessed.
CD8 and CD4 KSHV-specific responses were investigated in 14 KSHV-
seropositive individuals. Unexpectedly, both the CD8 and CD4 T-cell responses
against KSHV were found to be skewed towards ORFs expressed in the early and
late phases of the viral lytic cycle. The most frequently recognised CD8 target was
a pool of late lytic KSHV ORFs, [ORF28/ORF36/ORF37].4
Identification of novel KSHV CD8 epitopes from within the late lytic ORF pool
was attempted. Peptide-MHC binding and denaturation assays identified peptides
that had the highest affinity for HLA-A*0201. Recognition of these potential
epitopes  was  tested  in  clinical  samples  by  IFNγ  ELISpot,  and  compared  with 
recognition of nine previously published HLA-A*0201-restricted KSHV epitopes.
Finally, the use of pentamers as tools to investigate the memory phenotypes and
functions of virus-specific T cells was explored.5
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CHAPTER 1: Introduction
1.1 Kaposi’s Sarcoma-associated Herpesvirus (KSHV) and
its Related Diseases
Kaposi’s sarcoma-associated herpesvirus (KSHV) [or human herpesvirus 8
(HHV8)] is an oncogenic herpesvirus that is the aetiological agent of Kaposi’s
sarcoma (KS), a mesenchymal tumour characterised by de novo vascular formation
and lymphocyte infiltration. KSHV is also involved in the pathogenesis of at least
two lymphoproliferative disorders, primary effusion lymphoma and multicentric
Castleman’s disease.
1.1.a The Discovery of KSHV – a Causative Agent of KS?
As early as the 1960s, the uneven geographical distribution of KS observed in
epidemiological studies gave rise to suspicion that KS was caused by an infectious
agent (Oettle, 1962). This suspicion was compounded by the dramatic rise in KS
incidence amongst immunosuppressed individuals (acquired or iatrogenic) in the
1980s (Beral, 1991). Moreover, the high prevalence and uneven distribution of KS
observed among those with acquired immune deficiency syndrome (AIDS) pointed
towards a sexually transmitted agent for KS. KS occurs predominantly amongst
homosexual men with human immunodeficiency virus (HIV), with a lower
incidence seen in those who acquired HIV through heterosexual contact and rare
incidence amongst those with parenterally acquired HIV, for example, intravenous
drug users and individuals with haemophilia (Beral et al., 1990).22
In 1994, Chang et al. identified novel herpesvirus DNA sequences from KS lesions
from individuals with AIDS (Chang et al., 1994). Molecular and serological
epidemiology studies confirmed that this new herpesvirus (the eighth to be
discovered, hence human herpesvirus 8 [HHV8]) was present in individuals with all
forms of KS, but was not ubiquitous in the general population (Huang et al., 1995;
Kedes et al., 1996; Gao et al., 1996). Furthermore, detection of high levels of
HHV8 DNA in the peripheral blood of individuals with AIDS was found to predict
subsequent development of KS (Whitby et al., 1995; Moore et al., 1996b). PCR in
situ hybridisation demonstrated that HHV8 was present in endothelial cells and
spindle (tumour) cells of KS lesions from all epidemiological forms of KS (Boshoff
et al., 1995), and so the virus rapidly became known as KS-associated herpesvirus
(KSHV). The observation that KSHV is latently expressed in more than 90% of
tumour cells in advanced KS lesions (Dupin et al., 1999) provided further evidence
that KSHV was indeed causally related to KS.
Significantly, a serological study by Gao et al. found no evidence of KSHV
infection in healthy US blood donors, whereas they observed intermediate to high
seroprevalence of KSHV amongst control populations from Italy (four percent) and
Uganda (51%) – two countries where KS is endemic (Gao et al., 1996). Lennette et
al. reported a similar pattern of KSHV seroprevalence, with dramatically higher
incidence in the general population of Africa compared to the US, although the
actual rates they observed were much higher than the previous study (80% in
Uganda and between four percent and 28% in the US depending on the ages of the
individuals being studied) (Lennette et al., 1996). These, and further studies into the
epidemiology of KSHV infection, revealed that KSHV is a necessary but not23
sufficient factor in KS pathogenesis, with immunosuppression representing another
important co-factor.
Apparent disparities in the actual levels of KSHV prevalence reported by different
groups likely arise from differences in the sensitivities of the assays used. Most
serological studies use immunofluorescence assays (IFA) to determine the presence
of KSHV-specific antibodies in peripheral blood serum samples. Early studies
performed IFA using smears of Epstein-Barr virus (EBV)-negative KSHV-positive
cell lines and analysed by microscopic examination (Lennette et al., 1996; Gao et
al., 1996), a methodology that is susceptible to variations in interpretation between
different laboratories. More latterly, enzyme-linked immunofluorescence assays
(ELISAs) have been developed and those that detect both lytic- and latent-specific
antibodies provide an arguably more accurate and less subjective method for
detection of KSHV antibodies. Other studies use IFA in conjunction with a PCR-
based test for the presence of KSHV DNA sequences in peripheral blood
mononuclear cells (PBMCs) (Stebbing et al., 2003a).
1.1.b Transmission of KSHV
The exact mode of transmission of KSHV is not known. In the West, the high
prevalence of KSHV amongst homosexual men and association with HIV infection
indicates a role for sexual transmission (Martin et al., 1998). KSHV has been
detected in semen (Howard et al., 1997) and risk of infection correlates with the
number of sexual partners (Blackbourn et al., 1999). However, the route of
transmission between sexual partners is not known. Strikingly, there is little24
evidence of heterosexual transmission (Campbell et al., 2009; McDonald et al.,
2009). An extensive study by Dukers et al. into the risk factors for contraction of
KSHV amongst homosexual men found that orogenital sex was significantly
associated with KSHV seroconversion, and that this practice was more important
than just having a high number of sexual partners (Dukers et al., 2000). KSHV
DNA is readily detectable in saliva and nasal secretions, and cell-free salivary fluid
has been demonstrated to infect cell lines in vitro (Koelle et al., 1997; Vieira et al.,
1997; Blackbourn et al., 1998). Together, this implicates the oropharynx as a
possible site of KSHV replication and indicates a role for saliva in KSHV
transmission. This is in keeping with the mode of transmission of Epstein-Barr virus
[(EBV), the most closely related human herpesvirus to KSHV (Morgan et al.,
1979)] but has not been definitively confirmed.
Within African, Middle Eastern and Mediterranean populations,
seroepidemiological studies point towards horizontal, non-sexual transmission of
KSHV, with seroconversion frequently occurring before puberty and
seroprevalence increasing linearly with age (Bourboulia et al., 1998; Olsen et al.,
1998; Mayama et al., 1998; Gessain et al., 1999; Plancoulaine et al., 2000;
Davidovici et al., 2001; Cattani et al., 2003). As with transmission between sexual
partners, oral routes of transmission (for example, kissing or ‘licking’ to ease
mosquito bites) have been suggested and would explain both mother-to-child and
sibling-to-sibling transmission. Alternatively, high mother-to-child transmission
rates (Bourboulia et al., 1998) could indicate a role for breast milk, although there is
as yet no evidence to support this.25
1.1.c Kaposi’s Sarcoma – Epidemiological Forms
Kaposi’s sarcoma (KS) is named after Moritz Kaposi, an Austro-Hungarian
dermatologist who was the first to describe the disease. In 1872 Kaposi published
the case histories of five patients suffering from what he described as “idiopathic
multiple pigmented sarcomas” of the skin. This form of the disease is now known
as ‘Classic KS’. It is a relatively indolent disease, often confined to the extremities.
It is generally a chronic condition persisting for several years before unrelated
fatality. Classic KS is predominant in elderly patients, more frequently men, of
Mediterranean, Eastern European or Middle Eastern origin (Hengge et al., 2002).
A second form of KS, known as ‘Endemic KS’, was prevalent in Africa pre-dating
the emergence of HIV (Cook-Mozaffari et al., 1998). It is a much more aggressive
form of the disease, often spreading to the lymph nodes and affecting both adults
and children (Olweny et al., 1976). Retrospective examination of medical records
from the 1960s indicated that endemic KS accounted for between 4.5% and 7.0 %
of tumours seen in Ugandan men (de Thé et al., 1999; Wabinga et al., 2000).
However, until the 1980s, KS (endemic or classic) remained a relatively rare
neoplasm, particularly in North America and Western Europe.
In 1981 an unusual epidemic of KS cases in young men from New York City and
California was one of the first signs of the outbreak of AIDS (CDC Report, 1981;
Jaffe, 2008). This new form of KS, dubbed ‘AIDS-KS’, became an AIDS-defining
disease and is now the most frequently arising malignancy in individuals with
untreated HIV/AIDS (Boshoff and Weiss, 2002). Since the advent of highly active
antiretroviral therapy (HAART), KS incidence has declined substantially in the26
West (Ledergerber et al., 1999; Jones et al., 2000). However, AIDS-KS remains one
of the most common cancers across Africa, with KS recently estimated to account
for 12.9% of all cancers in African males and 5.1% of all cancers in African
females (Parkin et al., 2008). AIDS-KS is an aggressive disease, often affecting the
mouth, gastrointestinal tract or genitalia (Boshoff and Weiss, 2002).
The 1980s also saw the rise of a fourth epidemiological variety of KS. ‘Iatrogenic
KS’ occurs in transplant recipients, and other patients receiving immunosuppressive
therapy. KS is up to 150 times more common in transplant recipients than the
general Western population. Interestingly, transplant recipients in the West with
origins (first or second generation) in countries where classic or endemic KS is
prevalent are at greater risk of developing iatrogenic KS. This suggests an increased
risk of developing KS amongst these populations even after geographical relocation
(Boshoff and Weiss, 2001), which is likely to be simply explained by a higher
prevalence of KSHV infection. There is, however, evidence that iatrogenic KS can
arise from both pre-transplant KSHV infection and through receipt of a KSHV-
infected graft (Regamey et al., 1998; Cattani et al., 2001).
1.1.d KS Tumour Biology
KS is a complex tumour with three distinct phases referred to as patch, plaque and
nodular stages. Lesions are usually multi-focal, and can arise in the skin, viscera or
mucosa (Hengge et al., 2002). The KS tumour cell is considered to be the spindle
cell, which is distinguished by its spindle-shaped morphology and dominates final-
stage nodular lesions (Gessain and Duprez, 2005). The exact origin of the spindle27
cell is unclear. Early immunohistochemistry studies showed that most KS spindle
cells express endothelial markers such as CD31 and CD34. However, expression of
markers of macrophages, smooth muscle cells, fibroblasts and dendritic cells have
also been demonstrated (Boshoff and Weiss, 2001; Gessain and Duprez, 2005),
leading to speculation that spindle cells either represent a heterogenous population
of cells or are derived from a multipotent mesenchymal precursor. More recently,
evidence has pointed towards a lymphatic endothelial origin. Spindle cells were
shown to express lymphatic markers including VEGFR3 and podoplanin (Dupin et
al., 1999; Weninger et al., 1999). Gene expression microarrays revealed closer
similarity between the expression profile of KS spindle cells and lymphatic
endothelial cells (LECs) than between KS spindle cells and blood endothelial cells
(BECs), although both LEC and BEC markers are present in the KS spindle cell
expression signature (Wang et al., 2004). Further studies demonstrated that in vitro
infection of BECs with KSHV leads to lymphatic reprogramming of these cells
(Carroll et al., 2004; Hong et al., 2004), and so it has been suggested that in vivo,
blood vessel endothelial cells are converted towards a lymphatic phenotype by
latent KSHV infection, giving rise to the spindle cell (Gessain and Duprez, 2005).
Despite their different clinical manifestations, KS lesions observed in the four
epidemiological forms of KS outlined above are histologically indistinguishable at
comparative stages (Gessain and Duprez, 2005). At the earliest stage, the patch
stage, KS lesions are macular and characterised by a proliferation of small, irregular
endothelial-lined spaces surrounding normal dermal blood vessels with an
accompanying infiltration of inflammatory lymphocytes. At the plaque stage, the
lesions become palpable, and the abnormal vasculature spreads through the entire28
dermis and sometimes into the subcutaneous fat. Clusters of spindle cells expand
around the vascular spaces, and varying numbers of erythrocytes fill the channels.
Nodular-stage KS lesions develop areas of pigmentation and are composed of
sheets and large fascicles of uniform spindle cells, some of which are undergoing
mitosis. Erythrocytes are trapped within an extensive network of slit-like vascular
channels. The channels themselves, however, are not well defined, lacking pericytes
in their walls and with fragmentation of their endothelial lining and basal lamina
(Boshoff and Weiss, 2001; Hengge et al., 2002; Gessain and Duprez, 2005;
Grayson and Pantanowitz, 2008). Figure 1.1 shows examples of KS lesions and
histological sections from KS lesions of different stages.
An unusual feature of KS tumour biology is the important role played by
inflammatory infiltrates, particularly at KS onset. Peripheral blood mononuclear
cell (PBMC) infiltration at the patch stage precedes the formation of spindle cells
and appears to be essential to tumour formation (Ensoli et al., 2001). KS onset is
associated with a generalised disturbance of the immune system, with activation of
CD8 cytotoxic T lymphocytes (CTLs) and increased production of T helper 1-type
(Th1) cytokines, in particular interferon-γ (IFNγ), by circulating PBMCs (Ensoli et 
al., 2001). Early lesions are infiltrated by T cells (mostly CTLs), monocyte-
macrophages and dendritic cells, and these cells also produce high levels of Th1
cytokines, including  IFNγ; tumour necrosis factor-α (TNFα); interleukin (IL)1β;
and IL6 (Sirianni et al., 1998; Fiorelli et al., 1998). These inflammatory cytokines
could help to trigger the production of angiogenic factors, initiating angiogenesis
and oedema and activating KSHV-infected endothelial cells (ECs) to form spindle29
a. b.
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e. f.
FIGURE 1.1: Kaposi’s sarcoma lesions and their histopathology. a. Cutaneous KS
lesion (nodular stage) from an individual with AIDS-KS. b. KS in the mouth of an
individual with AIDS-KS (both a and b from National Cancer Institute Visuals Online).
c – e. Haematoxylin and eosin stained sections of patch- (c), plaque- (d) and nodular- (e)
stage KS lesions (from Grayson and Pantanowitz, 2008). At the patch stage,
inflammatory cell infiltrates and newly formed slit-like vessels containing red blood
cells are evident. At the plaque stage, the new vasculature is more extensive and
erythrocytes can be seen in the channels. Spindle cells begin to form. By the nodular
stage sheets of monomorphic spindle cells are evident and surround slit-like channels
containing erythrocytes. f. Punctate LANA1 expression in the nucleus of spindle cells is
revealed by immunohistochemistry staining (also from Grayson and Pantanowitz,
2008).30
cells (Ensoli et al., 2001). Significantly, in early-stage lesions the proportion of
KSHV-infected ECs is low, and these cells show markers of latent infection
(Boshoff et al., 1995; Davis et al., 1997; Dupin et al., 1999). High levels of Th1
cytokines recruit KSHV-infected circulating macrophage cells to the site of the
tumour. These cells, in contrast to the KSHV-infected ECs, are lytically infected
and so produce mature KSHV viral particles (Blasig et al., 1997). They thus may be
essential both for increasing the number of infected ECs, as indicated by evidence
of polyclonal KSHV DNA within most KS lesions (Gill et al., 1998); and for
maintaining infection of spindle cells, as indicated by the loss of KSHV infection
by these cells upon culture (Lebbe et al., 1997; Grundhoff and Ganem, 2004). It is
also possible that these KSHV-infected circulating macrophage cells are
incorporated into KS lesions and differentiate into spindle cells, explaining the
expression of macrophage markers by spindle cells (Ensoli et al., 2001; Gessain and
Duprez, 2005).
The development of KS may thus be seen as a multi-factorial process in which
infection by KSHV is a requirement; immunosuppression is an important co-factor;
and, paradoxically, some level of systemic and localised immune activation in the
form of increased Th1 cytokine production (induced either by KSHV infection,
HIV infection or unknown causes) is also involved. The Th1 cytokine upregulation
initiates an inflammatory-angiogenic process that leads to sites of activated tissue
that are vulnerable to KS lesion formation (Ensoli et al., 2001). Recruitment of
KSHV-infected cells and other PBMCs to these sites establishes a tissue
microenvironment that has high levels of inflammatory cytokines and is
increasingly rich in KSHV-infected cells of both macrophage and endothelial31
origin. This positively reinforces cell recruitment, and promotes the formation and
survival of spindle cells and the production of further cytokines, angiogenic factors
and growth factors that contribute to the development of advanced KS lesions.
There has been much debate as to whether KS represents a true sarcoma or is more
akin to a reactive hyperplasia as lesions are symmetrical; appear at several sites
simultaneously; do not generally show signs of aneuploidy; and can regress
spontaneously (Boshoff and Weiss, 2001; Ensoli et al., 2001). However, although
generally diploid, some aneuploid spindle cells have been detected, and KS lesions
from individuals with AIDS-KS have been shown to have high levels of
microsatellite instability – a hallmark of tumour cells (Bedi et al., 1995; Ensoli et
al., 2001). Several groups have examined the clonality of KS lesions in order to
determine whether or not KS represents a disseminating monoclonal cancer in
which cellular transformation occurs before the clonal expansion and metastasis of
KS spindle cells. Early studies produced conflicting results. One study of the X-
chromosome inactivation pattern of the human androgen receptor gene in cells from
lesions from 12 women found that the majority of lesions were oligoclonal in
nature, indicating that KS is not a clonal malignancy (Gill et al., 1998). Conversely,
another study that used a very similar experimental procedure to examine clonality
of lesions from eight women found evidence that spindle cells from multiple KS
lesions from the same individual were predominately monoclonal (Rabkin et al.,
1997). An alternative methodological approach examined the terminal repeat
regions of KSHV episomes isolated from nodular KS lesions, and found that these
displayed all patterns of clonality (Judde et al., 2000). In an attempt to clarify the
clonality status of KS lesions, a recent extensive study examined KSHV clonality in32
59 tumour samples (mostly nodular stage) taken from male and female individuals
with all four epidemiological forms of KS, including 26 samples taken from
multiple sites from six individuals with disseminated KS (Duprez et al., 2007).
Eleven of the 59 samples were monoclonal, and 48 were oligoclonal. Samples from
disseminated lesions were either monoclonal or oligoclonal. The authors concluded
that whilst some KS lesions represent a true monoclonal expansion, the majority of
advanced lesions are oligoclonal proliferations. Moreover, disseminated lesions
represent distinct expansions of KSHV-infected spindle cells, indicating that most
KS lesions are reactive proliferations rather than true metastatic malignancies.
1.1.e Primary Effusion Lymphoma
Primary effusion lymphoma (PEL) is a non-Hodgkin’s B-cell lymphoma that
usually occurs in the context of HIV-infection. It is clinically characterised by its
unusual pathogenesis, commonly arising as lymphomatous effusions in body
cavities such as the pleural, pericardial and peritoneal spaces in the absence of a
solid tumour mass. This rare disorder (originally referred to as body cavity-based
lymphoma) was first postulated to be a unique disease based on these peculiar
clinical manifestations as well as its unusual morphologic and immunophenotypic
characteristics (Knowles et al., 1989; Green et al., 1995). In 1995, Cesarman et al.
demonstrated the presence of high levels of KSHV DNA in all cases of this atypical
lymphoma, but not in any other HIV- or non-HIV-related non-Hodgkin’s
lymphoma (Cesarman et al., 1995). By definition, therefore, PEL patients must
show evidence of KSHV infection although the mechanisms by which KSHV
promotes oncogenesis in PEL are not fully understood. The vast majority of PEL33
cells are also coinfected with EBV, making it difficult to determine the precise role
of KSHV in the pathogenesis of this disease.
Recently, a number of other distinct KSHV-associated lymphomas have been
defined (Carbone et al., 2009). In HIV-infected individuals these include solid
lymphomas that either precede the development of, or follow the resolution of,
PEL; and solid, extracavitary lymphomas that occur without serous effusions and
are seen either within the lymph nodes or in extranodal tissue. In HIV-uninfected
individuals, a unique KSHV-associated lymphoproliferative disorder that
preferentially involves the germinal centres of lymph nodes has also been
described.
1.1.f Multicentric Castleman’s Disease
Multicentric Castleman’s disease (MCD) is a rare, atypical lymphoproliferative
disorder defined clinically by generalised polylymphadenopathy and evidence of
multi-organ involvement (Oksenhendler et al., 1996). Its close association with KS,
particularly in individuals with AIDS, prompted Soulier et al. to search for the
presence of KSHV sequences in MCD samples (Soulier et al., 1995). They, and
others (Parravinci et al., 1997), found KSHV DNA in MCD lesions from all HIV-
related and about 40% of HIV-unrelated cases of MCD. It is therefore likely that
there is more than one cause for this unusual disease. Nonetheless, a correlation
between increased KSHV viral load in PBMCs and clinical exacerbations of MCD
supports a role for KSHV in MCD pathogenesis (Grandadam et al., 1997).34
There are two main pathological types of MCD – the hyaline-vascular and plasma-
cell types, defined by the histological features of the affected lymph nodes. The
former is more commonly seen in the localised, unicentric variant of Castleman’s
disease, whereas the latter is frequently multicentric. KSHV-positive MCD has
been recognised as a distinct subset of MCD (predominately of the plasma-cell
type) and designated plasmablastic MCD, since it is characterised by the presence
of large plasmablastic cells all of which harbour KSHV (Dupin et al., 2000).
1.2 KSHV Molecular Pathology
KSHV belongs to the lymphotrophic herpesvirus subfamily, gammaherpesviridae.
It is of the Rhadinovirus genus and, as such, is the first human gamma-2
herpesvirus to be identified. KSHV is most closely related to two old-world primate
gamma-2 herpesvirus, the chimpanzee rhadinoherpesvirus 1a (PanRHV1a) and the
gorilla rhadinoherpesvirus 1 (GorRHV1) (Lacoste et al., 2000). The most closely
related human virus to KSHV is the human gamma-1 herpesvirus, Epstein-Barr
virus (EBV) [or human herpesvirus 4 (HHV4)] (Moore et al., 1996a).
Like EBV, KSHV establishes latent infection in B cells (Decker et al., 1996).
However, it has an unusually wide cellular tropism, and has been detected in vivo in
endothelial cells (Boshoff et al., 1995), epithelial cells (Diamond et al., 1998),
macrophages and monocytes (Blasig et al., 1997). In vitro, KSHV has been shown
to infect a wide variety of human and animal cells, including human dendritic cells
(Rappocciolo et al., 2006). This broad tropism seems to be attributable, at least in35
part, to interaction between viral glycoproteins and the ubiquitous cell-surface
molecule, heparin sulphate (Akula et al., 2001; Wang et al., 2001a).
1.2.a The KSHV Genome
KSHV is a large double-stranded DNA virus. The KSHV genome is approximately
165kb long, with a continuous 145kb-long unique coding region flanked by
multiple GC-rich terminal repeat units approximately 800bp in length (Russo et al.,
1996). Over 90 open reading frames (ORFs) have been identified within the KSHV
genome, of which at least 81 ORFs are over 100 amino acids long. The genome
consists of seven highly conserved gene blocks separated by short regions of unique
or subfamily-specific genes. The conserved genes have homologues among other
herpesviruses and include genes that code for structural proteins and genes involved
in viral DNA replication and regulation of gene expression. A large number of the
viral genes (both conserved and unique) encode homologues of cellular genes that
have been captured from the host during the course of the virus’s evolution (Neipel
et al., 1997).
KSHV has developed several complex strategies for subverting the host’s adaptive
and innate immune system. Approximately one quarter of KSHV genes – both
cellular homologues and unique viral genes – are involved in immune evasion. The
roles of many viral genes in driving oncogenesis have also now been elucidated
and, in many cases, these oncogenic activities result from the same molecular
pathways employed by the virus in its immune-evasion activities (Moore and
Chang, 2003). The wealth of cellular processes modulated by KSHV viral genes36
includes the cell cycle; apoptosis; cytokine production; antigen presentation; cell
signalling; and signal transduction. Thus KSHV infection can result in aberrant cell
growth, proliferation, inflammation and angiogenesis, all of which contribute
towards tumour development.
1.2.b Viral Gene Expression
The KSHV ORFs are differentially expressed during the course of the virus’s life
cycle. During latent infection, the virus exists in the nucleus as a closed circular
episome and very few viral genes are expressed. During the lytic phase of the
virus’s life cycle (which is the replication phase) the virus linearises and most viral
genes are expressed in a temporally regulated fashion (Sarid et al., 1998; Jenner et
al., 2001). The constitutively expressed latent genes and lytically induced genes are
referred to as class I and class III transcription units respectively. Genes displaying
a third pattern of gene expression, designated class II transcription, are expressed at
low levels during latency but are also induced during lytic replication (Sarid et al.,
1998). Lytic genes are induced sequentially and can be further classified as
immediate-early, early or late genes based on their temporal appearance during
replication. The chronological expression of lytic genes correlates with their
function. Genes involved in transcription regulation are induced first, followed by
those involved in DNA replication and repair, and genes that are involved in virus
assembly or code for structural proteins are induced last (Jenner et al., 2001). Viral
homologues of cellular genes involved in immune evasion are predominately
immediate-early or early genes, in keeping with their function to prevent the virus
from attracting immune surveillance as it replicates in preparation for shedding of37
virions (Jenner and Boshoff, 2002). Figure 1.2 shows a schematic illustration of the
KSHV viral genome with the expression pattern of all known viral ORFs.
1.2.c Latent KSHV Genes
Latent infection itself is, arguably, the primary strategy in immune evasion, as the
highly restricted pattern of viral gene expression that defines latency minimises the
number of viral epitopes that are presented by infected cells to circulating cells of
the immune system. Latency is also the state assumed to lead to proliferation of
KSHV-infected cells, since lytic replication results in cell death and is therefore
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FIGURE 1.2: Schematic illustration of the KSHV genome showing viral gene
expression. Adapted from Russo et al., 1996. Arrow direction indicates direction of
transcription. Yellow, orange and red arrows indicate class III transcription units
expressed during lytic replication: yellow arrows indicate immediate-early lytic ORFs;
orange arrows indicate early lytic ORFs; red arrows indicate late lytic ORFs. White
arrows indicate class II ORFs that are expressed at low levels in latency and are also
induced during lytic replication. Purple arrow indicates the cluster of latently expressed
(class I) ORFs. Blue arrow indicates the position of the KSHV microRNAs. NB: arrows
are not drawn to scale with respect to the size of each ORF. ORFs are labelled with a
‘K’ suffix for the unique KSHV genes; where a suffix is absent this indicates an ORF
with a cellular homologue or a homologue in another virus.38
anti-tumourigenic (as the host cell is lysed to release active virions). However, in
early KS lesions, there is evidence that replicating latently infected KS spindle cells
do not efficiently transfer viral DNA to all progeny and a low level of lytic infection
is necessary to maintain infected cell numbers within the tumour (Grundhoff and
Ganem, 2004). The vast majority of tumour cells in KS and PEL are latently
infected, with only a few cells undergoing lytic replication. Tumour cells from
MCD, by contrast, express both latent and lytic proteins (Parravicini et al., 2000;
Katano et al., 2000).
Although latent infection is a characteristic of all herpesviruses, the latency genes
themselves are not conserved between members of the family, but rather are highly
evolved to adapt to their specific host-cell environment. The three class I KSHV
latent genes are ORF73, ORF72 and ORF71, respectively coding for the latent
nuclear antigen (LANA1); viral cyclin (v-cyclin); and vFLIP, which is the viral
[Fas-associated death domain (FADD)]-interleukin-1β-converting enzyme (FLICE)
inhibitory protein. These antigens are described in further detail below.
LANA1 is the major nuclear antigen of KSHV, the functional equivalent of the
EBV nuclear antigen 1 (EBNA1) although there is no sequence similarity between
the two genes. Like EBNA1, LANA1 is responsible for maintenance of the
episome. LANA1 binds histone H1, which tethers the viral episome to host
chromosomes during host-cell replication and so ensures persistence of the viral
genome in successive daughter cells (Ballestas et al., 1999; Cotter and Robertson,
1999). In addition to this, LANA1, like EBNA1, is a major regulator of gene
expression, interacting with a variety of both viral and cellular proteins to both39
transactivate and repress transcription (Friborg, Jr. et al., 1999; Lim et al., 2000;
Radkov et al., 2000). LANA1 maintains latency by transactivating expression from
the viral latency genes’ promoter (Renne et al., 2001) and by repressing the
promoter of ORF50 (Rta, the viral activator of the latency to lytic switch) thus
inhibiting the induction of lytic replication (Lan et al., 2004).
Recently, it was reported that LANA1, again like EBNA1, also acts to inhibit
antigen presentation, enabling the virus to evade the host’s immune system during
latency despite the expression of a long protein that could potentially yield a
number of viral epitopes (Zaldumbide et al., 2007). EBNA1 codes for a long
glycine- and alanine-rich repeat that inhibits its own proteasomal degradation
thereby preventing the generation of antigenic peptides through the action of an
acidic-repeat region of amino acids (Levitskaya et al., 1995). LANA1 contains a
central acidic-rich repeat region of 580 amino acids consisting almost exclusively of
aspartic acid, glutamine and glutamic acid residues that was reported to interfere in
cis with antigen processing (Zaldumbide et al., 2007). However, data presented by
Sabbah and Hislop at the 11
th International Workshop on KSHV & Related Agents,
Birmingham, UK (2008) demonstrated no inhibition of antigen presentation by this
repeat region, and thus the ability of LANA1 to evade immune recognition in this
way remains open to debate.
Viral cyclin (v-cyclin) is a homologue of cellular cyclin D (Chang et al., 1996).
Cyclin D binds the cyclin-dependent kinases CDK4 and CDK6 to create an active
complex that phosphorylates pRb, releasing the transcription factor E2F. E2F
activates the transcription of S-phase genes including cyclin E and so drives the G1-40
to S-phase transition. V-cyclin also forms an active complex with CDK6 and, to a
lesser extent, CDK4 that phosphorylates pRB to stimulate S-phase entry (Li et al.,
1997; Godden-Kent et al., 1997). Significantly, the v-cyclin-CDK complex is not
only less sensitive to the CDK inhibitors p16
INK4A, p21
CIP1 and p27
KIP1 than the
cyclin D-CDK complex (Swanton et al., 1997), it also phosphorylates p27
KIP1,
marking it for proteosomal degradation and thereby escaping its control (Ellis et al.,
1999; Mann et al., 1999). Thus v-cyclin expression blocks CDK inhibitor-imposed
G1 arrest, driving entry into S phase and deregulating the cell cycle. In addition to
this, the v-cyclin-CDK6 complex phosphorylates a much wider array of substrates
than the cyclin D-CDK complex, including cellular CDK2 targets, and thus causes
further deregulation throughout the cell-cycle (Li et al., 1997; Godden-Kent et al.,
1997; Jenner and Boshoff, 2002). A paradoxical feature of v-cyclin is that its
activity on pRB triggers S-phase entry, but for unknown reasons is often associated
with defective mitosis and so results in polyploidy. This in turn triggers p53
stabilisation, which induces growth arrest and apoptosis (Verschuren et al., 2002).
Thus v-cyclin can promote oncogenesis only in the absence of p53, when v-cyclin-
expressing cells can survive and expand as an aneuploid population.
Viral FLIP (vFLIP) is a homologue of cellular FLIP. vFLIP, like cellular FLIP,
sequesters procaspase 8 and prevents its cleavage to the active form, thereby
inhibiting the activity of the Fas death receptor and protecting cells from Fas-
mediated apoptosis (Belanger et al., 2001). Furthermore, murine B cells transduced
to express vFLIP are resistant to death receptor-induced apoptosis triggered by
CTLs (Djerbi et al., 1999). vFLIP also inhibits apoptosis by activating the NFκB 
pathway, primarily through binding and activating the IκB kinase complex (IKK) 41
(Chaudhary et al., 1999; Liu et al., 2002; Field et al., 2003). Constitutive activation
of NFкB by vFLIP has been shown to be essential for PEL cell survival (Guasparri
et al., 2004) and also for cellular transformation by vFLIP (Sun et al., 2003),
making this pathway an attractive therapeutic target for treatment of KSHV-
associated lymphomas (Direkze and Laman, 2004; Godfrey et al., 2005).
1.2.d Lytic KSHV genes
As mentioned above, the temporal pattern of lytic gene expression correlates with
gene function. The first viral gene to be expressed on the initiation of lytic
replication is the transactivator ORF50, which encodes Rta and is both necessary
and sufficient for lytic cycle induction (Lukac et al., 1998; Gradoville et al., 2000).
This is closely followed by other genes involved in the regulation of gene
expression, notably, K8 (which encodes K-bZIP, another transactivator and a
homologue of EBV Zta,) and ORF57, a post-transcriptional regulator of gene
expression. Next to be expressed are genes involved in viral DNA replication and
repair, such as the viral DNA polymerase (ORF9) and its processivity factor
(ORF59), and the single strand DNA binding protein (ORF6). The genes that are
induced last are those that encode structural proteins or those involved in virus
assembly, such as the glycoproteins gB (ORF8), gH (ORF22) and gp35/37 (K8.1);
the major and minor capsid proteins (ORF25 and ORF26, respectively); and the
capsid-interacting protein ORF65 (Nealon et al., 2001). Viral homologues of
cellular genes involved in immune evasion are generally immediate-early or early
genes, aiding the virus to avoid immune system recognition as the full complement
of its genes are expressed during the course of the lytic cycle and ensuring that viral42
replication is successful. Table 1.1 briefly summarises some of the most well
characterised KSHV genes.
1.2.e KSHV microRNAs
KSHV encodes a cluster of microRNAs (miRNAs) within the latency-associated
region of its genome (Samols et al., 2005; Cai et al., 2005). miRNAs are short (19
to 24 nucleotides long), non-coding RNAs that post-transcriptionally regulate gene
expression by binding messenger RNAs (mRNAs), inhibiting their translation and
promoting their degradation (Nilsen, 2007). They have been implicated in a host of
cellular and biological functions, including development, oncogenesis and immune
system function. A total of 17 KSHV miRNAs have been identified, derived from
12 pre-miRNAs. They are detectable at high levels in latently infected cells (Cai et
al., 2005) and are postulated to modulate host gene expression in order to create a
favourable environment for latent infection.
The cellular targets of the KSHV miRNAs are not yet fully understood. One group
used microarray expression profiling to identify changes in gene expression in cells
ectopically expressing ten of the known KSHV miRNAs (Samols et al., 2007).
They identified 81 genes whose expression was significantly regulated by the
KSHV miRNAs. Out of these 81 genes, eight showed a downregulation of more
than four-fold, and of these eight, five were genes with roles important to immune
evasion or tumourigenesis, such as proliferation, angiogenesis, apoptosis and
immune modulation. Interestingly, one of these genes, Thrombospondin 1 (THBS1)43
KSHV
ORF
Gene
Product Function(s) Reference(s)
Latent
ORF71* vFLIP Anti-apoptotic (Belanger et al., 2001)
ORF72* v-cyclin Homologue of cellular cyclin D (Li et al., 1997)
ORF73* LANA1 Maintenance of the episome, gene expression
Immune evasion – inhibition of antigen presentation?
(Ballestas et al., 1999; Renne et
al., 2001)
Expressed at low-levels in latency and induced during lytic cycle
K11.1* vIRF2 Immune evasion – disruption of host anti-viral interferon response (Burysek et al., 1999)
K12* Kaposin Oncogenic, promotes cell proliferation (Muralidhar et al., 2000)
K15-P* LAMP Immune evasion – down regulates B-cell receptor signal transduction
Activates NFкB, ERK2 and JNK1 pathways
(Choi et al., 2000)
Immediate-Early Lytic
ORF50* Rta Gene expression – transactivator of lytic replication; both necessary and sufficient for
lytic cycle induction
(Lukac et al., 1998; Gradoville
et al., 2000)
K8* K-bZIP Gene expression – transactivation (homologue of EBV Zta)
ORF57** MTA Gene expression – post-transcriptional regulation (homologue of EBV SM protein) (Gupta et al., 2000)
ORF9 DNA replication – viral DNA polymerase (Lin et al., 1998)
ORF6 SSB DNA replication – single strand DNA binding protein (Wu et al., 2001)
ORF16 vBCL2 Anti-apoptotic – inhibits BAX-mediated and virus-induced apoptosis (Sarid et al., 1997)
K7 vIAP Anti-apoptotic – protects against apoptosis induced by various stimuli (Wang et al., 2002a)
K2* vIL6 Binds gp130 directly to activate the JAK/STAT signalling pathway
Anti-apoptotic – inhibits IFN-mediated apoptosis
Immune evasion – inhibition of chemokine-driven recruitment of neutrophils (Fielding et al., 2005)
K6*
K4*
vCCL1
vCCL2
Immune evasion – skewing of CD4 T-cell response to Th2-type (less effective against
intracellular pathogens)
(Kledal et al., 1997; Dairaghi et
al., 1999; Weber et al., 2001)
K5* MIR2 Immune evasion – downregulates expression of MHC-I, CD86, ICAM1, PECAM1 and
CD1d
(Coscoy and Ganem, 2000)
K14* vCD200 or
vOX2
Immune evasion – inhibits myeloid cell activation, reduces production of Th1-attracting
cytokines, inhibits neutrophil function
(Foster-Cuevas et al., 2004;
Rezaee et al., 2005)
TABLE 1.1: KSHV ORFs. * indicates genes that were contained in the KSHV lentiviral library prior to October 2006; **indicates known or putative
immunogenic KSHV genes cloned into lentiviral expression vectors and added to the lentiviral library in the course of this research (see section 3.1.a).
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KSHV
ORF
Gene
Product
Function(s) Reference(s)
ORF45* Immune evasion – disruption of host anti-viral interferon response by interfering with
IRF-7 activity
(Zhu et al., 2002)
ORF74* vGPCR Binds IL8; constitutively active GPCR
Immune evasion – downregulates Toll-like receptor 4
(Couty and Gershengorn, 2004)
(Lagos et al., 2008)
ORF58* Unknown function, homologue of EBV envelope protein BMRF2 (Russo et al., 1996)
Early Lytic
ORF59** PF8 DNA replication –processivity factor, needed for efficient extension by the viral DNA
polymerase
(Lin et al., 1998)
ORF61** DNA replication – large ribonucleotide reductase
K4.1* vCCL3 Immune evasion – skewing of CD4 T-cell response to Th2-type (Stine et al., 2000)
K3* MIR1 Immune evasion – downregulates expression of MHC-I and CD1d (Coscoy and Ganem, 2000)
K9* vIRF1 Immune evasion – disruption of host anti-viral interferon response; downregulates
MHC-I; downregulates Toll-like receptor 4
(Gao et al., 1997; Lagos et al.,
2007; Lagos et al., 2008)
ORF4 CBP or KCP Immune evasion – inhibition of complement (Spiller et al., 2003)
ORF49* Activates the JNK and p38 MAP kinase pathways (Gonzalez et al., 2006)
ORF8** gB Structural – glycoprotein B
ORF65** Structural – capsid-interacting protein (Nealon et al., 2001)
Late Lytic
K1* Immune evasion – downregulates B-cell receptor surface expression (Lee et al., 2000)
ORF28* Structural - envelope glycoprotein (Zhu et al., 2005)
ORF33* Structural? – tegument protein, homologue of EBV BGLF2 (Russo et al., 1996)
ORF36* Serine protein kinase - activates the JNK pathway (Hamza et al., 2004)
ORF37* SOX Immune evasion – host mRNA shut off (Glaunsinger and Ganem, 2004)
K8.1* gp35/37 Structural – glycoprotein 35/37
ORF22 gH Structural – glycoprotein H
ORF25 Structural – major capsid protein (Nealon et al., 2001)
ORF26 Structural – minor capsid protein (Nealon et al., 2001)
TABLE 1.1 continued: KSHV ORFs. * indicates genes that were contained in the KSHV lentiviral library prior to October 2006; **indicates known or
putative immunogenic KSHV genes cloned into lentiviral expression vectors and added to the lentiviral library in the course of this research (see section 3.1.a).
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is a potent inhibitor of angiogenesis and was previously known to be downregulated
in KS lesions although no KSHV protein had been identified that mediated this
suppression (Taraboletti et al., 1999). Another study used multiple screens to
identify changes in mRNA transcript levels under different conditions of miRNA
expression or inhibition in a variety of different cell types (Ziegelbauer et al., 2009).
They identified a BCL2-associated factor, BCLAF1, as a target for the KSHV
miRNAs, in particular mir-K5. BCLAF1 inhibition sensitised latently infected cells
to stimuli inducing lytic replication, and the authors suggested that this activity thus
plays an important role in the KSHV life cycle, since latent infection alone does not
permit viral replication or the dispersal of virions to new cells.
1.3 The T-cell Immune Response Against KSHV
In immunocompetent hosts, KSHV can establish persistent, asymptomatic infection.
KSHV infection has been reported in three to 20 percent of US blood donors
(Lennette et al., 1996; Pellett et al., 2003) and 40 to 80 percent of the general
population of East African countries (Lennette et al., 1996; Gao et al., 1996; Hladik
et al., 2003). However, upon immunosuppression (acquired or iatrogenic) both the
seroprevalence of KSHV, and the incidence of KS in KSHV carriers, significantly
increase. KS is more than 100 times more common in immunosuppressed
individuals such as HIV-infected individuals and transplant recipients compared to
immunocompetent individuals (Boshoff and Weiss, 2002). This indicates that loss
of immune control allows KSHV-infected cells to proliferate unchecked and
KSHV-related tumours to develop. Furthermore, a dramatic clinical improvement is
seen in iatrogenic KS patients when general immunity is restored following the46
withdrawal of immunosuppressive drugs (Nagy et al., 2000), and spontaneous
tumour regression has been reported in individuals with AIDS-KS after starting
anti-HIV therapy (Cattelan et al., 1999). Recent evidence indicates that a positive
clinical outcome is associated with the restoration of KSHV-specific immunity
(Bourboulia et al., 2004; Bihl et al., 2007a). Thus, successful immunity targeted
against KSHV plays a key role in containing KSHV infection, enabling the virus to
establish controlled life-long infection and to co-exist with its host.
Establishing such an equilibrium with the host’s immune system is a common
biological feature of human herpesviruses, with T cells mediating chronic infection
by recognising and eliminating infected cells (Rickinson and Moss, 1997;
Komanduri et al., 1998). Identifying the targets of the host’s cellular immune
responses is important to our understanding of how herpesvirus infections are
controlled in immunocompetent individuals and is a crucial step towards
developing treatments such as immunotherapies, or even vaccines, against
herpesvirus-related diseases. The adaptive T-cell immune responses against many
human herpesviruses are well characterised. For example, Epstein Barr virus
[(EBV),  a  γ-herpesvirus closely related to KSHV] infects 80-90% of the adult
population and several EBV genes that elicit both CD4 and CD8 T-cell responses
have been described (Landais et al., 2005a). The CD8 responses to EBV are heavily
skewed towards EBV genes expressed early in the lytic cycle (Pudney et al., 2005).
However, the KSHV-specific T-cell immune responses remain poorly described.
T-cell responses to KSHV have been studied mostly in KS patients and
asymptomatic carriers of KSHV. Responses have been detected against several lytic47
and latent proteins (Osman et al., 1999; Brander et al., 2001; Wang et al., 2001b;
Wilkinson et al., 2002; Micheletti et al., 2002; Stebbing et al., 2003b; Woodberry et
al., 2005; Lambert et al., 2006; Ribechini et al., 2006; Guihot et al., 2006; Bihl et
al., 2007b). Some of these responses have been demonstrated to be functionally
cytotoxic in vitro (by the specific lysis of target cells expressing KSHV ORFs by
cytotoxic T lymphocytes (CTLs) from KSHV-seropositive individuals) (Osman et
al., 1999; Wang et al., 2000); and there is some evidence they exert evolutionary
pressure on the virus in vivo (Stebbing et al., 2003b). A few HLA-restricted KSHV-
specific T-cell epitopes have been identified [(Brander et al., 2001; Wilkinson et al.,
2002; Micheletti et al., 2002; Wang et al., 2002b; Stebbing et al., 2003b; Lambert et
al., 2006; Ribechini et al., 2006; Guihot et al., 2006; Bihl et al., 2007b); summarised
in Table 1.2]. However, these are almost exclusively CD8 epitopes and they elicit
weak T-cell responses compared to epitopes from other viruses such as HIV-1 and
EBV (Brander et al., 2001; Bihl et al., 2007b). Neither the breadth of the antigenic
repertoire of the KSHV-specific T-cell immune response, nor its immunodominant
targets are fully understood.
1.3.a The CD8 T-cell Response Against KSHV
i. CD8 T-cell Responses to Primary Infection
Unlike primary EBV infection, which in adolescents and adults often results in
acute infectious mononucleosis, primary KSHV infection is not apparently
associated with any specific severe illness. Studies of cohorts at risk of KSHV
infection have identified adults and children undergoing KSHV seroconversion and48
Expression KSHV
ORF
Epitope
Position
Epitope Sequence HLA Restriction Other Responsive
HLA Types
Reference
T-cell subtype not determined
Latent(?)
and Lytic
K10.5 Not determined Not determined N/A N/A Bihl et al., 2007b
CD4
*K12 aa46-60 RGPVAFRTRVATGAH Not determined N/A Guihot et al., 2006 Latent and
induced in
Lytic Cycle *K15 aa171-185 GNIKLVSSVSFICAG Not determined N/A Guihot et al., 2006
Late Lytic *K8.1 Not determined Not determined N/A N/A Barozzi et al., 2008
CD8
Latent *ORF 73
aa71-79
aa238-246
aa1116-1124
FTSGLPAFV
WATESPIYV
QMARLAWEA
A2
A2
A2
A26/A29
A26/A29; A39/A69
A26/A29; A2/A69
Guihot et al., 2006
Guihot et al., 2006
Guihot et al., 2006
*K12
aa17-25
aa16-25
aa31-45
LLNGWRWRL
VLLNGWRWRL
LVCLLAISVVPPSGQ
A*0201
A2
B7
None identified
None identified
B7/B53; B7/B14;
B35/B49; B7/B51
Brander et al., 2001
Micheletti et al., 2002
Guihot et al., 2006 Latent and
induced in
Lytic Cycle *K15 aa123-131
aa155-163
aa166-175
ILFTSTFAV
FTLSLPFLY
ATVKTGNIKL
A2
B44
B7
A2/A24
B44/B49
None identified
Guihot et al., 2006
Guihot et al., 2006
Guihot et al., 2008
*K5 aa154-163 ALYAANNTRV A2 None identified Ribechini et al., 2006
ORF 6 aa1050-1058 VLGDEVLSL A*0201 None identified Lambert et al., 2006 Immediate-
Early Lytic *ORF 57 aa212-220 ISARGQELF B57 B58? Bihl et al., 2007b
TABLE 1.2: Known immunogenic KSHV ORFs and CD8 and CD4 epitopes. * indicates ORFs included in the KSHV lentiviral library.
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Expression KSHV
ORF
Epitope
Position
Epitope Sequence HLA Restriction Other Responsive
HLA Types
Reference
CD8
*K3
aa72-81
aa96-105
aa127-137
LPRLTYQEGL
GLAAATWVWL
FVFYQLFVV
B7
A2
A2
None identified
None identified
None identified
Ribechini et al., 2006
Ribechini et al., 2006
Ribechini et al., 2006
*ORF 8 aa492-500 LMWYELSKI A2 None identified Wang et al., 2002b
*ORF 61 aa505-513 GLADVFAEL A*0201 None identified Lambert et al., 2006
*ORF 65 aa35-43 NMSQAEYLV A*0201 None identified Lambert et al., 2006
Early Lytic
ORF 70
aa108-116
aa255-264
aa259-267
aa236-245
aa253-261
aa296-305
VVQELLWFL
SLLTYMLAHV
YMLAHVTGL
LYQRSGDMGL
SYSLLTYML
TPRPFPRLEI
A2
A2
A2
A24
A24
B7
None identified
None identified
None identified
None identified
None identified
None identified
Ribechini et al., 2006
Ribechini et al., 2006
Ribechini et al., 2006
Ribechini et al., 2006
Ribechini et al., 2006
Ribechini et al., 2006
*K1 aa58-66
aa82-90
aa91-99
aa93-101
FRLTERTLF
HRQSIWITW
YPQPVLQTL
QPVLQTLCA
Cw3
B*2702
B51
B55
None identified
None identified
None identified
None identified
Stebbing et al., 2003b
Stebbing et al., 2003b
Stebbing et al., 2003b
Stebbing et al., 2003b
*K8.1 aa131-145
aa211-225
aa209-217
ELTDALISAFSGSYS
LILYLCVPRCRRKKP
LVLILYLCV
A24
Not determined
A2
None identified
N/A
None identified
Wilkinson et al., 2002
Wilkinson et al., 2002
Bourboulia et al., 2004
ORF 22 aa59-68 FLNWQNLLNV A2 None identified Micheletti et al., 2002
ORF 25 Not determined Not determined N/A N/A Wang et al., 2000
Late Lytic
ORF 26 aa103-111
aa125-134
aa203-211
FQWDSNTQL
IVLESNGFDL
VLDDLSMYL
A2
A2
A2
None identified
None identified
None identified
Ribechini et al., 2006
Ribechini et al., 2006
Ribechini et al., 2006
TABLE 1.2 continued: Known immunogenic KSHV ORFs and CD8 and CD4 epitopes. * indicates ORFs included in the KSHV lentiviral library.
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report occasional mild symptoms of fatigue, diarrhoea, fever and localised rash
(Wang et al., 2001b; Andreoni et al., 2002). This lack of notable symptoms makes
identifying primary KSHV infection a challenge, and thus little is known about the
T-cell response to KSHV at acquisition. One 15-year longitudinal study of HIV-
negative adults at risk of KSHV infection identified five individuals who had
seroconverted during the study period and retrospectively analysed cryopreserved
PBMCs from blood samples taken from these individuals for several years before
and after KSHV seroconversion (Wang et al., 2001b). The authors first looked for
global changes in T-cell phenotype around the time of KSHV seroconversion, as
expansion of activated CD8 T cells is a classic finding in EBV mononucleosis in
adults (Callan et al., 1996; Lynne et al., 1998). They observed no generalised
expansion of CD8 or CD4 T-cell populations after primary KSHV infection, and no
changes in the expression of naïve and memory markers CD45RA and CD45RO, or
of activation and costimulatory markers CD38, CD28 and HLA-DR (Wang et al.,
2001b). They additionally observed no immunosuppressive effects of primary
KSHV infection as measured by responses to mitogen and a nominal recall antigen,
in contrast to the transient immunosuppression associated with primary
symptomatic EBV infection (Mangi et al., 1974; Perez-Blas et al., 1992). The
authors were, however, able to detect KSHV-specific CD8 T-cell responses
(measuring CTL precursor frequency by limiting dilution and  IFNγ  production) 
directed against a broad spectrum of immediate-early, early and late lytic KSHV
ORFs (cloned into recombinant vaccinia viruses). Such responses were observed at
the time of primary KSHV infection in all KSHV seroconverters. The authors
observed no dominant CTL target between the study subjects (Wang et al., 2001b).51
A second study examined two HLA-A2-positive KSHV-negative recipients of
kidneys from KSHV-positive donors. Both recipients remained consistently clear of
detectable KSHV infection (by serology and PCR) for 24 and 11 months after
transplantation respectively. Strikingly, CD8 T cells specific for both lytic and
latent KSHV ORFs were detected in one of these recipients (by staining with HLA-
A2-restricted KSHV-specific tetramers based on peptides shown in Table 1.2)
whose donor was also HLA-A2-positive. The second recipient, whose donor was
HLA-A2-negative, showed no detectable response. The authors therefore suggest
that KSHV-specific CTLs are restricted by shared donor/recipient HLA alleles, in
this case HLA-A2. In the first recipient, the majority of tetramer-positive CD8 T
cells were of a terminally differentiated effector memory phenotype
(CD45RA+CCR7-) and expressed perforin, indicating that the generation of a
functional KSHV-specific CTL response can lead to abortive infection (Lambert et
al., 2006). In keeping with this, KSHV-specific T-cell responses have also been
detected in KSHV-seronegative individuals defined as being at high risk of KSHV
infection [responses measured by IFNγ release by whole PBMCs after stimulation 
with overlapping peptides spanning the entire length of a latent (ORF73) and a lytic
(ORF65) gene product] (Woodberry et al., 2005). The authors argued that overall
evidence from this study indicated that those individuals who did not show a
detectable KSHV serologic response but who showed positive KSHV-specific T-
cell responses were indeed KSHV-infected. It is possible, therefore, that a very low
level of viral replication may be sufficient to prime a KSHV-specific T-cell immune
response that may confer protection against chronic KSHV infection. However, it is
perhaps more likely that the current serological and PCR-based methods for52
detecting KSHV infection are not sensitive enough to identify low-level latent
infection.
ii. Frequency and Diversity of CD8 T-cell Responses in Asymptomatic
Infection and Disease
Following seroconversion, the frequencies of both CD8 CTL precursors and CD8
IFNγ-producing cells directed against lytic KSHV antigens increase to a peak one
to two years after primary infection, after which they decrease in correlation with
declines in antibody titres, possibly due to decreased viral replication and lower
antigenic burden (Wang et al., 2001b). One study found that T-cell responses to
KSHV increased with viral load in the peripheral blood and were more readily
detectable in individuals with active KS than those who did not present with active
KS (Woodberry et al., 2005). However, other groups have been unable to confirm
this and there is otherwise strong evidence (discussed below) that high levels of
KSHV-specific CD8 T-cell responses confer protection against KS oncogenesis.
Responses to KSHV CD8 peptides have been found to be of higher frequency and
of greater diversity in their antigenic repertoire in asymptomatic carriers of KSHV
compared to those with either AIDS-related, classic or iatrogenic KS (Lambert et
al., 2006; Guihot et al., 2006; Barozzi et al., 2008). KSHV-specific T-cell responses
(measured by IFNγ release by whole PBMCs in response to pools of nine-, 10-, and
20-mer peptides and recombinant proteins from lytic and latent gene products)
appeared concurrent with clinical improvement in iatrogenic KS patients after a
reduction of their immunosuppressive therapy or a conversion from calcineurin
inhibitors (which block calcineurin-activated transcription of IL2) to sirolimus (also53
known as rapamycin, which acts through mTOR to inhibit responses to IL2)
(Barozzi et al., 2008). A longitudinal study of an iatrogenic KS patient who
presented with recurrent episodes of remission and relapse of KS lesions found a
correlation between reduced frequency of KSHV-specific CD8 T cells and
recurrence of active KS (Lambert et al., 2006). Furthermore, both the magnitude
and the frequency of responses to KSHV CD8 peptides increase with immune
reconstitution through HAART, which apparently correlates with spontaneous KS
regression (Wilkinson et al., 2002; Bourboulia et al., 2004).
To address whether low frequencies of KSHV-specific CD8 T cells in the
peripheral blood of KS patients is due to recruitment of these cells to the site of the
tumour, one group performed in situ tetramer staining and confocal laser scanning
microscopy on KS biopsy specimens from two patients who had detectable
circulating KSHV-specific CD8 T cells at the time of biopsy. They found large
numbers of KSHV-tetramer-negative CD8 T-cell infiltrates in the vicinity of
LANA1-positive spindle cells, but observed very few CD8 T cells that costained
with KSHV tetramers. The few tetramer-positive CD8 infiltrates that were seen
were mainly found in LANA1-negative tissue (Lambert et al., 2006). Thus, in this
one small study, KSHV-tetramer-specific CD8 T cells do not appear to be
preferentially recruited to inflammed tumour tissue. Further investigation is
warranted to confirm these findings and to understand their biological relevance.
Together, the above data indicate that KS oncogenesis is associated with loss of
CD8 T cell-mediated control of KSHV-infected cells. Interestingly, a recent study
investigating KSHV-specific CD8 T-cell responses in multicentric Castleman’s54
disease (MCD) found that individuals with MCD had similar frequencies of KSHV-
specific CD8 T-cell responses, and these were directed against a similar antigenic
repertoire, as compared to asymptomatic KSHV carriers (Guihot et al., 2008).
These findings were corroborated by a second, smaller study which reported high
numbers  of  IFNγ-secreting KSHV-specific CD8 T-cells in two individuals with
MCD (Barozzi et al., 2009). This is in direct contrast to what is observed in KS, and
indicates that whilst KSHV-specific CD8 T cells may confer protection against the
emergence of KS, they do not apparently protect against the development of MCD.
iii. Functional Properties and Phenotypes of KSHV-specific CD8 T Cells in
Asymptomatic Infection and Disease
The precise role of KSHV-specific CD8 T cells in the pathogenesis or control of
KSHV-related diseases may additionally depend on the functional properties and
differentiation phenotypes of these cells. EBV-specific and HIV-specific CD8 T
cells have been shown to produce a range of cytokines besides interferon IFNγ
(Lichterfeld et al., 2004), and there is evidence that polyfunctional T-cell responses
may be a correlate of control of HIV-infection (Betts et al., 2006). However, little is
known about the functionality of KSHV-specific CD8 T cells in asymptomatic
infection and disease. One study compared cytokine release by CD8 T cells from
four individuals with AIDS-KS that spontaneously regressed after initiation of
HAART (‘KS non-progressors’) with cytokine release by CD8 T cells from three
individuals with AIDS-KS that progressed and required additional chemotherapy
despite initiation of HAART (‘KS progressors’) (Bihl et al., 2009). They found that
KSHV-specific CTL responses from KS non-progressors were more frequently55
polyfunctional (production of both IFNγ and TNFα) than CTL responses from KS
progressors. By contrast, KSHV-specific CD8 T cells from both individuals with
MCD and asymptomatic carriers of KSHV were demonstrated to be polyfunctional
(secretion of two or more of IFNγ, IL2, TNFα, MIP1ß or mobilisation of CD107a)
after stimulation with pools of both lytic and latent peptides (Guihot et al., 2008).
Another study compared the functionality of KSHV-specific CD8 T cells directed
against lytic or latent antigens in HIV-positive asymptomatic carriers of KSHV.
They assessed T-cell release of IFNγ and TNFα, as well as the ability to degranulate 
(as measured by mobilisation of CD107a to the cell surface) after antigen contact.
Multifunctional KSHV-specific T cells were more frequently detected in CD8 T-
cell populations that responded to latent antigens than those targeted to lytic
antigens, in keeping with observations in EBV-specific T cells (Bihl et al., 2007b).
Human memory CD8 and CD4 T cells can be divided into phenotypic subsets based
on their functions and expression of certain cell surface markers. These subsets are
broadly defined as central memory (TCM), effector memory (TEM) and terminally
differentiated effector memory (TEMRA; a subset of CD8 T cells only) (Sallusto et
al., 2004). Effector memory T cells can be further subdivided into early-,
intermediate- and late- effector memory cells (van Baarle et al., 2002). TCM cells
have little or no effector function but migrate to lymph nodes and readily proliferate
and differentiate into TEM cells in response to stimulation by their specific antigen
(Sallusto et al., 1999). TEM cells migrate to inflamed tissues and are characterised
by rapid effector function upon antigenic stimulation. Early and intermediate TEM
cells have low cytolytic activity and maintain high proliferative capacity. Late TEM
cells have less proliferative capacity but strong effector cytolytic function (van56
Baarle et al., 2002; Appay et al., 2002). TEMRA cells are a unique subclass of CD8
TEM cells that are fully differentiated, strongly cytolytic, carry large amounts of
perforin, and are non-replicative. They are a hallmark of a prolonged immune
response (Sallusto et al., 2004). Very few CD4 TEM cells reexpress CD45RA and so
TEMRA cells are generally not defined as a separate subset of CD4 T cells.
The expression of several cell-surface molecules can be used to define memory
subsets. Among the most commonly used of these are CD45RO, CD45RA, CCR7,
CD27 and CD28. CD45RO is expressed in response to antigen stimulation. It is
therefore absent in naïve T cells, but present in both TCM and TEM, but lost again on
differentiation to TEMRA. CD45RA is expressed by naïve cells, absent in TCM and
TEM, and reexpressed by TEMRA as their defining feature, signified by the ‘RA’
annotation. CCR7 is a lymphoid-homing receptor, and thus is expressed by naïve
and TCM cells, but lost by TEM and TEMRA cells. CD27 and CD28 are costimulatory
molecules that are expressed by naïve and TCM cells and gradually lost by TEM cells,
providing markers for early (CD27+CD28+), intermediate (CD27+CD28-) and late
(CD27-CD28-) TEM subdivisions (Sallusto et al., 1999; van Baarle et al., 2002;
Appay et al., 2002; Sallusto et al., 2004). CD8 T-cell marker expression is
summarised in Figure 1.3. Different viral infections are associated with varying
representation of memory subsets by both the circulating T-cell population as a
whole and by the virus-specific T cells. In certain viral infections, the representation
of memory subsets further varies in chronic infection and disease (Appay et al.,
2002). For example, HIV infection is associated with dramatically decreased
proportions of naïve and central memory cells within the total circulating CD8 T-
cell population and a correspondingly increased proportion of effector memory and57
terminally differentiated effector memory cells (Chen et al., 2001). Within the HIV-
specific CD8 population, cells are predominately CD45RA-CCR7- effector memory
cells, and show defective differentiation towards CD45RA+CCR7- terminally
differentiated effector cells (Champagne et al., 2001).
In a study of three iatrogenic KS patients, conversion of their immunosuppressive
drug regime from calcineurin inhibitors to sirolimus (also known as rapamycin, as
described on pages 52-53) led to an increase in the frequency of naïve and central
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FIGURE 1.3: Schematic illustration of a model for the differentiation of CD8 T
cells showing cell-surface marker expression. Open arrows indicate the path of
differentiation upon antigen exposure (naïve > TCM) and re-exposure to antigen (TCM >
Early TEM > Intermediate TEM > Late TEM > TEMRA). Naïve CD8 T cells lose expression
of CD45RA and express CD45RO on differentiation to TCM. Differentiation from TCM to
effector memory TEM is characterised by sequential loss of expression of CCR7, CD28
and CD27. Finally, terminally differentiated effector memory CD8 T cells lose
expression of CD45RO and reexpress CD45RA, and are thus known as TEMRA cells.
Some TEMRA cells may express CD27 and CD28, indicated by the dashed lines.58
memory T cells in the general population of circulating CD8 T cells in conjunction
with KS regression (Barozzi et al., 2008). A very recent study found, unexpectedly,
that treating mice with rapamycin (previously classified as an immunosuppressive
as it inhibits responses to IL2) following infection with lymphocytic
choriomeningitis virus (LCMV) enhanced both the quality and quantity of central
memory virus-specific T cells (Araki et al., 2009). Thus converting these iatrogenic
KS patients to sirolimus may be acting to promote an enrichment of their central
memory CD8 T cell pool, and these cells may be playing an important role in
keeping KSHV-infected cells in check and promoting regression of KS lesions.
There are few studies of the differentiation phenotype of KSHV-specific CD8 T
cells. The few reports to date are somewhat contradictory and on the whole rather
limited, particularly in terms of sample numbers. This, coupled with the
complication of the background of immunosuppression (acquired or iatrogenic) in
which the studies are conducted, means that a definitive understanding of the
differentiation phenotype of KSHV-specific T cells remains elusive.
Six transplant recipients who spontaneously controlled KSHV infection had
significantly higher proportions of CD45RA+CCR7- TEMRA KSHV-specific cells
and significantly lower proportions of CD45RA-CCR7- TEM KSHV-specific cells
compared to seven patients with active KS or five patients with KS in remission
(Lambert et al., 2006). In six MCD patients, the majority of KSHV-specific CD8 T
cells were also CD45RA-CCR7- TEM cells. However, in this study the dominance
of this phenotype did not differ from that of seven HIV-positive asymptomatic
carriers of KSHV. Furthermore, in the MCD patients, a significantly higher59
proportion of KSHV-specific CD8 T cells were found to be CD45RA-CCR7-CD27-
late effector memory T cells and a correspondingly lower proportion were
CD45RA-CCR7-CD27+ early and intermediate effector memory T cells, as
compared to asymptomatic carriers (Guihot et al., 2008). This more differentiated
phenotype correlated with increased viral load, and was postulated to result from
high antigenic burden.
In primary symptomatic EBV infection (infectious mononucleosis), EBV-specific
CD8 T cells show a uniform CD45RA-CCR7- TEM phenotype. However, with the
regression of infectious mononucleosis and the establishment of chronic
asymptomatic infection, the phenotype of EBV-specific CD8 T cells depends upon
whether the cell targets a latent or a lytic EBV antigen (Hislop et al., 2002). CD8 T
cells directed against latent EBV antigens are predominately of a CD45RA-CCR7-
TEM phenotype with a low proportion of cells of a CD45RA+CCR7- TEMRA
phenotype. By contrast, CD8 T cells directed against lytic EBV antigens are
predominately CD4RA+CCR7- TEMRA cells, with a lower proportion of cells that
are CD45RA-CCR7- TEM cells (Hislop et al., 2001; Hislop et al., 2002; Catalina et
al., 2002).
Two studies have compared the phenotypes of KSHV-specific T cells targeting
either lytic or latent antigens. One group reportedly observed no difference between
the differentiation phenotype of KSHV-specific CD8 T cells targeted against latent
or lytic antigens (Lambert et al., 2006). However, it was not made clear whether or
not they compared T cells specific for different antigens from within the same
individual, or if they only compared lytic-antigen-specific T cells from one60
individual with latent-antigen-specific T cells from another individual. Neither was
it clear how many responses were investigated or in how many individuals.
Another group reported that the phenotype of KSHV-specific T cells targeting lytic
or latent antigens concurs with the differences seen in EBV-specific T cells directed
against latent or lytic antigens (Bihl et al., 2007b). They compared five KSHV lytic-
antigen-specific T-cell populations to four KSHV latent-antigen-specific T-cell
populations. Again, it was not made clear if these were from within the same
individual or from different individuals. The authors reported that CD8 T cells that
recognised latent KSHV antigens were predominately of a CD45RA-CCR7- TEM
phenotype with a low proportion of cells of a CD45RA+CCR7- TEMRA phenotype,
whereas a much higher proportion of CD8 T cells directed against lytic KSHV
antigens were CD45RA+CCR7-. Interestingly, KSHV-specific T cells were overall
more differentiated (higher proportions of CD45RA+CCR7- cells) than EBV-
specific T cells (Bihl et al., 2007b).
1.3.b The CD4 T-cell Response Against KSHV
The CD4 T-cell response against KSHV remains largely unexplored. Although
some studies have looked at responses to KSHV by mixed CD8 and CD4 T-cell
populations (Woodberry et al., 2005; Bihl et al., 2007a; Bihl et al., 2007b), there has
been almost no investigation specifically into the CD4 T-cell response against
KSHV. One of the studies with mixed T cells used intracellular cytokine staining to
determine whether the observed responses were mediated by CD4 or CD8 T cells.
However, they found that the responses were mostly CD8 T-cell mediated with only61
two samples out of 11 showing borderline CD4 T-cell reactivity (Bihl et al., 2007b).
They did not state which of the two antigens they were testing [ORF57 (lytic) and
ORF73 (latent)] initiated these CD4 responses. Another group reported the
identification of two CD4 T-cell epitopes (the only ones described to date) from
within the latent antigens K12 and K15 in one individual with AIDS-KS using an
IFNγ  enzyme-linked immunospot (ELIspot) assay (Guihot et al., 2006). The
longitudinal study of three iatrogenic KS patients described in the CD8 response
section above (pages 52 and 57) reported the emergence of CD4 responses to K12
(latent) and K8.1 (lytic) in conjunction with KS regression in two of these three
individuals (Barozzi et al., 2008). The one individual in which no KSHV-specific
CD4 responses were observed was the only one out of the three that did not achieve
full remission of their KS. The authors suggested that this was indicative of the
importance of KSHV-specific CD4 responses in controlling KSHV infection.
Although the small sample number and limited number of antigens make it difficult
to reach a firm conclusion from this study, it seems likely that CD4 T cells do play
a key role in the immune response against KSHV.
The final phases of KSHV virion assembly occur in the endosomal cellular
compartments with extensive targeting of viral proteins to endosomes. Thus viral
proteins can be efficiently processed through the intracellular endosome pathway,
resulting in the presentation of CD4-specific viral epitopes through MHC-II to
helper T cells. Processing of the EBV antigen EBNA1 for presentation in the
context of MHC-II is also known to occur through the autophagy pathway (Paludan
et al., 2005). Furthermore, the presentation of the EBV antigens EBNA2, EBNA3C
and BHRF1 through MHC-II occurs by intercellular transfer of an antigenic moiety62
(Landais et al., 2005b; Taylor et al., 2006; Taylor and Rickinson, 2007). This
process does not require cell contact, and the antigenic particle is taken up by
neighbouring cells and processed as exogenous antigen for MHC-II-mediated
presentation. It seems reasonable that one or all of these pathways may also be used
for the presentation of KSHV antigens through MHC-II.
The lack of known CD4 epitopes or antigens has limited studies into the association
between KSHV-specific CD4 responses and the control of KSHV or the
development (and subsequent resolution) of KSHV-related neoplasms. Low CD4
counts are associated with the incidence of KS, and KS can spontaneously regress
with immune reconstitution through HAART. A weak association was reported
between increased CD4 counts after starting HAART and reconstitution of KSHV-
specific immune responses (by PBMCs to overlapping peptides from lytic and
latent antigens) (Bihl et al., 2007a). Interestingly, however, clinical improvement of
KS after initiation of HAART was not found to be associated with increased CD4
count although it was significantly related to decreased HIV viral load (Gill et al.,
2002). In primary symptomatic EBV infection (infectious mononucleosis) there is a
significant, early CD4 T-cell response which, although lower in size than the
primary CD8 response to EBV, is comparable to other early CD4 responses to viral
infections such as lymphocytic choriomeningitis virus (LCMV) infection in mice
and HIV in humans (Amyes et al., 2003). After this primary burst, the frequency of
EBV-specific CD4 T cells drops off significantly, leaving a small population of
EBV-specific CD4 T cells that persists during chronic infection (Amyes et al.,
2003). Peripheral blood EBV viral load correlates with the frequency of EBV-
specific CD4 T cells, both at presentation with infectious mononucleosis and on63
establishment of chronic infection, indicating the EBV-specific CD4 responses are
antigen driven (Precopio et al., 2003). Immunocompetent individuals with EBV-
positive lymphomas have decreased EBV-specific CD4 responses compared to both
healthy EBV carriers and EBV carriers with EBV-negative lymphomas (Heller et
al., 2008).
The absence of known targets of the KSHV-specific CD4 response has also
restricted the investigation of the functionality and the differentiation phenotypes of
KSHV-specific CD4 T cells in chronic infection and disease. In the three iatrogenic
KS patients mentioned above (pages 52, 57, and 61), complete KS regression in two
of the patients was associated with an expansion of the naïve and central memory
compartments of the total circulating CD4 T-cell population. In the third patient,
who did not achieve complete resolution of their KS, there was no enrichment of
their central memory CD4 T-cell compartment, consistent with these cells playing a
role in KS control. EBV-specific CD4 T cells are predominately CD45RA-CCR7-
CD28+CD27+ (early effector memory phenotype) (Amyes et al., 2003). By
contrast, CMV-specific CD4 T cells are predominately of a later effector memory
phenotype, CCR7-CD27-, with heterogenous expression of CD28 and CD45RA
(Amyes et al., 2003; Gamadia et al., 2004). The majority of both EBV- and CMV-
specific CD4 T cells are Th1-polarised and produce the cytokines IFNγ and TNFα 
(Bickham et al., 2001; Gamadia et al., 2004). Limited production of Th2-type
cytokines IL4, IL5 and IL13 by EBV EBNA1-specific T cells has also been
reported in a of minority EBV-positive donors (Steigerwald-Mullen et al., 2000;
Bickham et al., 2001). Of note, the sensitivity of Th1 versus Th2 cytokine
production by helper T cells to subtle variations in culture conditions must always64
be considered in such investigations, particular when comparing results from
different studies.
1.3.c γδ T cells in the Control of KSHV
CD4 and CD8 T cells make up the majority of CD3 T cells found in the body and
are both characterised by T-cell receptors comprised of an α-chain and a β-chain. A
small proportion of CD3 T cells have T-cell receptors made up of a γ-chain and a δ-
chain and are thus known as γδ T cells. γδ T cells typically account for less than
five percent of circulating T cells, but are enriched in epithelial-rich tissues such as
the skin and intestines (Carding and Egan, 2002). There are two main sub-types of
γδ T cells designated Vδ1 and Vδ2. Vδ2 are the majority of γδ T cells found in 
healthy adults. They are found in the peripheral blood and thought to play a role in
defence against intracellular pathogens and haematological malignancies (Fisch et
al., 1997). Vδ1 are the minority overall in adults, but predominate at epithelial sites
such as the intestine and skin where they are suggested to provide first-line defence
against viral infections (Deusch et al., 1991; Maeurer et al., 1996). In certain
disease states, the representation of Vδ1 and Vδ2 shifts dramatically, for example in
HIV-1 infection Vδ2 cells are lost and Vδ1 cells expand (De Paoli et al., 1991; De
Maria et al., 1992). Although the significance of such changes is not understood,
they imply a role for γδ T cells in anti-viral immune responses (Carding and Egan,
2002). Unlike αβ T cells, γδ T cells do not recognise MHC-bound peptides but
instead bind their respective antigens in a manner more similar to antibodies,
independent of MHC presentation and more dependent on the conformational shape
of the antigen (Girardi, 2006). They recognise a range of both protein- and non-65
protein-derived antigens (Carding and Egan, 2002), including microbial products
and stress-induced self antigens, and thus are suggested to represent a bridge
between innate and adaptive immunity (Holtmeier and Kabelitz, 2005).
One group has examined the involvement of γδ T cells in the control of chronic
KSHV infection (Barcy et al., 2008). The authors observed a significant expansion
of  γδ T cells of the Vδ1 subtype in the peripheral blood of HIV-negative
asymptomatic carriers of KSHV as compared to age-matched, HIV-negative,
KSHV-negative healthy controls. Vδ1 T-cell expansion has been previously
described in two instances: in all stages of HIV infection and in transplant recipients
with active CMV infection (Dechanet et al., 1999). Asymptomatic KSHV infection
is, therefore, the second viral infection (after HIV) in which specific, long-lasting
Vδ1 T-cell expansion is observed during chronic stages of infection, and the only
viral infection in which Vδ1 expansion has been documented in immunocompetent
individuals. Barcy and colleagues further found that in asymptomatic carriers of
KSHV,  the  γδ  Vδ1  T-cell subpopulation displayed an increase in the relative
frequency of cells expressing an effector phenotype compared to KSHV-negative
controls. The same trend was seen in both the αβ CD4 and the αβ CD8 T-cell
subpopulations in the KSHV carriers in keeping with what has been observed in
other persistent viral infections (Brenchley et al., 2003; Palmer et al., 2005). In vitro
experiments demonstrated Vδ1 T-cell activation in response to infectious KSHV
particles; KSHV-infected cell lines; and the KSHV viral proteins glycoprotein B
(encoded by ORF8), K8.1 and ORF65 (Barcy et al., 2008). Moreover, Vδ1 T cells
prevented the release of infectious KSHV virions from KSHV-infected cell lines
following the induction of lytic replication (Barcy et al., 2008).66
1.3.d The T-cell Response Against KSHV – Remaining Questions
There is still much to learn about the adaptive T-cell responses against KSHV.
Although some CD8 epitopes have been identified, the evidence discussed above
indicates that there may be immunodominant epitopes yet to be determined. It
seems clear that the targets of the KSHV-specific CD4 response remain poorly
understood. Further characterisation of the functionality and differentiation
phenotypes of both CD8 and CD4 KSHV-specific T cells will be greatly aided by
first achieving a better understanding of the targets of these cells.
In the studies completed so far into the targets of the KSHV-specific CD8 T-cell
response a necessary limiting factor has been the size of the KSHV genome. Each
study has been confined to a handful of genes, selected either due to their homology
with immunogenic genes from other γ-herpesviruses (Lambert et al., 2006), their
expression profile (Micheletti et al., 2002; Ribechini et al., 2006), or evidence of
sequence variation arising from immunological pressure (Stebbing et al., 2003b).
Epitope identification has been performed using overlapping peptides for smaller
genes (Wilkinson et al., 2002; Stebbing et al., 2003b; Guihot et al., 2006; Bihl et al.,
2007b) or predictive algorithms for peptide HLA-binding affinity to identify
potential epitopes for larger genes (Brander et al., 2001; Micheletti et al., 2002;
Wang et al., 2002b; Ribechini et al., 2006; Guihot et al., 2006).
The work described in this thesis investigates further the immunogenic profile of
KSHV. Lentiviral-transduced dendritic cells were used to express a significant
number of the genes contained within the KSHV genome to perform a large-scale67
screen for immunogenic KSHV genes that elicit both CD8 and CD4 T-cell
responses.
1.4 The Use of Lentiviral-transduced Dendritic Cells to
Investigate T-cell Responses
1.4.a Dendritic Cells
Dendritic cells (DCs) are potent antigen presenting cells that act as the ‘sentinels’ of
the immune system. They constantly sample their microenvironment, taking up
antigens and presenting them through their class I and class II major
histocompatibility (MHC) complexes to CD8 and CD4 T cells respectively. They
express costimulation and adhesion molecules involved in T-cell activation and are
capable of stimulating both memory and naïve T cells (Banchereau and Steinman,
1998).
DCs arise from bone marrow-derived haematopoietic mononuclear progenitors and
are initially described as being in an ‘immature’ state. Immature DCs are found
throughout the body and are extremely efficient at taking up antigens, but have low
T-cell stimulatory capacity and are unable to prime a naïve T-cell response. In
response to stimuli alerting them to inflammation, tissue injury or pathogen attack,
immature DCs undergo a maturation process, whereby they lose their ability to
capture antigens but become potent stimulators of both memory and naïve T cells.
Mature DCs migrate to the T-cell areas of the lymph nodes, where they can recruit68
T cells and promote an immune response (Banchereau and Steinman, 1998). In
humans, two main subtypes of DCs can be identified in vivo based on their
expression of the cell-surface markers CD11c and CD123 (interleukin 3 receptor) –
myeloid DCs (mDCs) are CD11c-positive and CD123
lo and plasmacytoid DCs
(pDCs) are CD11c-negative and CD123
hi. However, both these DC subtypes are
difficult to isolate in sufficient numbers for meaningful ex vivo investigations.
Therefore, most DC research has been conducted on DCs grown in vitro from
precursor cells retrieved from the body.
DCs can be derived in vitro from CD14+ monocytes isolated from peripheral blood
(Sallusto and Lanzavecchia, 1994). After seven days’ culture in the presence of the
cytokines granulocyte/macrophage colony-stimulating factor (GMCSF) and
interleukin 4 (IL4), the monocytes take on a typical DC morphology and have the
antigen-capturing, processing and presenting capacities of immature DCs. They no
longer express CD14 and instead express cell-surface markers of immature DCs
such as the antigen-presenting protein complexes major histocompatibility complex
-1 (MHC-I) and -2 (HLA-DR); the costimulatory molecules CD40, CD80 and
CD86, which bind the T-cell molecules CD40L, CD28 and CTLA-4 respectively;
and the myeloid DC marker CD11c. From an immature state, these cells undergo a
maturation process in response to stimulation by proinflammatory cytokines such as
tumour necrosis factor α (TNFα) or microbial products such as lipopolysaccharides
(LPS) to become characteristic mature DCs, expressing CD83 and high levels of
cell-surface HLA-DR and with high T-cell stimulatory capacity (Sallusto and
Lanzavecchia, 1994; Romani et al., 1996; Shortman and Liu, 2002). They are thus69
closely related to myeloid DCs in terms of both morphology and function and are
known as monocyte-derived DCs (moDCs).
1.4.b Antigen Delivery to Dendritic Cells
As potent antigen-presenting cells, DCs loaded with antigens of interest have many
potential applications in basic immunology research. Moreover, the pivotal role
played by DCs in initiating T-cell immune responses in vivo has made them
attractive targets for novel immunotherapy strategies, particularly for the treatment
of cancer, due to their ability to generate primary anti-tumour T-cell responses
(Kirk and Mule, 2000). This has led to extensive investigations into methods of
efficient antigen delivery into DCs. DCs can be directly loaded with peptides or
antigens, but genetically modifying DCs to introduce an immunogenic gene is an
attractive alternative (Jenne et al., 2001). Not only does this technique potentially
enhance delivery, it also allows natural processing of the immunogenic protein by
the DC and thus presentation of the naturally occurring optimal epitopes, thereby
avoiding the limitations associated with the use of artificial peptides. Most
importantly, no prior knowledge of the optimal peptide is required and each
individual’s DCs can process the antigenic protein to produce the best-suited, HLA-
restricted peptide for that individual, regardless of their HLA type. In addition,
endogenous expression of the antigen should result in more sustained antigen
presentation than is achieved by introducing the antigen by pulsing DCs (Dyall et
al., 2001; Jenne et al., 2001; Esslinger et al., 2002; Collins and Cerundolo, 2004).70
Monocyte-derived DCs (moDCs) are quiescent in culture and therefore difficult to
introduce foreign genetic material into using non-viral methods of gene transfer
(Arthur et al., 1997). Likewise, vectors derived from oncogenic retroviruses, which
cannot deliver into non-dividing cells, show low transduction efficiency into
moDCs (Chinnasamy et al., 2000). Adenovirus- and vaccinia-based vectors
efficiently transduce non-dividing cells. However, a major disadvantage of using
vectors based on these viruses is that they are both highly immunogenic and are
prevalent in all human populations and have the potential, therefore, to elicit a
notable T-cell response to viral proteins encoded in the vector construct itself.
Strong anti-vector T-cell responses could interfere with any target transgene-
specific immune responses, making these vectors less attractive for use in both
immunotherapies and basic research. The introduction of HIV-1- and HIV-2-
derived lentiviral vectors and their demonstrated ability to transduce non-dividing
cells (Miyake et al., 1998) thus offered a promising alternative vehicle for moDC
gene delivery. For safety reasons, lentiviral vectors based on HIV-1 are designed as
so-called ‘gutless vectors’ – although they are constructed from HIV viral proteins,
they do not express any HIV viral proteins when in their target cell (see section
1.4.d., Construction of Lentiviral Vectors). This minimises the potential problem of
pre-existing immunity to viral vector proteins interfering with antigen-specific
responses as a result of stimulating anti-vector over anti-transgene CTLs
(Palmowski et al., 2004; Collins and Cerundolo, 2004). Furthermore, lentiviral
vectors, unlike adenovirus- and vaccinia-based vectors, integrate into the cellular
genome resulting in stable gene expression.71
1.4.c Lentiviral Transduction of Dendritic Cells
The first report of successful transduction of moDCs by an HIV-1-based lentiviral
vector system was by Unutmuz et al. (Unutmaz et al., 1999). However, the first
extensive study in this area was by Schroers et al. (Schroers et al., 2000). The
authors showed efficient transduction of moDCs by a lentiviral vector encoding the
enhanced yellow fluorescence protein (eYFP) reporter gene. Interestingly, they and
others found that immature moDCs are more efficiently transduced than mature
moDCs (Schroers et al., 2000; Gruber et al., 2000; Dyall et al., 2001). Esslinger et
al. made a direct comparison of the transduction efficiency of adenoviral and
lentiviral vectors encoding the green fluorescence protein (GFP) and found the
lentiviral vectors were twice as efficient at transducing human moDCs and ten
times more efficient at transducing murine moDCs (Esslinger et al., 2002). Kinetic
analysis by Schroers et al. revealed that maximum transgene (eYFP) expression, in
terms of both number of cells transduced and fluorescence intensity, was reached
four to five days post-transduction, but no decrease in fluorescence activity was
seen up to 10 days post-transduction. A similar pattern was observed by others
(Dyall et al., 2001) and one group reported stable transgene expression for up to 28
days (Rouas et al., 2002). Several studies have demonstrated that lentiviral vectors
integrate into the moDC cellular genome thus providing for stable gene expression
(Schroers et al., 2000; Chinnasamy et al., 2000; Dyall et al., 2001).
Lentiviral-transduced moDCs have a normal morphology (Gruber et al., 2000;
Esslinger et al., 2002) and their viability is not affected at low multiplicities of
infection (MOI) (less than ten) (Gruber et al., 2000; Dyall et al., 2001). Some72
groups report no loss of viability at higher MOIs (Esslinger et al., 2002). At low
MOIs, lentiviral-transduced moDCs maintain their immunophenotype, as
characterised by their expression of DC cell-surface markers CD11c, CD40, CD80,
CD83, CD86 and HLA-DR (Koya et al., 2003; Dullaers et al., 2004). These markers
are upregulated appropriately by lentiviral-transduced moDCs in response to
maturation stimuli such as CD40 ligand, LPS and a ‘cocktail’ of inflammatory
cytokines (Gruber et al., 2000; Chinnasamy et al., 2000; Jenne et al., 2001; Dullaers
et al., 2004). Lentiviral transduction at very high MOIs, however, seems to have
some effect on immunophenotype and maturation. One group reported that at a high
MOI of 50 to 100, lentiviral-transduced moDCs showed reduced expression of DC
cell-surface markers after maturation (Chen et al., 2004). Conversely, another group
reported activation of moDCs and upregulation of cell-surface markers after
lentiviral transduction at high MOIs (Tan et al., 2005). Importantly, however, in
allogenic mixed lymphocyte reactions, lentiviral-transduced moDCs show no
decrease in their T-cell stimulation capacity as compared to non-transduced moDCs
(Schroers et al., 2000; Chinnasamy et al., 2000; Dyall et al., 2001; Chen et al.,
2004) even after transduction at high MOIs (Chen et al., 2004; Tan et al., 2005). In
addition, Gruber et al. demonstrated peptide-specific lysis of moDCs lentivirally
transduced with an empty vector and subsequently loaded with the melanoma-
associated tyrosinase CTL epitope by a CD8 tyrosinase peptide-specific cell line
(Gruber et al., 2000). Together, these findings indicate that lentiviral transduction
does not affect the antigen-presenting function of moDCs.
There is limited knowledge regarding the effects of lentiviral transduction on moDC
cytokine secretion and their induction of Th1- or Th2-type immune responses. Two73
studies using high MOIs reported conflicting results. Chen et al. found that
lentiviral transduction impaired moDC-mediated Th1 immunity. They saw a
dramatic reduction in the proportion of IFNγ-producing Th1 cells in a T-cell
population that had been incubated with lentiviral-transduced moDCs as compared
to a T-cell population that had been incubated with non-transduced moDCs. The
proportion of Th2 cells in each population was essentially the same (Chen et al.,
2004). In contrast, Tan et al. found that lentiviral transduction promoted increased
secretion of the Th1 cytokines IL1β, IL6 and IL12 by immature moDCs. This
upregulation of Th1 cytokines was less than was seen after adenoviral transduction,
and was also only seen in immature moDCs. Mature moDCs showed no change in
their production of Th1 cytokines after lentiviral transduction (Tan et al., 2005). At
MOIs of less than 20, Rouas et al. saw no difference in the amount of the bioactive
IL12 (an important Th1 cytokine) secreted by lentiviral-transduced or non-
transduced moDCs (Rouas et al., 2002).
Dyall et al. were the first to demonstrate that moDCs lentivirally transduced to
express a foreign peptide can activate a strong peptide-specific cytotoxic T-cell
(CTL) response (Dyall et al., 2001). They compared the T-cell stimulatory capacity
of moDCs transduced with a lentiviral vector encoding the optimal HLA-A*0201
influenza matrix protein peptide with that of non-transduced moDCs pulsed with
the same peptide. By using a lentiviral vector encoding the influenza peptide they
were able to make a direct comparison with pulsed moDCs, as in this case the
antigen does not require processing by the transduced moDCs and is not part of a
larger protein that could encode additional T-cell epitopes including T-helper
epitopes. The lentiviral-transduced moDCs were able to stimulate an influenza-74
specific primary CTL response in a mixed T-cell population that was comparable to
stimulation by the peptide-pulsed moDCs. This was despite the transduced moDCs
displaying a relatively low transduction efficiency with only 15-18% of cells
expressing the antigen. Furthermore, the lentiviral-transduced moDCs were able to
restimulate primed CTLs and could also stimulate a CTL response in a pure CD8
CTL population without CD4 T-cell help or the addition of endogenous cytokines.
Further in vitro studies demonstrated that moDCs lentivirally transduced with
melanoma-associated antigens stimulated both primary and recall anti-cancer T-cell
responses. Lentiviral-transduced moDCs expressing the melanoma-associated
antigens tyrosinase or Melan-A stimulated antigen-specific CD8 T-cell lines or T-
cell clones derived from tumour-infiltrating lymphocytes from melanoma patients
(Esslinger et al., 2002; Firat et al., 2002; Lizee et al., 2004). moDCs lentivirally
transduced to express the HLA-A2 restricted Melan-A27-35 epitope were also shown
to stimulate the expansion of naïve T cells from HLA-A2 blood donors (Lopes et
al., 2006). Furthermore, and very importantly for the work described in this thesis,
lentiviral-transduced DCs were demonstrated to efficiently process and present both
MHC class I- and II-restricted epitopes and so prime both CD8 and CD4 T-cell
responses (Dullaers et al., 2004; He et al., 2005).
Several studies in mice have shown that intravenous injection of murine DCs
lentivirally transduced with an antigenic epitope can induce antigen-specific T-cell
responses in vivo (Esslinger et al., 2002; Zarei et al., 2004; Palmowski et al., 2004;
He et al., 2005). These responses are stronger and longer-lasting than those elicited
by peptide- or protein-pulsed or mRNA-electroporated DCs (Dullaers et al., 2004;75
He et al., 2005). In a murine model of aggressive melanoma, immunisation with
DCs lentivirally transduced with a tumour antigen significantly inhibited growth of
established tumours and resulted in prolonged survival (He et al., 2005). In a
murine model of lymphocytic choriomeningitis virus (LCMV), immunisation with
DCs lentivirally transduced with an LCMV epitope protected against primary
LCMV infection (Zarei et al., 2004). Together, these studies indicate the initiation
of functional antigen-specific T-cell responses as a result of in vivo priming with
lentiviral-transduced DCs. Significantly, immunisation with lentiviral-transduced
DCs resulted in less activation of non-specific CD8 T cells than immunisation with
DCs transduced with adenovirus-based vectors, possibly indicating less of an anti-
vector immune response (Esslinger et al., 2002).
In addition to their potential use in immunotherapies, lentiviral-transduced DCs
have the capacity to be a useful tool in immunology research. Breckpot et al. used
moDCs lentivirally transduced with the melanoma-specific antigenic protein
MAGE-3 to identify a new antigenic peptide (Breckpot et al., 2004). T cells from a
blood donor without cancer were stimulated with the lentiviral-transduced moDCs
and a responding anti-MAGE-3 CTL was isolated that recognised a previously
unknown peptide.
1.4.d Construction of Lentiviral Vectors
Lentiviral gene-delivery vectors based on HIV-1 were developed as an
improvement on existing retroviral vectors (Naldini et al., 1996). They have the
major advantage of being able to mediate stable gene delivery in to non-dividing76
cells, and so have many potential applications in basic, translational and even
clinical research.
For safety reasons, lentiviral vectors are separated into cis- and trans- acting
elements encoded on separate plasmids – a transfer plasmid and a packaging
plasmid, respectively (Dullaers and Thielemans, 2006; Breckpot et al., 2007). The
ENV gene is deleted from the packaging plasmid and a third plasmid encodes the
envelope (Delenda, 2004). Active virions are produced through the transfection of a
packaging cell line such as HEK 293T cells with all three plasmids (see Figure 1.4).
The transfer plasmid contains the expression cassette encoding the transgene of
interest, along with cis-acting HIV factors required for packaging, reverse
transcription, integration and transcription. Self-inactivating vectors were developed
by deleting the U3 region of the 3’ long terminal repeat (LTR) of the transfer
plasmid in order to further reduce the risk of generating a replication-competent
virus (Miyoshi et al., 1998; Zufferey et al., 1998). The following additional
elements have been added to the transfer plasmid to improve transgene transfer and
expression (Delenda, 2004). The HIV POL gene’s central polypurine tract (cPPT)
enhances nuclear import of pre-integration complexes thereby enhancing vector
efficiency in both dividing and non-dividing cells (Follenzi et al., 2000). The
woodchuck hepatitis B post-transcriptional regulatory element (WPRE) improves
transgene expression through its post-transcriptional activities, modifying
polyadenylation, RNA export or translation (Zufferey et al., 1999).
In the original lentiviral vectors (so-called first-generation vectors) the packaging
plasmid encoding the trans-acting HIV factors contained GAG, POL, the regulatory77
genes REV and TAT, and the accessory genes VIF, VPR, VPU and NEF. Safety
was further improved in second-generation vectors by deleting the four accessory
genes from the packaging plasmid – these are required for viral pathogenesis in vivo
but were found to be unnecessary for gene transfer. In third-generation lentiviral
vectors a split-genome packaging system was introduced, whereby the REV gene is
expressed from a separate, non-overlapping plasmid and the TAT gene is deleted
and replaced by a strong constitutional promoter in the 5’ LTR of the transfer
plasmid (Delenda, 2004).
p8.91
pMD.G
Gene of Interest
HEK 293T cells
Self-inactivating HIV-1 Virions
encoding Gene of Interest
Envelope Plasmid:
encodes VSV-G envelope gene
Packaging Plasmid:
encodes GAG, POL,
TAT and REV
Transfer Plasmid:
encodes cPPT, WPRE,
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mutiple cloning site (MCS)
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FIGURE 1.4: Schematic illustration of the lentiviral packaging system for the pSIN
vector. The gene of interest is cloned into the transfer plasmid at the multiple cloning site
(MCS). VSV-G-pseudotyped virions are produced by co-transfection of a packaging cell
line of transformed human embryonic kidney cells (HEK 293T) with the transfer plasmid,
the packaging plasmid (encoding the HIV-1 genes GAG, POL, TAT and REV) and the
envelope plasmid (encoding VSV-G-derived envelope gene).78
The envelope plasmid can be pseudotyped to provide optimal delivery to the target
cell type. The most widely used heterologous envelope is the vesicular stomatitis
virus glycoprotein (VSV-G), as this envelope has a broad host cell tropism
(Breckpot et al., 2007). By acting through a ubiquitous cellular receptor, VSV-G
facilitates efficient virion entry into a wide range of cell types (Cronin et al., 2005).
Several studies have compared the moDC transduction efficiency of lentiviral
vectors carrying the different modifications outlined above (Dullaers and
Thielemans, 2006). Self-inactivating vectors resulted in comparable, or even higher,
transduction efficiencies than vectors without this modification (Breckpot et al.,
2003; Koya et al., 2003). The inclusion of cPPT is universally agreed to enhance
transduction efficiency into DCs (Firat et al., 2002; Rouas et al., 2002; Breckpot et
al., 2003). There are some reports that the addition of WPRE does not improve
transduction efficiency of lentiviral vectors in moDCs and that its presence may
result in increased cell death (Breckpot et al., 2003), however, many groups have
used vectors with this inclusion in moDCs with success (Koya et al., 2003; Lizee et
al., 2004; Dupuy et al., 2005).
Some comparisons of different transgene promoters have been made. The most
commonly used are constitutively active promoters such as the phosphoglycerate
kinase promoter (PGK), the promoter of elongation factor 1-α (EF1α) and the
cytomegalovirus (CMV) immediate early promoter (Dullaers and Thielemans,
2006). Dupuy et al. made a direct comparison of transgene expression from either
an EF1α or a CMV promoter in different vectors and different cell types. In
moDCs, HIV-1-based vectors with the EF1α promoter resulted in significantly
higher levels of transgene expression than those with the CMV promoter (Dupuy et79
al., 2005). This was in contrast to DCs derived from CD34-positive progenitors,
which showed better transgene expression from the CMV promoter. To the best of
my knowledge, there is no reported use of the spleen focus-forming virus promoter
(SFFV; the promoter in the vector used in the work described in this thesis) in
moDCs. However, the SFFV promoter results in improved transgene expression as
compared to the CMV promoter in CD34+ haematopoietic stem cells and other
cells of the myeloid lineage (Demaison et al., 2002; Yam et al., 2002).
1.5 Aims and Hypothesis
There are several lines of evidence to indicate that KS oncogenesis is associated
with the loss of KSHV-specific T cells. Although some KSHV epitopes have been
identified, neither the breadth of the KSHV-specific T-cell response, nor its
immunodominant targets, are fully understood. Furthermore, the phenotype and
function of KSHV-specific T cells remain largely unexplored. The aim of this PhD
thesis was to characterise further the T-cell response against KSHV. My initial
hypothesis was that the KSHV gene products that elicit the strongest T-cell
responses are those that are expressed early in the viral lytic cycle, as this is the
pattern observed in the T-cell response against EBV (the most closely related
human herpesvirus to KSHV) (Rickinson and Moss, 1997; Pudney et al., 2005;
Landais et al., 2005a). Early in the lytic cycle is also the time when it is most
important for the host to keep the virus in check in order to prevent uncontrolled
replication.80
Lentiviral-transduced moDCs have proved to be powerful tools for priming immune
responses both in vitro and in vivo, and have the advantage of providing an
autologous system for optimal antigen presentation without requiring prior
knowledge of HLA-restriction or the immunodominant epitopes from within an
ORF. Members of the Cancer Research UK Viral Oncology Group at University
College London previously constructed a library of lentiviral expression vectors,
each coding for one of 26 key KSHV ORFs for use in experiments investigating the
precise effects of different KSHV ORFs on the host cell (Vart et al., 2007). These
26 genes are indicated by a single asterisk in Table 1.1. It was thus proposed to
utilise this lentiviral library to transduce moDCs and then use these transduced
moDCs (which present KSHV antigens) in culture with autologous T cells to
investigate further the targets of the KSHV-specific CD8 and CD4 T-cell responses.
The first aim of this thesis was, therefore, to perform preliminary experiments to
prepare for and design a protocol to use lentiviral-transduced moDCs to screen for
immunogenic KSHV ORFs. The KSHV lentiviral library was first expanded to
include five further KSHV ORFs that are known or putative T-cell immunogens
(also indicated on Table 1.1). This expanded library was then used to transduce
moDCs and expression of each of the KSHV ORFs within the library by the
moDCs was demonstrated. A GFP-encoding lentiviral construct was used to
optimise transduction conditions for moDCs (multiplicity of infection and time-
point) and to ensure that lentiviral transduction did not affect the antigen-presenting
surface phenotype of moDCs or their maturation. moDCs transduced with an
adenovirus expressing the immunodominant CMV gene phosphoprotein 65
(CMVpp65) were used to determine the best culture conditions (culture medium81
serum supplement and maturation stimulus) for moDCs for use in such assays, and
to refine a CFSE dye-based assay for measuring T-cell responses. Based on the
results of these experiments, a protocol for the use of the KSHV lentiviral library to
screen for immunogenic KSHV ORFs was developed.
The second aim of this thesis was to use the KSHV lentiviral library to perform a
large-scale screen to identify the targets of the KSHV-specific CD4 and CD8 T-cell
responses. moDCs from 14 KSHV-seropositive individuals (12 HIV-positive, two
HIV-negative) were transduced with KSHV-ORF-encoding lentiviral vectors and
then cocultured with autologous T cells. A CFSE dye-based T-cell response assay
was used to assess which of the KSHV ORFs yield antigens that are recognised by
CD8 and CD4 KSHV-specific T cells.
The third and final aim of this thesis was to identify potential new KSHV CD8
epitopes, and to compare recognition of these epitopes with recognition of nine
previously published epitopes in order to determine patterns of immunodominance.
Pentamer staining was proposed for the investigation of the memory phenotype and
function of KSHV-specific CD8 T cells upon the identification of an
immunodominant epitope to target in such studies. Potential new epitopes were
identified from within KSHV ORFs indicated as strongly immunogenic by our
lentiviral-based experiments. The MHC-binding properties of these peptides were
investigated and the peptides that formed the strongest complexes with HLA-
A*0201 were identified. Responses to these peptides were tested in 18 A*0201-
positive KSHV-seropositive individuals, and compared to responses to nine
previously published A*0201-restricted KSHV epitopes. The memory phenotype of82
the whole population of circulating CD8 T cells in KSHV-infected individuals in
chronic infection and disease was also investigated. Finally, the use of pentamers in
conjunction with staining for cell-surface markers and the production of
intracellular cytokines to investigate the memory phenotypes functional properties
of virus-specific T cells was investigated.83
CHAPTER 2: Materials and Methods
2.1 Lentivirus Production
2.1.a Cloning KSHV ORFs into the Lentiviral Vector
i. Preparation of Plasmids pSIN-MCS, p8.91 and pMD.G
The lentiviral vector (pSIN-MCS) was previously derived by members of the
Cancer Research UK Viral Oncology Group at University College London from the
green fluorescence protein (GFP)-encoding vector pCSGW (a kind gift from
Professor Adrian Thrasher, Institute of Child Health, University College London).
The two packaging plasmids (p8.91 and pMD.G) were a kind gift from Professor
Didier Trono, l’École Polytechnique Fédérale de Lausanne, Switzerland).
The three plasmids were prepared from glycerol stocks as follows. Luria-Bertani
(LB) Broth (Sigma, Poole, UK) and plates of LB Agar (Sigma) were prepared
according to the manufacturer’s instructions and supplemented with 100µg/ml
ampicillin (Amp, Sigma). Glycerol stocks of transformed bacteria containing each
of the plasmids were streaked onto LB Amp Agar plates and incubated overnight at
37ºC. The following morning single colonies were picked and used to inoculate
starter cultures of 5ml of LB Amp Broth which were shaken at 200rpm and 37ºC
for 8 hours (hr) and then used to inoculate 250ml LB Amp Broth in conical flasks.
These large cultures were shaken at 200rpm and 37ºC overnight. The following84
morning, a Maxiprep Kit (Qiagen, Hilden, Germany) was used following the
manufacturer’s instructions to isolate plasmid DNA. At the end of the procedure the
DNA pellet was resuspended in 500µl double-distilled (dd) H2O.
ii. PCR Amplification of KSHV ORFs of Interest
For each of the novel KSHV ORFs of interest (ORF8, ORF57, ORF59, ORF61 and
ORF65), primers were designed for the 5’ and 3’ ends of the gene according to the
National Center for Biotechnology Information (NCBI)’s published KSHV genome
sequence (NC 003409). Restriction sites complementary to those present in the
multiple cloning site (MCS) of the pSIN-MCS vector were added to each primer to
allow for directional cloning of each KSHV ORF into pSIN. In addition, “junk
DNA” was added to each primer to enhance restriction site recognition by
restriction enzymes, as recommended by New England Biolabs. Table 2.1 shows
the primers designed for each KSHV ORF.
In order to minimise the introduction of point mutations in the PCR product, the
proof-reading enzyme Pfu Ultra (Stratagene, La Jolla, CA, USA) was used to
amplify KSHV ORFs from genomic DNA from BC-3 cells (a KSHV-positive,
EBV-positive cell line). The basic PCR reaction mix (total volume 50.0µl) was:
5.0μl Pfu Ultra PCR Buffer (10x); 38.5μl ddH2O; 2.0μl forward primer (10μM);
2.0μl reverse primer (10μM); 1.0μl dNTPs (10mM, Invitrogen); 1.0μl BC-3 DNA
template; and 0.5μl Pfu Ultra Enzyme. A DNA Engine Dyad™ Peltier thermal
cycler was used to perform the PCR amplifications. The basic PCR programme
used for each amplification was: 95ºC for 2 minutes (mins); 35 cycles of85
denaturation at 95ºC for 1 min, annealing at XºC for 1 min and extension at 72ºC
for Y mins; and 72ºC for 5 mins. A heated lid (110ºC) was used to prevent reaction
evaporation. X and Y were variable parameters dependent on the annealing
temperature of the primers (X) and the length of the KSHV ORF (Y). For each
KSHV ORF, the parameters used were: ORF 8: X = 56, Y = 2.5; ORF57: X = 60, Y
= 0.75; ORF59: X = 58, Y = 1.25; ORF61: X = 58, Y = 2.5; ORF65: X = 60, Y =
0.5.
KSHV
ORF
Forward Primer (Top) and Reverse Primer (Bottom)
(5’………..3’)
ORF 8 CGCGGATCCATGACTCCCAGGTCTAGATTG
ATAAGAATGCGGCCGCTCACTCCCCCGTTTCCGG
ORF 57 CGCGGATCCATGATAATTGACGGTGAGAG
ATAAGAATGCGGCCGCTTAGAAAGTGGATAAAAGAATAAAC
ORF 59 CGCGGATCCATGCCTGTGGATTTTCACTATG
ATAAGAATGCGGCCGCTCAAATCAGGGGGTTAAATGTG
ORF 61 CGCGGATCCATGTCTGTCCGGACATTTTG
ATAAGAATGCGGCCGCCTACTGACAGACCAGGCACTCG
ORF 65 CGCGGATCCATGTCCAACTTTAAGGTGAG
ATAAGAATGCGGCCGCCTATTTCTTTTTGCCAGAGG
After amplification, the PCR products were visualised and purified by gel
electrophoresis followed by gel extraction. One percent weight/volume agarose
(Sigma) gels were prepared in TAE buffer (tris-acetate 0.4M, ethylene diamino
tetraacetic acid [EDTA] 0.01M). PCR products were diluted 5:1 with loading dye
TABLE 2.1: Primers used to amplify KSHV genes from BC-3 DNA. BOLD text
indicates ‘junk’ DNA used to enhance restriction site recognition. BOLD
UNDERLINED text indicates restriction site. REGULAR text indicates gene-specific
primer sequence. GGATCC is the restriction site for BamHI and CGC is the ‘junk’
DNA sequence appropriate for improved BamHI restriction site recognition.
GCGGCCGC is the restriction site for NotI and ATAAGAAT is the ‘junk’ DNA
sequence appropriate for improved NotI restriction site recognition.86
(Fermentas, York, UK) and run in parallel with a 1kb ladder (New England Biolabs,
Ipswich MA, USA). Electrophoresis was performed at 100 volts for approximately
1 hr. Gels were visualised with a UV transilluminator and photographed using a
VersaDoc imaging system (Bio-Rad). Bands were excised using a UV light box
(Anderman), and DNA was purified using a QIAquick Gel Extraction Kit (Qiagen)
according to the manufacturer’s instructions. At the end of the protocol, DNA was
eluted in 30µl ddH2O and the concentration of DNA in the elutant was measured
using a NanoDrop spectrophotometer (NanoDrop Technologies, Wilmington, DE,
USA).
iii. Restriction Enzyme Digestion of the PCR Product and the pSIN-MCS
Vector
The purified PCR product and pSIN plasmid were digested with the appropriate
restriction enzymes in preparation for ligation. For all five KSHV ORFs, the
restriction sites BamHI and NotI were used. PCR products were digested in a
24.0µl reaction as follows: 20.5µl purified PCR product; 2.5µl Restriction Enzyme
Buffer D (New England Biolabs); 1.0µl Not I (New England Biolabs). The reaction
was incubated at 37ºC overnight. The following morning, 1.0µl BamHI was added
to the reaction mix (to make 25.0µl volume) and incubated for a further 2 hr at
37ºC.
Digested PCR products were purified using a QIAquick Gel Extraction Kit
(Qiagen). Digested PCR products were not run on an agarose gel prior to
purification. Instead, 300µl of Buffer QG was added directly to the digestion87
mixture and then the protocol was followed according to the manufacturer’s
instructions omitting the incubation to dissolve the gel slice. At the end of the
protocol the digested PCR products were eluted in 25µl ddH2O and quantified using
a NanoDrop spectrophotometer (NanoDrop Technologies). Digested PCR products
were stored at -20ºC.
The pSIN vector was digested in a 20.0µl reaction as follows: Xµl (volume
calculated to be equivalent to 1-2µg) pSIN vector; 2.0µl Buffer D (New England
Biolabs); 1.0µl NotI (New England Biolabs); 1.0µl BamHI (New England Biolabs);
(20.0 – X) µl ddH20. The reaction mix was incubated at 37°C for 2 hr. Due to the
presence of the MCS in the reaction mix after digestion, the digested vector was
purified by running the reaction mix on a 1% agarose gel (Sigma, prepared as
above) at 100V for 1 hr. The digested vector was then excised from the gel and
purified using a QIAquick Gel Extraction Kit (Qiagen) as above.
iv. Ligation of the KSHV Gene Insert into the pSIN-MCS Vector
After digestion and purification of the inserts and vector, each KSHV ORF was
ligated into pSIN using T4 DNA ligase (New England Biolabs). A ligation reaction
mix of a total volume of 20.0µl was used, containing insert and vector to a molar
ratio of 8:1. Ligation reactions (total volume 20.0μl) were set up as follows: Xµl
(=100ng) digested pSIN vector; Yµl (8:1 molar ratio to vector) digested KSHV
gene insert; 2.0µl Ligation Buffer (10x; New England Biolabs); 1.0µl T4 Ligase
(New England Biolabs); (17.0 – X – Y) µl ddH2O. Ligation reactions were88
incubated at room temperature for 1 hr, with the exception of the ORF8 ligation
reaction, which was incubated at 16ºC overnight.
v. Plasmid Amplification by Bacterial Transformation
After ligation, plasmids containing the KSHV ORF inserts were amplified by
transformation of chemically competent bacteria. Two microlitres of ligation mix
was used to transform one vial of One Shot® TOP10 Chemically Competent E. coli
cells (Invitrogen, Paisley, UK) following the manufacturer’s instructions. At the end
of the protocol, the transformation mix was plated on LB Amp plates and incubated
overnight at 37ºC. Transformed bacteria carrying the ampicillin-resistance gene
encoded by pSIN formed colonies on the LB Amp plates. Eight single colonies
were picked and used to inoculate individual 5ml cultures of LB Amp Broth.
Inoculated cultures were left shaking overnight at 37ºC and 200 rpm. The following
morning the bacterial suspension was spun at 3000 rpm for 15 mins. The
supernatant was discarded, and plasmid DNA was isolated from the bacterial pellet
using a QIAprep Spin Miniprep Kit (Qiagen) according to the manufacturer’s
instructions. At the end of the protocol, plasmid DNA was eluted in 50µl ddH2O.
Plasmid DNA was then stored at -20ºC.
vi. Confirming the Presence of a KSHV ORF Insert in the pSIN-MCS
Vector
To screen each plasmid DNA solution for the presence of each KSHV ORF insert
in the pSIN vector, plasmids were digested with the same restriction enzymes used89
to insert the KSHV ORF into the MCS of the pSIN vector. Restriction digestions
(total volume 15.0µl) were set up as follows: 5.0µl plasmid DNA solution; 1.5µl
Buffer D (New England Biolabs); 1.0µl NotI (New England Biolabs); 1.0µl BamHI
(New England Biolabs); 6.5µl ddH2O.
Restriction digestions were incubated at 37ºC for 1 hr and then visualised by gel
electrophoresis. Three microlitres of loading dye (Fermentas) was added to 15µl
restriction digestion mix and samples were loaded on to a 1% agarose gel (prepared
as above) alongside a 1kb ladder (New England Biolabs). Electrophoresis was
performed at 100v for approximately 1 hr. Gels were visualised with a UV
transilluminator and photographed using a VersaDoc imaging system (BioRad).
Plasmid DNA solutions were assessed for presence of the linearised vector (10kb)
and a second DNA fragment of the correct length for the inserted KSHV ORF.
vii. Sequencing the KSHV ORF Inserts
Plasmids containing the desired KSHV ORF were sequenced to ensure that there
were no mutations in the insert that may have occurred during PCR or due to
recombination during transformation. For all sequencing, the SFFV_MOD forward
primer and pSIN_rev primer were used, as these primers bind to pSIN at either side
of the MCS. For inserts larger than 500bps, internal primers were also used in order
to sequence the entire length of the insert. Sequencing was carried out by the
Scientific Support Services at the Wolfson Institute for Biomedical Research, UCL,
on a Beckman Coulter CEQ 8000 using WellRed dye-terminator chemistry
(Beckman Coulter, Fullerton, California, USA). Sequence data was analysed using90
Bioedit software and insert sequences were compared to the published KSHV gene
sequences (NC 003409; NCBI) using the NCBI’s Basic Local Alignment Tool
(BLAST) software.
2.1.b Lentivirus Production: 293T Transfection
Thirty millilitres of each KSHV ORF-encoding lentivirus (including the five ORFs
cloned into the vector as outlined above as well as the 26 ORFs already present in
the lentiviral library, listed in Table 2.3 and indicated in Table 1.1), plus the empty
lentiviral vector and the GFP-encoding lentivirus, were produced by transfection of
293T cells. Twenty-four hours before transfection, confluent 10cm culture dishes
(Corning Incorporated, New York, USA) of 293T cells were split 1:7, and replated
on 10cm culture dishes. For each lentivirus, three 10cm plates were transfected
using the transfection reagent Fugene (Roche, Basel, Switzerland) following the
manufacturer’s instructions.
One hour prior to transfection, 293T cells were washed once with sterile phosphate
buffered saline (PBS; Sigma), and culture media was replaced with 8ml Optimem
(Gibco, Invitrogen, Paisley, UK). Cells were returned to a 37ºC, 5% CO2 incubator.
For each plate of cells to be transfected, a Fugene master mix was prepared from
15µl Fugene and 35µl Optimem and incubated at room temperature for 5 mins.
DNA mixes were prepared as follows. For each plate, a total of 5µg of DNA was
used, consisting of 1.5µg p8.91, 1.5µg of pMD.G and 2µg of pSIN (either empty
vector, or encoding GFP or KSHV ORF of interest). Each DNA mix was prepared
to a final volume of 50µl per plate in Optimem. Fugene mix was then added directly91
to the DNA mix, and incubated for 20 mins at room temperature. 100µl
Fugene/DNA mix was then added drop-wise to each plate of 293T cells, and plates
were returned to the incubator for 5 hr. After this incubation, cells were washed
once in PBS, and Optimem was replaced with 10ml DMEM (Gibco) supplemented
with 10% FCS (Sigma, Poole, UK) and penicillin-streptomycin (Sigma). Plates
were then returned to the incubator. After 48 hr, virion-containing supernatant was
harvested by careful aspiration, filtered through a 45µm filter (Nalgene, Rochester,
NY, USA), divided into 1ml aliquots, and immediately stored at minus 80ºC.
2.2 Culture and Transduction of Monocyte-derived Dendritic
Cells
2.2.a PBMC Isolation
Peripheral blood samples were collected from consenting volunteers into lithium
heparin tubes (BD Biosciences, Oxford, UK). Monocyte-derived dendritic cells
(moDCs) were isolated from peripheral blood following an established protocol
(Sallusto and Lanzavecchia, 1994). Briefly, whole blood was diluted 1:2 with PBS.
Four parts blood/PBS was layered over one part Histopaque-1077 (Sigma) and spun
in a Mistral 3000E centrifuge (MSE, London, UK) at 2000rpm for 30 mins at room
temperature with the brake off. Peripheral blood mononuclear cells (PBMCs) were
collected from the interface and washed three times in PBS + 1% foetal calf serum
(FCS; Sigma).92
2.2.b moDC Isolation, Culture and Maturation
PBMCs were resuspended in 80µl MACs Buffer [2mM EDTA (Gibco) in
PBS/2%FCS] per 10
7 cells and 20µl CD14+ MACs Beads (Miltenyi Biotech,
Bergisch Gladbach, Germany) per 10
7 cells, and incubated at 4°C for 15 mins.
PBMCs were then washed in 2ml MACs Buffer per 10
7 cells, resuspended in 500µl
MACs Buffer and passed through an equilibrated MS column (Miltenyi Biotech).
The MS column was washed three times with 500µl MACs Buffer and CD14-
negative cells were collected in the flow-through. CD14-positive cells were eluted
in 1ml MACs Buffer. Both CD14-negative and CD14-positive monocytes were
washed twice in PBS/1%FCS. CD14-negative cells were stored at -80ºC in a freezer
mix made up from 50% RPMI 1640 (Sigma), 40% FCS and 10% dimethyl
sulfoxide (DMSO; Sigma), and reserved for later isolation of T cells (see section
2.3.a).
CD14-positive monocytes were plated on 24-well plates (Cellstar, Greiner Bio-one,
Gloucestershire, UK) at 3 x 10
5 cells per well and cultured in RPMI 1640 with
Hepes modification (Sigma) supplemented with l-glutamine (Sigma), penicillin-
streptomycin (Sigma) and either Human AB Serum (Lot Number 027K0432;
Sigma) at a final concentration of either 2% or 5%, or FCS (Sigma) at a final
concentration of 10%. The cells were further supplemented with 75ng/ml
interleukin 4 (IL4; R and D Systems, Oxford, UK) and 75ng/ml
granulocyte/macrophage colony-stimulating factor (GMCSF; R and D Systems) in
order to drive differentiation into immature moDCs. Cells were fed with fresh
media and cytokines every second day. Immature moDCs were matured by93
stimulation with either 20ng/ml lipopolysaccharides (LPS; Sigma) for 24 hr or a
“cytokine cocktail” made up from 1µg/ml prostaglandin E2 (PGE2; Sigma), 5ng/ml
TNFα (R and D Systems), 5ng/ml IL1ß (R and D Systems) and 150ng/ml IL6 (R
and D Systems) for 48 hr.
2.2.c Flow Cytometric Analysis of Cell-surface Marker
Expression by moDCs
moDCs were analysed for expression of cell-surface markers by multi-parameter
flow cytometry. All antibodies and isotype controls used were purchased from BD
Biosciences and are shown in Table 2.2. GFP-transduced moDCs were not stained
with antibodies conjugated to FITC, as GFP expression is measured through
fluorochrome 1. GFP-transduced moDCs were therefore only stained for expression
of the cell-surface markers MHC-I, CD80, CD83 and CD40.
moDC
cell-
surface
molecule
Fluoro-
chrome
Clone Antibody
Catalogue
Number
Isotype Isotype
Control
Clone
Isotype
Catalogue
Number
MHC-I APC G46-2.6 555555 IgG1κ MOPC-21 555751
HLA-DR FITC TU36 555560 IgG2bκ 27-35 555742
CD80 PE L307.4 340294 IgG1κ MOPC-21 555749
CD86 FITC 2331 555657 IgG1κ MOPC-21 555748
CD40 PECy5 5C3 555590 IgG1κ MOPC-21 555750
CD83 PE HB15e 556855 IgG1κ MOPC-21 555749
TABLE 2.2: Antibodies and isotype controls used for characterisation of moDCs
by immunostaining and flow cytometry. All antibodies were mouse anti-human, and
all isotype controls were from mice.94
For all staining, moDCs were harvested by aspiration, spun at 1400 rpm for 8 mins
and resuspended in 95µl PBS/1%FCS. Five microlitres of antibody or isotype
control was added to give a final antibody dilution of 1 in 20. Cells were stained on
ice for 30 mins, protected from light. Cells were then washed once in PBS/1%FCS,
and resuspended in 250µl PBS/1%FCS. Four-colour flow cytometric analysis was
performed on a FACSCalibur (BD Biosciences) and analysed with CELLQuest (BD
Biosciences) software. Ten thousand events were collected for each sample. moDCs
were gated on the live-cell population according to the expected forward scatter and
side scatter. Isotype controls were used to set gates for positive staining for each of
the antibodies used to detect cell-surface marker expression.
2.2.d Transduction of moDCs with a GFP-encoding Lentivirus
On day four in culture, immature moDCs were transduced with a pSIN lentivirus
encoding GFP (pCSGW). pCSGW lentivirus was thawed on ice for 30 mins, and
then warmed to 37ºC in a water bath directly prior to use. Lentivirus was added
directly to the cells in their culture dishes. After transduction, moDCs were fed
every second day with fresh media and cytokines.
i. Time-point Optimisation
Immature moDCs were transduced with 1ml pCSGW per well. On days four, five,
six and seven post-transduction, moDCs were harvested by aspiration, spun at
1400rpm for 8 mins, resuspended in 250µl PBS/1%FCS and analysed for GFP
expression by flow cytometry performed on a FACSCalibur (BD Biosciences).95
Non-transduced moDCs were used as a negative control and 10, 000 events were
collected for each sample.
ii. Multiplicity of Infection
Immature moDCs were transduced with 50µl, 100µl, 300µl, 1ml or 1.5ml pCSGW
per well. On day six post-transduction, moDCs were harvested by aspiration for
either flow cytometric analysis of GFP expression (section 2.2.d.i) or DNA
extraction to determine the multiplicity of infection (MOI) by quantitative real-time
PCR (qPCR). For DNA extraction, cells were pelleted and washed once in PBS.
DNA extraction was performed using a QIAamp DNA Mini Kit (Qiagen) according
to the manufacturer’s instructions. At the end of the protocol, DNA was eluted in
70µl AE Buffer and four aliquots were prepared for future use to avoid sample
contamination. DNA solutions were quantified using a NanoDrop
spectrophotometer (NanoDrop Technologies).
qPCR was performed in sterile conditions in an isolated, DNA-free laboratory to
avoid sample contamination. To determine the number of lentiviral copies per cell,
qPCR was performed for the lentiviral packaging signal using the glyceraldehyde 3-
phosphate dehydrogenase (GAPDH) gene as the reference signal. GAPDH primers
and probes were used as previously described (Bourboulia et al., 2004) and as
follows: GAPDH forward primer 5’-GGAGTCAACGGATTTGGTCGTA-3’;
GAPDH reverse primer 5’-GGCAACAATATCCACTTTACCAGAGT-3’;
GAPDH TaqMan probe 5’-FAM-CGCCTGGTCACCAGGGCTGC-3’-TAMRA.
Primers were used at a final concentration of 0.7μM and probe at 0.15 μM. The96
primers and probe for the lentiviral packaging signal and their concentrations were:
Lenti forward primer 5’-GCACGGCAAGAGCGA-3’ (0.3μM); Lenti reverse
primer 5’-CGCACCCATCTCTCTCCTTCTA-3’ (0.3μM); Lenti TaqMan probe 5’-
FAM-CGGCGACTGGTGATACGCCAAAAAT-3’-TAMRA (0.15μM). Each
reaction contained 25.0μl 2x Absolute QPCR ROX and dUTP mix (ABgene
Limited, Epsom, UK) and 10.0μl genomic DNA (concentration 50-100 ng/μl) and
were made up to a total final volume of 50.0μl with ddH2O. Reactions were
performed in duplicate and run alongside: standard DNA mixes containing a known
number of copies of either linearised pcDNA3.1/V5-His-TOPO GAPDH (GAPDH
standard) or linearised pSIN plasmid vector (Lenti standard); non-transduced moDC
DNA samples; and ddH2O negative controls. qPCR was carried out on a Perkin-
Elmer 7700 sequence detector (Perkin-Elmer Applied Biosystems, Waltham,
Massachusetts, USA) using the following conditions: 50ºC for 2 mins; 95ºC for 15
mins; 40 cycles of 95ºC for 15 seconds (secs) followed by 60ºC for 1 min.
Lentiviral copy number per cell was determined by adjusting the number of
lentiviral particles per sample to the number of cells present in that sample (as
determined by the number of copies of GAPDH present).
2.2.e Transduction of moDCs with the KSHV Lentiviral Library
moDCs were cultured in RPMI supplemented with 5% human AB serum. On day
four in culture, moDCs were singly transduced with 300µl of each of the
lentiviruses encoding KSHV ORFs from the lentiviral library. Lentiviral
preparations were thawed on ice for 30 mins then warmed to 37ºC in a water bath
directly prior to use. Lentivirus was added directly to cells in their culture dishes.97
After transduction, moDCs were fed with fresh media and cytokines every second
day. On day eight in culture (day four post-transduction), moDCs were matured by
stimulation with a “cytokine cocktail” (see section 2.2.b). On day 10 in culture (day
six post-transduction), moDCs were harvested by aspiration, pelleted and stored at -
80ºC. Cell pellets were thawed on ice, and either RNA was extracted to confirm
viral gene expression through the creation of cDNA libraries, or DNA was extracted
in order to determine lentiviral copy number per cell for moDCs transduced with
each of the different lentiviruses.
i. Confirmation of Viral Gene Expression by RT-PCR
RNA was extracted from cell pellets using an RNeasy kit (Qiagen) according to the
manufacturer’s instructions including the optional DNase steps to ensure no
contamination from plasmid DNA. At the end of the protocol, RNA was eluted in
25.0µl RNase-free water. The RNA was used as a template to synthesise cDNA by
reverse transcription using SuperScript® II Reverse Transcriptase (Invitrogen)
according to the manufacturer’s instructions. The resulting cDNA was used as a
template to confirm viral gene expression by reverse transcription (RT)-PCR. PCR
primers were designed for each ORF according to the published KSHV genome
sequence (NC 003409; NCBI). Table 2.3 shows the primers used for each ORF.
PCR products were visualised by gel electrophoresis as described above. PCR
reactions (total volume 50.0µl) were set up as follows: 38.5µl ddH2O; 5.0µl Taq
10x Buffer (Invitrogen); 2.0µl forward primer (10μM); 2.0µl reverse primer
(10μM); 1.0µl DNTPs (10Mm; Invitrogen); 1.0µl cDNA or no reverse-transcriptase
control; 0.5µl Taq Polymerase (Invitrogen). PCR was performed using a DNA98
KSHV
ORF
Forward Primer
(5’………..3’)
Reverse Primer
(5’………..3’)
K1 GCAACGATACTCGGCTTCTC TGATGGTTGTCCACACAAGG
K2 ATGGGTGATCGATGAATGCT ATCGGCGAGCTTTTTAAGG
K3 GAGAGCTCGAGAACGTCCAT TTCCAGACCCTCCTGGTAAG
K4 ATGGACACCAAGGGCATCCTG TCAGCGAGCAGTGACTGGTAAT
K4.1 GAGAATTCCCTGTCCAGTGC ATCTCCGTGTGCTTCTCCAT
K5 GGTGACCGTACTGCCATACC CGTCACGTTCTTTGTCTCCA
K6 CTGCGTTAGCGTACGCTTG TCAGCTGCCTAACCCAGTTT
K8 AAGCTCGCTGTTGTCAACCT ATCTGCGAGTTGGAAGCTGT
K8.1 CACCACAGAACTGACCGATG GTAGTGCGCGTCTCTCTTCCTC
K9 GCGTCAATCAAGGATTGGAT CTTGCAAGAGACGTGCCATA
K11.1 GGAATGGCTCACGGACTTTA CTCAGTCTCCGGGATTTCTG
K12 AGGCTTAACGGTGTTTGTGG CTCGTGTCCTGAATGCTACG
K14 CCAGGAGCAGTTCACTGACA TAGGCCCACCAGAGTAATGG
K15-P CCTATGCTTGCTTAATCACCAC GGACCAGCATGTTTGTCATC
ORF8 ATGACTCCCAGGTCTAGATTG TCACTCCCCCGTTTCCGG
ORF28 CTGCGTCTACTGCTGCATTC AGGGCTCCTGGGTAGCTATG
ORF33 GTCGCCGGGTCTATCTAACA GGGGTTGGGTGGCTAGTTAT
ORF36 TGGGAGCAAGTGGACTAACC GTGTAGCCCAACGAGGACAT
ORF37 ATGGAGGCCACCCCCACACC TTCCACGTCTACGGGCTGTGAG
ORF45 CATGGGATGGGTTAGTCAGG GGGTCGCTGTATGGTGAACT
ORF49 GCACGTCCCTAACTCTCCTG AATGGTGTAGGTGGGAGCAG
ORF50 CAAGGTGTGCCGTGTAGAGA TCCCAAAGAGGTACCAGGTG
ORF57 ATGATAATTGACGGTGAGAG TTAGAAAGTGGATAAAAGAATAAAC
ORF58 GCCGCCAATAGTACACAGGT TGCCTAAATGCAAAAGTCC
ORF59 ATGCCTGTGGATTTTCACTATG TCAAATCAGGGGGTTAAATGTG
ORF61 ATGTCTGTCCGGACATTTTG CTACTGACAGACCAGGCACTCG
ORF65 ATGTCCAACTTTAAGGTGAG CTATTTCTTTTTGCCAGAGG
ORF71 AGCTGTGTGCGAGGGATATT GGCGATAGTGTTGGGAGTGT
ORF72 ACGAGGTCAACACCCTGATT CGCCTGTAGAACGGAAACAT
ORF73 TTGCCACCCACGCAGTCT GGACGCATAGGTGTTGAAGAGTCT
ORF74 CGCTGCACTGTTAATTGCAT GTCGCCTTAGCAGAGTGTCC
TABLE 2.3: Primers used to detect expression of KSHV ORFs by transduced
moDCs using reverse transcription PCR.99
Engine Dyad™ Peltier thermal cycler. The typical PCR programme used for each
ORF’s amplification was 95ºC for 15 mins; 40 cycles of denaturation at 95ºC for 1
min, annealing at 56ºC for 1 min and extension at 72ºC for 1 min; and 72ºC for 5
mins. Exceptions to this were ORF8, ORF57, ORF59, ORF61 and ORF65, for
which the PCR programmes used were the same as described in section 2.1.a.ii; and
K4, ORF 37 and ORF 73, for which the PCR programmes used are shown in Table
2.4.
Temperature and Time Step Process
K4 ORF 37 ORF 73
1 Start 95ºC, 15 mins 95ºC, 15 mins 95ºC, 15 mins
2 Denaturation 95ºC, 1 min 95ºC, 1 min 95ºC, 30 secs
3 Annealing 54ºC, 1 min 64ºC, 1 min 60ºC, 30 secs
4 Extension 72ºC, 45 secs 72ºC, 2 mins 72ºC, 15 secs
5 Repeat steps 2-4 for 35 cycles
6 Finish 72ºC, 5 mins 72ºC, 5 mins 72ºC, 5 mins
7 End 4ºC Forever 4ºC Forever 4ºC Forever
ii. Titre of Lentivirus by qPCR.
DNA was extracted from cell pellets using a QIAamp DNA Mini Kit (Qiagen)
according to the manufacturer’s instructions. qPCR was performed in sterile
conditions as described in section 2.2.d to determine the MOI of each lentiviral
preparation.
TABLE 2.4: PCR programmes used to confirm KSHV gene expression by
transduced moDCs using reverse transcription PCR.100
iii. Multiple Transductions
Seven wells of moDCs were transduced simultaneously with one, two or three
different KSHV-ORF-encoding lentiviral constructs (see section 3.2.d; Figure
3.12). Transductions were normalised to an MOI of approximately 6 for each
construct. On day six post-transduction, RNA was extracted from which cDNA was
synthesised and RT-PCR performed as outlined in section 2.2.e.i.
2.2.f Transduction of moDCs with an Adenovirus Encoding the
CMV Gene Phosphoprotein 65
moDCs transduced to express the immunodominant CMV gene phosphoprotein 65
(CMVpp65) were used to refine and establish protocols for T-cell response assays,
and later as a positive control when investigating the immunogenic profile of
KSHV. Unfortunately, all attempts at cloning the CMV gene phosphoprotein 65
(CMVpp65) into the lentiviral vector using the methods outlined in Materials and
Methods section 2.1.a were unsuccessful (discussed in more detail in section 3.1.b).
Therefore, an adenovirus encoding CMVpp65 (Adpp65) was used to transduce
moDCs.
Adpp65 was a kind gift from Dr. Magnus Essand of Uppsala University and used as
previously described (Carlsson et al., 2003). Briefly, on day eight in culture,
immature moDCs were harvested by aspiration, spun at 1400rpm for 8 mins,
washed once in PBS, counted using a disposable Glasstic® haemocytometer (Hycor
Biomedical Ltd., Pencuik, UK) and resuspended in 250µl media. moDCs were101
transduced with Adpp65 (thawed on ice for 30 mins prior to use) to a final MOI of
300, at 37ºC for 2 hr. moDCs were then plated on 24-well plates (Cellstar) in
medium to a final volume of 1ml per well. moDCs were supplemented with
75ng/ml IL4 (R and D Systems) and 75ng/ml GMCSF (R and D Systems) in order
to maintain an immature phenotype or stimulated with a “cytokine cocktail” to
induce maturation (see section 2.2.b). On day two post-transduction (day 10 in
culture), moDCs were harvested by aspiration and cultured with autologous T cells
(see section 2.3.d). Expression of pp65 by moDCs was confirmed by RT-PCR using
the same protocol as for the KSHV ORFs (section 2.2.e.i). The primers for pp65
were: Forward, 5’ ATGATATCCGTACTGGGTCCC 3’; and reverse, 5’
CGGGTCTTCGTGGGAGGTC 3’. The PCR programme was 95ºC for 2 mins; 40
cycles of 95ºC for 1 min, 60ºC for 1 min, 72ºC for 2 mins; and 72ºC for 7 mins.
2.3 T-cell Response Assays
2.3.a T-cell Isolation
T cells were isolated from fresh or cryogenically preserved CD14-negative PBMCs
using a standard protocol for immunodepletion to avoid activating the cells. A Pan
T-cell Isolation Kit (magnetic beads labelled with monoclonal antibodies directed
against CD14, CD16, CD19, CD36, CD56, CD123 and Glycophorin A; Miltenyi
Biotec) was used according to the manufacturer’s instructions. Briefly, cells were
resuspended in 40µl MACs Buffer per 10
7 cells and 10µl Biotin Antibody Cocktail
per 10
7 cells, and incubated at 4ºC for 10 mins. 30µl of MACs Buffer per 10
7 cells102
and 20µl Anti Biotin Beads per 10
7 cells was then added to the cells, and the cells
were incubated at 4ºC for a further 15 mins. The cells were then washed once in
5ml MACs Buffer, resuspended in 500µl MACs Buffer and passed through an
equilibrated LS column (Miltenyi Biotech). The LS column was washed three times
with 3ml MACs Buffer, and T cells were collected in the flow-through. The non-T-
cell fraction was discarded. T cells were washed three times in PBS/1%FCS, and
then stained with CFSE (section 2.3.b)
2.3.b CFSE Staining
T cells were resuspended in 5µM carboxy fluoroscein succinimidyl ester (CFSE;
Molecular Probes, Invitrogen) solution and incubated at room temperature for 5
mins, then blocked with FCS and incubated at room temperature for a further 15
mins. CFSE-stained cells were washed three times in PBS/1%FCS, and then plated
for culture.
2.3.c Allogenic Mixed Lymphocyte Assays
CFSE-stained T cells were cultured in round-bottomed 96-well plates (Cellstar) at
100,000 cells per well in 200µl T-cell media (RPMI supplemented with 10%
Human AB Serum, l-glutamine and penicillin-streptomycin). T cells were cultured
with allogenic moDCs at four different ratios of moDCs to T cells: 1 to 160, 1 to 80,
1 to 40 and 1 to 20. After six days in culture, T cells were harvested by aspiration
and their CFSE-fluorescence was measured by flow cytometry performed on a103
FACSCalibur (BD Biosciences). Fifteen thousand events were collected for each
sample. The data were analysed with CELLQuest software (BD Biosciences).
2.3.d Autologous Memory T-cell Responses Assays
CFSE-stained T cells were cultured with moDCs as for allogenic mixed lymphocyte
reactions (section 2.3.c) but with either transduced or non-transduced autologous
moDCs. After six days in culture with moDCs, T cells were harvested by aspiration,
T-cell proliferation was assessed by CFSE fluorescence (section 2.3.b), and T cells
were stained for cell-surface markers and intracellular cytokine production (section
2.3.e). The maximum number of events possible (10 000 – 30 000) were collected
per sample. The data were analysed with CELLQuest software (BD Biosciences).
Gating and controls were performed as described in section 2.3.e.
2.3.e Flow Cytometric Analysis of Cell-surface Marker
Expression and Th1/Th2 Intracellular Cytokine Production
by T cells
For intracellular staining for the production of Th1 and Th2 cytokines, T cells were
cultured with moDCs at a ratio of 20 to 1. After six days in culture, T cells were
stimulated by the addition of 12-O-tetradecanoylphorbol-13-acetate (TPA; Sigma)
to 50ng/ml and ionomycin (Sigma) to 500ng/ml. T cells were then incubated at
37ºC for 1 hr then blocked with 10µg/ml Brefeldin A (BFA; Sigma). T cells were
incubated at 37ºC for a further 4 hr, and then harvested and stained for cell-surface104
marker expression and intracellular cytokine production. All antibodies used were
purchased from BD Biosciences along with their appropriate isotype control and are
shown in Table 2.5.
Cells were washed once in PBS and stained for cell-surface marker expression by
resuspension in 95µl PBS/1%FCS and 5µl of antibody or isotype control to give a
final antibody dilution of 1 in 20. Cells were stained on ice, protected from light for
30 mins. Cells were then washed once in PBS/1%FCS and fixed and permeabilised
by resuspension in 250µl Cytofix™ Fixation Buffer (BD Biosciences) and
incubation on ice for 20 mins. After permeabilisation, cells were washed once in
Cell Permwash (BD Biosciences), and then stained for intracellular cytokine
production by resuspension in 100µl Cell Permwash and 2µl of IFNγ-PE or 1µl
IL4-APC (diluted1:1 in Cell Permwash). Cells were stained on ice for 30 mins,
protected from light. Finally, cells were washed once in Cell Permwash and
resuspended in 250µl Cell Permwash for analysis.
T-cell -
surface
marker or
intracellular
cytokine
Fluoro-
chrome
Clone Antibody
Catalogue
Number
Isotype Isotype
Control
Clone
Isotype
Catalogue
Number
CD8 PECy5 RPA-T8 555368 IgG1κ MOPC-21 555750
CD4 PECy5 RPA-T4 555348 IgG1κ MOPC-21 555750
IFNγ PE 4S.B3 554552 IgG1κ MOPC-21 554680
IL4 APC MP4-
25D2
554486 IgG1κ R3-34 554686
..
TABLE 2.5: Antibodies and isotype controls used for characterisation of T cells by
cell-surface marker expression and intracellular cytokine production. All
antibodies were mouse anti-human and all isotype controls were from mice with the
exception of IL4-APC, which was rat anti-human, and its corresponding isotype control
IgG1к-APC, which was from rat.105
Four-colour flow cytometric analysis was performed on a FACSCalibur (BD
Biosciences) and 15 000 events were collected for each sample. Data were analysed
with CELLQuest software (BD Biosciences). The live lymphocyte gate was set
according to expected forward scatter and side scatter. Isotype controls were used to
set gates for positive staining for each of the antibodies. CFSE fluorescence was
used to gate for proliferating or non-proliferating cells.
2.4 Protocol for a Screen for Immunogenic KSHV ORFs
Using Lentiviral-Transduced moDCs
2.4.a Study Participants
Fourteen KSHV-seropositive (12 HIV-seropositive) and seven KSHV-seronegative
individuals (four HIV positive) were recruited from Chelsea and Westminster
Hospital, London, UK. All participants provided written, informed consent. All
participants were male, apart from one HIV-seropositive KSHV-seronegative
female. Study participants’ age on date of venesection ranged from 30 to 74 years.
All HIV-seropositive individuals were on HAART and had an undetectable HIV
viral load (<50 copies per ml). CD4 counts of HIV-seropositive individuals ranged
from 171 to 785 cells/mm
3. Study participant characteristics are discussed in more
detail in section 4.1.a and summarised in Table 4.1. Individual characteristics of all
HIV-seropositive study participants are shown in Table 2.6.106
Group Participant
ID
Age CD4
Count
HIV
Viral
Load
Receiving
HAART?
KSHV-related
Disease History
KSHV-related
Disease Status
Cancer-specific
Treatment (Tx)
Yrs since
KS/MCD/Tx
C122 70 144 <50 Y None NA NA NA
D403 40 411 <50 Y None NA NA NA
D919 49 174 <50 Y None NA NA NA
2
S810 32 652 <50 Y None NA NA NA
3 H419 56 373 <50 Y None NA NA NA
A556 49 226 <50 Y KS Remission Chemotherapy 3.5
B196 49 209 <50 Y KS Remission Chemotherapy <1
B625 39 406 <50 Y KS Remission None <1
D208 46 785 <50 Y KS Remission Chemo/radiotherapy <1
K058 46 565 <50 Y PEL Remission Chemotherapy 3.5
M620 38 496 <50 Y KS Remission Chemo/radiotherapy 8.5
P940 36 645 <50 Y KS and MCD Remission Chemotherapy <1
S079 74 183 <50 Y KS Remission None 2
T328 40 308 <50 Y KS Remission None <1
T541 51 171 <50 Y KS Remission Chemotherapy 5
4
V689 53 281 <50 Y KS and MCD Remission Chemotherapy 1.5
TABLE 2.6: Individual characteristics of HIV-positive study participants in the screen for immunogenic KSHV ORFs. Y = yes; NA = not
applicable.
1
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2.4.b moDC Isolation, Culture and Transduction with the KSHV
Lentiviral Library
Sixty millilitres of peripheral blood was collected in to lithium heparin tubes, and
moDCs were isolated and cultured as outlined in sections 2.2.a and 2.2.b. moDCs
were cultured in media supplemented with 5% human AB serum. On day four in
culture, moDCs were transduced by incubation with lentiviral preparations (MOI =
3 to 8). moDCs were transduced with up to three KSHV ORFs grouped according
to each ORF’s expression during the viral life cycle in PEL cells (Jenner et al.,
2001; Jenner and Boshoff, 2002) (Table 2.7). KSHV ORFs known to affect the
expression of MHC-I (K3, K5, K9 and ORF 71) were used to singly transduce
moDCs, since these genes’ functions may affect T-cell priming by moDCs thus
skewing the results.
Controls Latent Immediate-early Lytic
No lenti pSIN ORF71 ORF72
ORF73
K11.1
K12
K15
ORF45
ORF50
ORF58
ORF74
K2
K4
K6
K8
K14
Immediate-early
Lytic
Early Lytic Late Lytic
ORF57 K5 ORF8
ORF49
ORF61
ORF59
ORF65
K4.1
K3 K9 ORF28
ORF36
ORF37
ORF33
K1
K8.1
TABLE 2.7: Plate map for transduction of moDCs. moDCs were transduced with up
to three KSHV ORFs simultaneously. KSHV ORFs were grouped according to their
expression profile in the KSHV viral life cycle. ORFs known to affect the expression of
MHC-I (K3, K5, K9 and ORF71) were used to singly transduce moDCs since these
genes’ functions may affect the T-cell response. ORF57 was simply the remainder after
the other immediate-early ORFs had been grouped in threes.108
After transduction, moDCs were fed with fresh media and cytokines every second
day. On day eight in culture (day four post-transduction) moDCs were matured by
stimulation with a “cytokine cocktail”. On day 10 in culture (day six post-
transduction) moDCs were harvested for use in T-cell response assays (section
2.5.c). Any surplus transduced moDCs were stained with antibodies against CD80
and HLA-DR and analysed by flow cytometry (as described in section 2.2.c).
2.4.c T-cell Responses to Lentiviral-transduced moDCs
Expressing KSHV ORFs
After the culture and transduction of moDCs (section 2.5.b), autologous T cells
were isolated from cryogenically-preserved CD14-negative PBMCs (section 2.3.a)
and stained with CFSE (section 2.3.b). CFSE-stained T cells (100 000) were plated
for culture in proliferation reactions with 2 500 autologous transduced or non-
transduced moDCs (i.e. 40 T cells to 1 moDC) in round-bottomed 96-well plates
(Cellstar) in a total volume of 200μl T-cell media (section 2.3.c). In addition, for
each experiment the following control wells were set up: 1) T cells only; 2) T cells
+ non-transduced moDCs + 5µg/ml phytohemagglutinin (PHA; Sigma); 3) T cells +
moDCs transduced with Adpp65. All conditions were performed in triplicate.
After six days of culture, cells were harvested, stained with a monoclonal antibody
against CD8 conjugated to PECy5 (mouse anti-human, clone RPA-T8, IgG1к; BD 
Biosciences) or the appropriate isotype control at a final antibody dilution of 1 in
20, for 30 mins on ice, protected from light. Cells were then washed twice in
PBS/1%FCS, resuspended in 250µl Cytofix (BD Biosciences) and incubated for 20109
mins on ice protected from light. Cells were washed once more in PBS/5%FCS, and
then resuspended in 300µl PBS/5%FCS for flow cytometric analysis. Flow
cytometry was performed on a FACSCalibur (BD Biosciences). The maximum
possible events (typically between 10 000 and 30 000) were collected for each
sample. Data were analysed with CELLQuest software (BD Biosciences). T cells
were gated on the live-lymphocyte population according to the expected forward
scatter and side scatter, and then on either CD8-positive or CD8-negative (CD4) T-
cell populations.
2.4.d Statistical Analysis
For T-cell responses to transduced moDCs, a positive response was designated as a
response that fitted three criteria of significance above the background response to
moDCs transduced with the empty lentiviral vector: 1) p<0.05; unpaired student T
test; 2) response > 3.5 standard deviations above background; and 3) response >
10% above background. A borderline response was designated as p<0.05 and
response > 3 standard deviations above background and > 9% above background.110
2.5 Identification of Potential New Late Lytic KSHV CD8
Epitopes
2.5.a ProImmune REVEAL™ Binding Assay
Ninety-four overlapping nine-mer peptides (off-set by one amino acid) were
generated to span the entire ORF28 gene sequence using PEPscreen® custom
peptide library synthesis and designated P1 to P94. Peptide sequences are shown in
Table 2.8. The binding affinity of each peptide to HLA-A*0201 was assessed in a
REVEAL™ MHC-peptide binding assay (ProImmune Ltd., Oxford, UK) as
previously described (Westrop et al., 2009). Briefly, binding was detected using an
antibody specific for the HLA-A*0201-peptide complex in a conformational
ELISA. Samples were taken at defined time-points and snap-frozen in liquid
nitrogen prior to analysis. Binding affinity was given as a percentage score relative
to the binding affinity of a known high-affinity A*0201-restricted T-cell epitope,
GILGFVFTL, from the Influenza Matrix protein. A known intermediate-affinity
A*0201-restricted T-cell epitopes acted as an additional control. The identity of this
epitope was undisclosed by the manufacturer, but was described as: ‘a known T-cell
epitope of marginal binding’. One of the best documented A*0201-restricted KSHV
CD8 epitope from ORF8 (aa492-500, LMWYELSKI; designated P95) was also
included in the assay for comparison. Peptides with a score of greater than 45%
were referred to as ‘passed’ peptides and included in future assays (P2, P12, P21,
P29, P30, P34, P36, P38, P45, P51, P55, P95; indicated on Table 2.8).111
Peptide ID Peptide Sequence Peptide ID Peptide Sequence
1 MSMTSPSPV 49 RVFLAARLW
2* SMTSPSPVT* 50 VFLAARLWR
3 MTSPSPVTG 51* FLAARLWRA*
4 TSPSPVTGG 52 LAARLWRAT
5 SPSPVTGGM 53 AARLWRATP
6 PSPVTGGMV 54 ARLWRATPL
7 SPVTGGMVD 55* RLWRATPLG*
8 PVTGGMVDG 56 LWRATPLGR
9 VTGGMVDGS 57 WRATPLGRA
10 TGGMVDGSV 58 RATPLGRAT
11 GGMVDGSVL 59 ATPLGRATV
12* GMVDGSVLV* 60 TPLGRATVA
13 MVDGSVLVR 61 PLGRATVAY
14 VDGSVLVRM 62 LGRATVAYQ
15 DGSVLVRMA 63 GRATVAYQV
16 GSVLVRMAT 64 RATVAYQVL
17 SVLVRMATK 65 ATVAYQVLR
18 VLVRMATKP 66 TVAYQVLRT
19 LVRMATKPP 67 VAYQVLRTL
20 VRMATKPPV 68 AYQVLRTLG
21* RMATKPPVI* 69 YQVLRTLGP
22 MATKPPVIG 70 QVLRTLGPQ
23 ATKPPVIGL 71 VLRTLGPQA
24 TKPPVIGLI 72 LRTLGPQAG
25 KPPVIGLIT 73 RTLGPQAGS
26 PPVIGLITV 74 TLGPQAGSH
27 PVIGLITVL 75 LGPQAGSHA
28 VIGLITVLF 76 Failed in Synthesis
29* IGLITVLFL* 77 PQAGSHAPP
30* GLITVLFLL* 78 QAGSHAPPT
31 LITVLFLLV 79 AGSHAPPTV
32 ITVLFLLVI 80 GSHAPPTVG
33 TVLFLLVIG 81 SHAPPTVGI
34* VLFLLVIGA* 82 HAPPTVGIA
35 LFLLVIGAC 83 APPTVGIAT
36* FLLVIGACV* 84 PPTVGIATQ
37 LLVIGACVY 85 PTVGIATQE
38* LVIGACVYC* 86 TVGIATQEP
39 VIGACVYCC 87 VGIATQEPY
40 IGACVYCCI 88 GIATQEPYR
41 GACVYCCIR 89 IATQEPYRT
42 ACVYCCIRV 90 ATQEPYRTI
43 CVYCCIRVF 91 TQEPYRTIY
44 VYCCIRVFL 92 QEPYRTIYM
45* YCCIRVFLA* 93 EPYRTIYMP
46 CCIRVFLAA 94 PYRTIYMPD
47 CIRVFLAAR
48 IRVFLAARL 95** LMWYELSKI**
TABLE 2.8: Overlapping nine-mer peptides (off-set by one amino acid) spanning
the entire KSHV ORF28 gene sequence. * indicates peptides that scored highest in the
REVEAL™ Binding Assay and were included in later assays for further analysis. **
indicates known KSHV control peptide from within ORF8 (aa492 – 500).112
2.5.b ProImmune REVEAL™ Off-rate Assay
The twelve highest scoring peptides in the REVEAL™ Binding Assay (P2, P12,
P21, P29, P30, P34, P36, P38, P45, P51, P55, P95; indicated on Table 2.8) were
further analysed for the stability of their resulting peptide-MHC complexes in a
REVEAL™ Off-rate Assay (ProImmune Ltd.). The rate of dissociation for each
peptide-A*0201 complex was measured at 0 hr, 2 hr and 24 hr at 37ºC. At each
time-point, samples were snap-frozen in liquid nitrogen prior to analysis by
conformational ELISA. The percentage denaturation at each time-point was used in
the following equation to calculate K (the rate of dissociation):
Y = (Y0 – Plateau)*exp(-K*X) + Plateau
Where: X = time; Y = % denaturation; Plateau = 0; Y0 and Plateau are the same
units as Y; and Y = Y0 when X = 0.
Half-life values [t1/2 (h)] were then calculated for each peptide-A*0201 complex
according to Y = 50, therefore X = ln (2)/K.
2.5.c In Silico Analysis of Potential Epitopes
Three different epitope-prediction computer algorithms were used to analyse
potential epitopes from the late lytic gene pool. These were Immune Epitope
Database (IEDB; www.immuneepitope.org); SYFPEITHI (www.syfpeithi.de); and
HLA_BIND (www-bimas.cit.nih.gov/molbio/hla_bind/). Each of these algorithms
has a different method for scoring potential peptides and different cut-off points are113
used to distinguish peptides that are good candidate epitopes. With IEDB, a low
score is best and a cut-off score of greater than 5000 was used to eliminate peptides
that are not considered likely to be epitopes. With SYFPEITHI, a high score is best,
and a cut-off score of less than 15 was used. With HLA_BIND a high score is best
and a cut-off score of less than 10 was used.
2.6 Recognition of Peptide Epitopes by T cells from A*0201-
positive KSHV-positive Individuals
2.6.a Study Participants
Eighteen KSHV-seropositive, HIV-seropositive, HLA-A*0201-positive individuals
were recruited from Chelsea and Westminster Hospital, London, UK. All
participants provided written, informed consent. Individual characteristics of
participants can be seen in Table 2.9. All participants were male, and their age at
venesection ranged from 29 to 67 years. CD4 counts ranged from 48 to 1467
cells/mm
3. All participants were on HAART except one (M907, who had previously
received HAART but had terminated treatment) and HIV viral loads ranged from
undetectable (<50 copies per ml) to 11164. Three individuals had active KS at the
time of venesection (B257, B792 and S314), the rest were either in remission from
KSHV-related neoplasia, or had quiescent (regressing) KS.
Peripheral blood samples were collected into lithium heparin tubes (BD
Biosciences) and PBMCs were isolated as in section 2.2.a.114
Participant
ID
Age CD4
Count
HIV
Viral
Load
Receiving
HAART?
KSHV-related
Disease History
KSHV-related
Disease Status
Cancer-specific
Treatment (Tx)
Yrs since
KS/MCD/Tx
B042 29 504 <50 Y KS Remission Chemotherapy <0.5
B066 45 114 <50 Y KS Remission Chemotherapy <0.5
B257 67 546 <50 Y KS Active None 0
B792 66 300 <50 Y KS Active None 0
C448 37 468 205 Y KS Remission Excision <0.5
D592 60 1467 <50 Y MCD Remission Chemotherapy 1
D850 48 761 250 Y MCD Remission Chemotherapy 2
G386 55 603 100 Y MCD Remission Chemotherapy 3
H501 43 707 <50 Y KS and MCD Remission Chemotherapy <1
H980 42 321 <50 Y KS Remission Unknown 6
J228 30 1001 <50 Y MCD Remission Chemotherapy 1
K331 51 302 <50 Y KS Remission Chemotherapy <1
M907 56 285 11164 N* KS Quiescent Chemotherapy 3
P896 40 500 <50 Y KS and MCD Remission Chemotherapy <0.5
P940 38 751 <50 Y KS and MCD Remission Chemotherapy 2
S314 42 48 <50 Y KS Active None 0
S929 56 873 <50 Y KS Remission Unknown 9
T541 53 262 <50 Y KS Remission Chemotherapy 7
TABLE 2.9: Characteristics of HIV-positive study participants used for testing HLA-A*0201-restricted peptides. Y = yes; N = no;
* = individual was not receiving HAART at the time of venesection for this experiment, but had done previously.
1
1
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2.6.b Measurement of IFNγ Production in Response to Peptides
Customised peptides were synthesised (ProImmune Ltd.) corresponding to the 12
highest scoring peptides in the REVEAL™ binding assay (P2, P12, P21, P29, P30,
P34, P36, P38, P45, P51, P55, P95; indicated on Table 2.8) and eight additional
previously published HLA-A*0201-restricted KSHV CD8 epitopes (sequences
shown in Table 2.10; more details and references shown in Table 1.2 and Table
5.1).
Expression KSHV ORF Epitope Position Epitope Sequence
Latent K12 aa17-25 LLNGWRWRL
K5 aa154-163 ALYAANNTRV Immediate-early
Lytic
ORF6 aa1050-1058 VLGDEVLSL
ORF61 aa505-513 GLADVFAEL
ORF65 aa35-43 NMSQAEYLV Early Lytic
ORF70 aa259-267 YMLAHVTGL
K8.1 aa209-217 LVLILYLCV Late Lytic
ORF22 aa59-68 FLNWQNLLNV
IFNγ production by CD8 T cells in response to stimulation with these peptides was 
measured in ELISpot assays according to the manufacturer’s recommendations
(Mabtech, Stockholm, Sweden) and as described previously (Burton et al., 2006).
TABLE 2.10: Sequences of previously published HLA-A*0201-restricted KSHV
epitopes tested for recognition by T cells from KSHV-positive individuals.116
Briefly, 96-well polyvinylidene difluoride-backed plates (Millipore, Watford,
United Kingdom) were coated with 100µl/well anti-IFNγ  monoclonal  antibody 
(diluted to 5μg/mL in sterile PBS; Sigma) for 1 hr at room temperature or overnight
at 4ºC. Plates were washed six times and then blocked with culture media (RPMI
1640 supplemented with penicillin-streptomycin, 2mM l-glutamine and 10% heat
inactivated Human AB Serum; all Sigma) for 1 hr at room temperature. PBMCs (2
x 10
5) and 5 or 20µg/ml peptide were added to each well in culture media to a final
volume of 200µl/well. Plates were incubated for 18 – 24 hr at 37ºC and 5% CO2.
Plates were then washed six times in PBS, 100µl of a biotinylated anti-cytokine
detection antibody (0.5µg/mL in sterile PBS) was added to each well and plates
were incubated for 24 hr at 4ºC. Plates were washed again six times with PBS and
treated with 100µl/well streptavidine-alkaline phosphatase conjugate (diluted
1:2000 in PBS) for 1 hr at room temperature. Plates were washed a further six times
with PBS and then developed with 100µl/well chromogen (AP Conjugate Substrate
Kit; Bio-Rad, Hemel Hempstead, UK; prepared according to manufacturer’s
instructions) for 10 to 15 mins at room temperature, away from intense light. The
chromogen was then discarded and plates were washed three times under slow
running tap water and then left to dry for 24 hr before analysis. Plates were
analysed using a Compact ELISpot Reader (Zeiss, Munich, Germany). The
following were included in each assay as controls: PHA (5µg/ml); a pool of
Influenza, EBV, and CMV peptides (FEC; 5µg/ml; National Institute for Biological
Standards and Control [NIBSC], Hertfordshire, UK); the immunodominant HLA-
A*0201-restricted epitopes from HIV GAG (SLYNTVATL; NIBSC; 5μg/ml) and
CMV pp65 (NLVPMVATV; ProImmune Ltd.; 5μg/ml); and T-cell media alone. A
positive response was designated as a response that was greater than 20 spot-117
forming cells (SFC) per million PBMCs above the background response to media
alone and greater than five times the background response.
2.6.c Enhancing Peptide Recognition by Autologous moDC
Presentation
moDCs were isolated as outlined above (section 2.2.a and 2.2.b). After maturation,
moDCs were pulsed with 50μg/ml peptide for 2 hr at 37ºC. Pulsed moDCs were
then washed three times, and used as stimuli in the place of peptide solutions in an
ELISpot assay with autologous PBMCs. ELISpots were performed as described in
section 2.6.b.
2.7 Flow Cytometric Analysis of the Memory Phenotypes
and Functions of Virus-specific T cells
Pentamers (ProImmune Ltd) were used to identify virus-specific CD8 T cells by
flow cytometry. These pentamers were used in conjunction with immunostaining
for cell-surface markers to investigate the phenotype of virus-specific T cells. The
use of pentamers in conjunction with intracellular cytokine production to determine
the functions of virus-specific T cells was also investigated. Pentamers directed
against T-cell receptors specific for the immunodominant HLA-A*0201-restricted
epitopes from HIV GAG (SLYNTVATL) and CMV pp65 (NLVPMVATV) were118
used to establish assays. Unfortunately no suitable KSHV peptide to target a
pentamer against was identified during the course of this work.
2.7.a Memory Phenotypes of Virus-specific CD8 T cells
The pentamer-specific PE fluorotag was spun in a chilled centrifuge (14 000g) for 5
mins prior to starting and then stored on ice, protected from light until use. Two to
three million PBMCs per staining condition were aliquoted into FACS tubes
(Greiner Bio-one) and washed with 2ml BSA Stain Buffer (BD Biosciences) and
spun at 1000g and 4ºC for 5 mins. The supernatant was discarded and cells were
resuspended in the residual liquid (~50µl). One test of unlabelled pentamer (2µl for
SLYNTVATL- and NLVPMVATV-specific pentamers) was added per tube and
mixed by pipetting. Cells were incubated on ice for 40 mins, then washed once as
before, the supernatant was discarded and cells were resuspended in the residual
liquid. Optimal amounts of monoclonal antibodies for T-cell-surface markers or
isotype controls (Table 2.11) were added to cells along with 8µl of the chilled
fluorotag and mixed by pipetting. Cells were incubated on ice, protected from light
for 20 mins. Cells were washed twice as above and then resuspended in 300µl in
Stabilising Fixative (BD Biosciences) before analysis on an LSR II flow cytometer
(BD Biosciences). One hundred thousand CD8 events were acquired for each
sample and data were analysed using BD FACSDiva software (BD Biosciences).
The live lymphocyte gate was set were according to expected forward scatter and
side scatter. Isotype controls were used to set gates for positive staining for each of
the antibodies. A sample labelled with the fluorotag alone without a pentamer was
used as a negative control.119
T-cell -
surface
molecule
Antibody- or
Isotype-
Fluorochrome
Clone Isotype
Antibody
Catalogue
Number
Volume
per Test
(µl)
CD3 CD3-PerCP SK7 IgG1κ 345766 3
CD8 CD8-FITC LT8 IgG1 A003-3B-G 1
CD45RA-PECy7 L48 IgG1κ 337186 3 CD45RA
IgG1κ-PECy7 MOPC-21 IgG1κ 557872 3
CCR7-APC 150503 IgG2A FAB197A 10 CCR7
IgG2A-APC 20102 IgG2A IC003A 10
2.7.b Functions of Virus-specific CD8 T cells
PE-labelled NLVPMVATV-specific pentamer (ProImmune Ltd) was spun in a
chilled centrifuge at 14 000g for 5 mins prior to starting and then stored on ice,
protected from light until use. Two to three million PBMCs per staining condition
were aliquoted into polypropylene culture tubes (BD Biosciences), washed with
2ml BSA Stain Buffer (BD Biosciences) and spun at 1000g and 4ºC for 5 mins. The
supernatant was discarded and cells were resuspended in the residual liquid (~50µl).
One test of pentamer (10µl) was added per tube and mixed by pipetting. Cells were
incubated on ice for 40 mins, then washed once as before, the supernatant was
discarded and cells were resuspended in 500μl RPMI 1640 media supplemented
with penicillin-streptomycin, l-glutamine and 10% heat-inactivated human AB
serum (all Sigma). Cells were stimulated with 1μl Leukocyte Activation cocktail
(LAC; Sigma) and placed in a 37ºC humidified CO2 incubator. After 1 hr, 10μg/ml
TABLE 2.11: Antibodies used to distinguish T-cell memory subsets of pentamer-
positive virus-specific T cells. All antibodies and isotypes were purchased from BD
Biosciences apart from CCR7 and its isotype, which were from R and D systems and
CD8 which was from ProImmune Ltd. All antibodies were mouse anti-human and all
isotype controls were from mice.120
Brefeldin A was added to the appropriate tubes (LAC contains Brefeldin A) and
then cells were returned to the incubator for 15 hr. Tubes were then centrifuged at
1000g for 5 mins at 4ºC, the supernatant was aspirated, and cell pellets were
resuspended in 50μl BSA Stain Buffer containing anti-CD3 and anti-CD8
antibodies (Table 2.12). Cells were incubated on ice, protected from light for 20
mins, then washed in 500μl BSA Stain Buffer and spun as before. The supernatant
was aspirated, and cell pellets were resuspended in 200μl 4% paraformaldehyde and
incubated on ice for 20 mins. Cells were then washed in 200μl permeabilisation
buffer (0.1% saponin, 1% FCS, 0.1% sodium azide in PBS; all Sigma) and spun as
before. Supernatant was aspirated and pellets resuspended in 100μl permeabilisation
buffer and incubated at room temperature. Antibodies against intracellular
cytokines (Table 2.12) were added to tubes and cells were incubated for a further 20
mins at room temperature. Cells were washed once in permeabilisation buffer as
before, supernatant aspirated, then resuspended in 300μl Stabilising Fixative (BD
T-cell -
surface
molecule or
intracellular
cytokine
Antibody-
Fluorochrome Clone Isotype
Antibody
Catalogue
Number
Volume
per Test
(µl)
CD3 CD3-APCCy7 SK7 IgG1κ 341110 5
CD8 CD8-PerCP MEM-31 IgG2A ab65949 25
IFNγ IFNγ-FITC 4S.B3 IgG1κ 554551 1
TNFα TNFα-PECy7 MAb11 IgG1κ 557647 3
IL2 IL2-APC 5344.111 IgG1κ 341116 3
TABLE 2.12: Antibodies used to determine functions of pentamer-positive virus-
specific T cells. All antibodies and isotypes were purchased from BD Biosciences apart
from CD8, which was from Abcam, Cambridge, UK. All antibodies were mouse anti-
human.121
Biosciences), and transferred to FACS tubes (Greiner Bio-one) before analysis on
an LSR II flow cytometer (BD Biosciences). One hundred thousand CD8 events
were acquired for each sample and data were analysed using BD FACSDiva
software (BD Biosciences). The live lymphocyte gate was set were according to
expected forward scatter and side scatter. Un-stimulated controls were used to set
gates for positive staining for each of the intracellular antibodies.
2.8 Flow Cytometric Analysis of the Representation of T-cell
Memory Subsets in KSHV-infected Individuals
2.8.a Study Participants
Eleven HIV-negative, KSHV-negative and 25 HIV-seropositive, KSHV-positive
individuals (all male) were recruited at the Chelsea and Westminster Hospital,
London, UK. All participants provided written, informed consent. Of the 25 HIV-
seropositive, KSHV-positive individuals, nine had active KS and 15 were in
remission from a KSHV-related neoplasm (eight KS and seven MCD). Participants’
ages ranged from 24 to 73 years at venesection. All HIV-seropositive participants
were on HAART apart from one individual with active KS. CD4 counts of HIV-
seropositive individuals ranged from 159 to 811. HIV viral loads ranged from
undetectable (<50 copies per ml) to 12599. These characteristics are summarised in
Table 5.10 and discussed in section 5.4.a. Individual characteristics of HIV-
seropositive study participants are shown in Table 2.13.122
Group Participant
ID
Age CD4
Count
HIV
Viral
Load
Receiving
HAART?
KSHV-
related
Disease
History
KSHV-
related
Disease
Status
B862 74 447 <50 Y MCD Remission
C473 57 638 <50 Y KS Remission
C991 58 406 <50 Y KS Remission
D850 48 600 69 Y MCD Remission
E043 43 188 <50 Y KS Remission
F667 42 458 <50 Y KS Remission
H501 43 707 <50 Y KS and
MCD
Remission
J228 30 687 <50 Y MCD Remission
K331 51 302 <50 Y KS Remission
N047 56 810 <50 Y MCD Remission
S343 42 413 <50 Y KS Remission
S433 38 682 <50 Y MCD Remission
S583 40 811 <50 Y MCD Remission
2
V685 32 625 <50 Y KS Remission
B257 67 546 <50 Y KS Active
C448 37 432 12599 N KS Active
E881 40 575 102 Y KS Active
N484 45 444 <50 Y KS Active
N494 34 313 <50 Y KS Active
R632 71 513 <50 Y KS Active
V313 45 350 <50 Y KS Active
W375 39 243 384 Y KS Active
3
W481 40 159 110 Y KS Active
2.8.b Whole Blood Staining
Peripheral blood samples were collected into EDTA tubes (BD Biosciences). One
hundred microlitres whole blood was aliquoted into FACS tubes (Greiner Bio-one,
Gloucestershire, UK) and 5µl of each antibody or isotype control (Table 2.14) were
added and incubated for 30 mins at room temperature. Red blood cells were lysed
TABLE 2.13: Individual characteristics of HIV-positive study participants for
whole-blood phenotyping. Y = yes; N = no.123
with 2ml FACS Lysing Solution (BD Biosciences) (10 mins, room temperature)
then cells were washed three times in PBS and resuspended in 250µl CellFIX (BD
Biosciences) before analysis on an LSR II flow cytometer (BD Biosciences).
Twenty thousand CD4 events were collected for each sample and data were
analysed using BD FACSDiva software (BD Biosciences). The live lymphocyte
gate was set according to expected forward scatter and side scatter. Isotype controls
were used to set gates for positive staining for each of the antibodies.
T-cell-
surface
molecule
Fluoro-
chrome
Clone Antibody
Catalogue
Number
Isotype Isotype
Control
Clone
Isotype
Catalogue
Number
CD3 APCCy7 SK7 557832 IgG1κ MOPC-21 557873
CD8 APC RPA-T8 555369 IgG1κ MOPC-21 555751
CD4 PerCPCy5.5 SK3 332772 IgG1κ MOPC-21 550795
CD45RA PeCy7 L48 337186 IgG1κ MOPC-21 557872
CCR7 PE 150503 FAB197P IgG2A 20102 IC003P
2.9 Study Participant Characterisation Techniques
The following assays were used to characterise the phenotypes of participants from
each of the studies described in this thesis (section 2.4.a; 2.6.a; and 2.8.a).
TABLE 2.14: Antibodies used to distinguish T-cell memory subsets in whole blood.
All antibodies and isotypes were purchased from BD Biosciences apart from CCR7 and
its isotype, which were from R and D systems. All antibodies were mouse anti-human
and all isotype controls were from mice.124
2.9.a Serology for KSHV Infection
An in-house developed MIX-MAP ELISA was used to detect KSHV seropositivity
as previously described (Bourboulia et al., 2004) but with an improved, modified
peptide containing two copies each of a lytic and a latent epitope
(RSHLGFWQEGWSGQVYQDWLGRMNCSYENM derived from K8.1, and
QPGPSREYRYVLRTSPPHRPGVRMRRV derived from ORF73, respectively).
Briefly, 96-well plates (Nunc, Thermo Fisher Scientific, Rochester, New York,
USA) were coated with 100µl/well peptide solution diluted to 2µg/ml in sterile PBS
(Sigma) and incubated overnight at 4ºC. Plates were washed four times in a wash
buffer of PBS/0.1%Tween-20 (Sigma) and then blocked with 200µl/well of
blocking buffer [PBS/0.1%Tween-20/5% Milk (Premier International Foods Ltd.,
Spalding, Lincs., UK)] for 30 mins at 37ºC. Plates were washed as before and 95µl
of serum samples or controls (diluted 1:101 in blocking buffer) were added to
appropriate wells and incubated for 90 mins at room temperature. After another
wash as above, 100µl/well secondary antibody solution (rabbit anti-human IgG,
P0214; DAKO, Glostrup, Denmark; diluted 1:4000 in blocking buffer) was added
and incubated for 1 hr at 37ºC. After a final wash as above, 200µl/well substrate
solution (TMB Microwell Peroxidase Substrate System; KPL, Gaithersburg,
Maryland, USA) was added and incubated for 20 mins at room temperature.
Reactions were stopped by the addition of 50µl/well 2M H2SO4 (Sigma). Plates
were read using a Varioskan plate reader (Thermo Electron, Thermo Fisher
Scientific) at 450nm optical density. All experiments were performed in triplicate.
A positive result was designated as a reading greater than the mean of four negative125
control samples (each in triplicate) plus five times the standard deviation of the four
negative controls.
2.9.b HLA Typing
i. From Cryogenically-preserved PBMC Samples
This method was used for HLA-typing the seven study participants who responded
to the [ORF28/ORF36/ORF37] in the screen for immunogenic KSHV ORFs using
lentiviral-transduced moDCs (section 2.4.a). Genomic DNA was extracted from a
minimum of 5 x10
6 PBMCs using the standard Nucleon® BACC2 kit (Tepnel Life
Sciences, Manchester, UK) protocol. HLA typing was performed by the
Department of Histocompatibility and Immunogenetics, Clinical Immunology
Laboratory, Hammersmith Hospital, London. Low resolution typing was performed
using PCR-sequence specific primers (PCR-SSP). High resolution typing was
achieved using reference strand conformational analysis (RSCA).
ii. From Whole Blood Samples
This method was used to identify HLA-A*0201 positive individuals with a history
of KSHV-related neoplasia to test A*0201-restricted peptides and pentamers from
ORF28 (section 2.5.c). Participants were recruited from the Chelsea and
Westminster HIV-Oncology clinic and provided written, informed consent.
Peripheral blood samples were collected into EDTA tubes and snap-frozen in liquid
nitrogen before storage at -80ºC until use. Genomic DNA was extracted from 200μl126
whole blood using a QIAamp DNA Blood Mini Kit (Qiagen) according to the
manufacturers’ instructions. At the end of the protocol, DNA was eluted in 200μl of
the provided elution buffer. HLA typing was performed by the Histocompatibility
Laboratories, Anthony Nolan Trust, Royal Free Hospital, London, UK. High and
low resolution typing was performed by PCR-sequence specific oligonucleotides
(PCR-SSO).
2.10 Statistics
Statistics were performed on Microsoft Office Excel 2003 software and GraphPad
Prism 5.0 software. Significance was tested using a student T test or a Mann-
Whitney test where appropriate.127
CHAPTER 3: Preparation for and Design of a
Lentiviral-based System for Investigating the CD8
and CD4 T-cell Responses Against KSHV
3.1 Cloning KSHV ORFs into the Lentiviral Vector
3.1.a Cloning Novel KSHV ORFs into the Lentiviral Vector
i. Cloning Novel KSHV ORFs into the pSIN Lentiviral Vector
Five putative immunogenic KSHV open reading frame (ORF) inserts (ORF8,
ORF57, ORF59, ORF61 and ORF65; marked with a double asterisk on Table 1.1)
were successfully cloned into the pSIN lentiviral vector. Plasmid DNA solutions
were screened for the presence of the transgene insert. The insert was excised from
the multiple cloning site of the plasmid vector by restriction digestion, and gel
electrophoresis was used to check for the presence of the linearised pSIN vector
(10kb) and a second DNA fragment of the expected length of the KSHV ORF insert
(Figure 3.1).
ii. Sequencing the KSHV Transgene Inserts
For each of the five plasmid vector preparations that contained an insert of the
expected size, the transgene was sequenced and compared to its published gene128
sequence. This was to ensure that no point mutations had been introduced during
the cloning process.
The lentiviral vectors encoding ORF59 and ORF65 contained no point mutations in
their respective KSHV gene sequences as compared to their published gene
sequences.
FIGURE 3.1: Electrophoresis gels showing lentiviral plasmid DNA after restriction
digestion to check for presence of KSHV ORF insert. a. ORF8 (2530bp) insert is
present in clones 3 and 8. b. ORF57 (830bp) insert is present in clones 1, 2, 3, 5, 6, 7
and 8. c. ORF59 (1190bp) insert is present in clones 4, 6, 7 and 8. d. ORF61 (2370bp)
insert is present in clones 2, 5, 6, 7 and 8. e. ORF65 (510bp) insert is present in clones 2,
5 and 6. DNA bands are very faint and do not reproduce well here and so presence is
indicated by white open boxes. In all gels, the bright band at 10kb is the linearised
lentiviral vector with the insert removed.
ORF8
10kb C1 C2 C3 C4 C5 C6 C7 C8
ORF57
10kb C1 C2 C3 C4 C5 C6 C7 C8
ORF59
10kb C1 C2 C3 C4 C5 C6 C7 C8
ORF61
10kb C1 C2 C3 C4 C5 C6 C7 C8
ORF65
10kb C1 C2 C3 C4 C5 C6 C7
a.
b.
c.
d.
e.
< 830bp
< 2530bp
< 1190bp
< 2370bp
< 510bp129
The lentiviral vector encoding ORF57 contained a single point mutation in the
ORF57 gene sequence at base pair 243, where a thymine base replaced a cytosine
base in the published sequence. This is, however, a silent mutation that converts the
codon CAC to the codon CAU, both of which code for the amino acid histidine.
The lentiviral vector encoding ORF61 contained three point mutations in the
ORF61 gene sequence. The first point mutation was at base pair 1644, where a
cytosine base replaced an adenine base in the published sequence. This is a silent
mutation that converts the codon GGA to the codon GGC, both of which code for
the amino acid glycine. The second point mutation was at base pair 1857, where a
cytosine base replaced a thymine base in the published sequence. This is a silent
mutation that converts the codon UCU to the codon UCC, both of which code for
the amino acid serine. The third point mutation was at base pair 2070, where a
thymine base replaced a cytosine base in the published sequence. This is also a
silent mutation that converts the codon GAC to the codon GAU, both of which code
for the amino acid aspartic acid.
The lentiviral vector encoding ORF8 contained two point mutations in the ORF8
gene sequence. One was at base pair 1422, where an adenine base was replaced by a
guanine base in the published sequence. This is a silent mutation that converts the
codon CAG to the codon CAA, both of which code for the amino acid glutamine.
The other point mutation was at base pair 1199, where a cytosine base replaced a
thymine base in the published sequence. This converts the codon GTC, which codes
for the amino acid valine, to the codon GCC, which codes for the amino acid
alanine. This mutation, however, lies outside of the coding sequence for the well-130
documented optimal CD8 T-cell epitope within ORF 8, aa492-500 (LMWYELSKI)
(Wang et al., 2002b). It is also not a particularly significant change as both valine
and alanine are non-polar, neutral amino acids with similar molecular structures.
The change was carefully noted, but it was considered acceptable to use this
expression vector in a screen for immunogenic KSHV genes.
3.1.b Cloning the CMV Gene Phosphoprotein 65 into the
Lentiviral Vector
A lentiviral vector encoding the immunodominant CMV gene phosphoprotein 65
(CMVpp65) was proposed for use as a positive control in a screen for immunogenic
KSHV genes. Unfortunately, however, all attempts at cloning CMVpp65 into the
pSIN lentiviral vector using the same strategy for cloning KSHV genes into pSIN
(as outlined in Materials and Methods section 2.1.a) were unsuccessful. Numerous
adjustments to the technique and alternative strategies were tried, but all to no avail.
Briefly, CMVpp65 was successfully amplified from both a pBluescriptII plasmid
vector containing the gene (a kind gift from Dr John Zaia, National Medical Center
and Beckman Research Institute, City of Hope, California, USA) and from total
genomic DNA extracted from CMV (strain AD169)-infected neonatal dermal
fibroblasts two days post-infection. However, all subsequent attempts at ligating
either product into the pSIN vector were unsuccessful. The following techniques
were tried to no avail: the use of different restriction enzyme sites from within the
multiple cloning site for insertion; varying all possible parameters in the restriction
digestion reaction; dephosphorylating the vector prior to ligation; varying all131
possible parameters in the ligation reaction; the use of different ligation enzymes;
the use of a ligation enzyme-free insertion system (In-Fusion™ PCR Cloning
System; Clontech, Takara Bio Inc., Shiga, Japan); the use of a sub-cloning
technique, successfully inserting CMVpp65 first into a TA vector (vector PCR 2.1,
Invitrogen), then transferring into pSIN (which was again, unsuccessful). Finally, a
biotechnology company, Biogenova Inc. (Ellicott City, Maryland, USA), was
employed to perform the cloning reaction, but they were also unsuccessful. An
adenovirus encoding CMVpp65 was thus used as a positive control to investigate
the use of transduced moDCs to detect antigen-specific T-cell responses (see
section 3.4).
3.2 Culture and Transduction of monocyte-derived
Dendritic Cells (moDCs)
3.2.a moDC Isolation and Culture: Survival
CD14-positive monocytes were isolated from peripheral blood and cultured for 10
days in the presence of the cytokines interleukin 4 (IL4) and
granulocyte/macrophage colony-stimulating factor (GMCSF), which promote
differentiation of the monocytes into monocyte-derived dendritic cells (moDCs)
(Sallusto and Lanzavecchia, 1994). moDCs were either left immature or matured by
stimulation with either LPS or a ‘cytokine cocktail’. The differentiating monocytes
were cultured in media supplemented with either 10% foetal calf serum (FCS), 5%
human AB serum (AB) or 2% AB. Media supplemented with 10% FCS is132
conventional for culturing moDCs, and the cells survive well in this serum (Jeras et
al., 2005). However, moDCs cultured in FCS prime a high background in T-cell
response assays when cultured with autologous T cells as they present antigens
from bovine proteins present in the FCS (Jonuleit et al., 2001). This raised concern
that subtle responses to KSHV genes could be masked in the proposed experiments.
Therefore, survival of moDCs cultured in human AB serum was compared with
survival of moDCs cultured in FCS, as moDCs grown in AB should prime a lower
background T-cell response. Different batches of AB (Sigma-Aldrich, Poole, UK)
were evaluated, and moDCs survived best in lot number 027K0432, so this batch
was used for all future experiments.
Figure 3.2 shows the yield of different populations of moDCs after 10 days in
culture in media supplemented with either 10% FCS or 5% or 2% AB (lot number
027K0432). Survival was measured as the number of live (trypan-blue excluding)
moDCs recovered by aspiration of the culture plate on culture day 10, divided by
the number of live monocytes plated on culture day 0. moDCs cultured in 2% AB
showed very poor survival and consequently a low yield of cells (15.0% to 16.7%).
However, there was no significant difference (p>0.05; student T test) between the
yield of moDCs after culture in either 10% FCS (43.3% to 46.0%) or 5% AB (36.1
to 42.9%). Therefore, 10% FCS or 5% AB serum supplements were used in further
experiments to compare the phenotype and function of moDCs cultured
conventionally in FCS or in the selected batch of AB serum.133
3.2.b moDC Cell-surface Marker Expression and Maturation
After 10 days culture in the presence of IL4 and GMCSF, immature and mature
moDCs were analysed for their expression of cell-surface markers by multi-
parameter flow cytometry. The cell-surface markers examined were the protein
complexes major histocompatibility complex I (MHC-I) and II (HLA-DR), which
present antigens to CD8 and CD4 T cells respectively; the costimulatory molecules
CD80 and CD86, which bind the T-cell molecules CD28 and CTLA-4 and provide
the necessary stimuli to activate a T-cell response to antigens; CD40, a
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FIGURE 3.2: Yield of moDCs after 10 days in culture in media with
different serum supplements. 10% FCS (blue bars), or 5% (purple bars) or 2%
(yellow bars) human AB serum. moDCs were either left immature (left), or were
matured by stimulation with either LPS (middle) or a cytokine cocktail (right). Survival
of moDCs was assessed by yield of viable cells. Means and standard deviations of five
(10% FCS and 5% AB) or two (2% AB) experiments are shown. moDCs did not survive
well in 2% human AB serum, but there was no significant difference in survival of
moDCs cultured in 10% FCS or 5% human AB serum (student T test).134
costimulatory molecule which binds CD40L on CD4 helper T cells; and CD83, a
cell surface molecule that is dramatically upregulated by DCs in response to
maturation stimuli. Figure 3.3 shows an example of marker expression by
immature and mature moDCs. Immature moDCs had high expression of MHC-I,
mid-range expression of HLA-DR, CD86 and CD40 and low expression of CD80
and CD83. All markers were upregulated after exposure to a maturation stimulus.
CD80 and CD83 showed the most dramatic upregulation, as these markers were
expressed at the lowest levels prior to maturation.
MHC-I HLA-DR CD80
CD86 CD40 CD83
Isotype control
Immature moDCs
Cytokine-matured moDCs
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FIGURE 3.3: Cell-surface marker expression by moDCs. Flow cytometry
histograms showing cell-surface marker expression by moDCs for one representative
experiment out of three. moDCs were cultured in 5% human AB serum supplemented
with IL4 and GMCSF for 10 days and either left in an immature state (black lines) or
exposed to a ‘cytokine cocktail’ maturation stimulus (red lines). MFI indicates mean
fluorescence intensity.135
Figure 3.4 summarises three experiments investigating cell-surface marker
expression by moDCs cultured in either 10% FCS (Figure 3.4.a) or 5% AB serum
(Figure 3.4.b) and either left in an immature state or exposed to different maturation
stimuli.
DC marker expression was comparable in moDCs cultured in either 10% FCS or
5% AB. The biggest variation in the immunophenotype between moDCs cultured in
the two serum supplements was seen in immature moDCs, indicating that
stimulating maturation strongly promotes moDC differentiation, giving rise to a
more homogenous population of moDCs. For the most part, the ‘cytokine cocktail’
induced greater marker upregulation than LPS, and nearly all markers were
expressed by 90% or more of moDCs after exposure to this maturation stimulus,
regardless of which serum supplement the cells were cultured in.
In FCS, 90.5 ± 8.5% (mean ± s.d.) of immature moDCs expressed MHC-I, and in
AB this rose slightly to 98.1 ± 2.7%. After exposure to either maturation stimuli
MHC-I expression was maintained by between 91.7% and 99.2% of moDCs in
either serum supplement. HLA-DR was expressed by 77.0 ± 21.8% of FCS-grown
and 88.4 ± 9.6% of AB-grown immature moDCs, and was upregulated by both
maturation stimuli so that 86.1% to 95.7% of moDCs cultured in either serum were
positive for this marker. CD80 and CD40 were both expressed at mid-range levels
by immature moDCs: 55.8% to 56.9% of moDCs cultured in either serum were
CD40-positive and 30.7 ± 11.1% of AB-cultured moDCs or 51.8 ± 2.8% of FCS-
cultured moDCs were CD80-positive.136
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FIGURE 3.4: Antigen-presenting surface marker expression by moDCs cultured in
either (a) 10% FCS or (b) 5% AB serum. moDCs were either left immature (white
bars) or exposed to either LPS (pale grey bars) or a ‘cytokine cocktail’ (dark grey bars)
maturation stimulus. Bars show the proportion of moDCs expressing each of the
markers (MHC-I, HLA-DR, CD80, CD86, CD40 and CD83), as measured by flow
cytometry. Means and standard deviations are shown (n = 3).137
After exposure to either maturation stimuli, these costimulatory molecules were
upregulated so that 77.8% to 93.0% of moDCs cultured in either serum expressed
both CD40 and CD80. The only exception was FCS-cultured moDCs stimulated
with LPS, which showed a slightly lower proportion of moDCs positive for CD80
(71.2 ± 4.4%). CD86 was expressed by 92.9 ± 2.9% of immature moDCs cultured
in AB compared to only 31.2 ± 13.9% of FCS-cultured immature moDCs. Exposure
to either maturation stimuli resulted in 80.2% to 96.7% of moDCs expressing this
marker, regardless of culture serum. Only a small proportion of immature moDCs
expressed CD83: 4.2 ± 2.2% of FCS-cultured moDCs and 22.0 ± 11.9% of AB-
cultured moDCs. After exposure to either LPS or a ‘cytokine cocktail’, 84.0% or
90.7% of AB-cultured moDCs and 48.9% or 69.5% of FCS-cultured moDCs were
CD83-positive, respectively.
Overall, the expression of these DC markers by the moDCs demonstrates that this
method for deriving DCs worked in my hands; that the resulting cells display an
antigen-presenting surface phenotype; and that the moDCs can be successfully
cultured in either 10% FCS or 5% human AB serum. The ‘cytokine cocktail’
appears to be the most potent maturation stimulus, resulting in a heterogenous
population of moDCs that expresses high levels of each the antigen-presenting cell-
surface markers.
This is further summarised in Figure 3.5, which shows a direct comparison between
the maturation profiles of moDCs cultured in either FCS or human AB serum
before and after exposure to different maturation stimuli. The maturation profile
was assessed as the percentage of cells that were both CD80-positive and HLA-DR-
positive. Immature moDCs cultured in FCS showed a greater proportion of double-138
positive mature cells than immature moDCs cultured in human AB serum (an
average of 50% compared to 29% respectively; p<0.005, student T test). This is in
correlation with the higher proportion of CD80-positive immature moDCs observed
after culture in FCS as compared to AB, as shown in Figure 3.4. Also in agreement
with the observations shown in Figure 3.4, Figure 3.5 reveals that the ‘cytokine
cocktail’ was the most potent maturation stimulus for moDCs cultured in either
serum. Although the cytokine-matured moDCs cultured in AB showed a slightly
lower proportion of double-positive mature cells than those grown in FCS (82%
compared to 94% respectively; p<0.05, student T test), there was still an average of
over 80% of cells that were positive for both CD80 and HLA-DR. This was a
higher proportion than that for moDCs cultured in either serum and matured by
stimulation with LPS (73% for moDCs cultured in AB and 79% for moDCs
cultured in FCS).
FIGURE 3.5: Maturation profiles of immature moDCs and moDCs exposed to
different maturation stimuli. moDCs were cultured in 10% FCS (blue bars) or 5%
human AB serum (purple bars). moDCs were left immature (left) or matured by
stimulation with either LPS (middle) or a ‘cytokine cocktail’ (right). The maturation
profile of each moDC population was assessed as the proportion of moDCs expressing
both CD80 and HLA-DR. Means of nine (10% FCS) or eight (5% AB) experiments, and
standard deviations are shown. P values are from a paired student T test for moDCs
isolated from the same donor, cultured in parallel in different serum supplements.
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3.2.c Transduction of moDCs with a GFP-encoding Lentivirus
i. Time-point Optimisation
To investigate the kinetics of lentiviral transduction, four wells of moDCs were
transduced with 1ml of GFP-encoding lentivirus (pCSGW). On each day post-
transduction, moDCs were examined for GFP-expression using a light fluorescence
microscope. On day four GFP-expressing cells were observed, and these increased
in number over each subsequent day. The percentage of moDCs expressing GFP
was analysed by flow cytometry on days four, five, six and seven post-transduction.
Figure 3.6 shows that the percentage of GFP-positive cells steadily increased over
time post-transduction (4.78% GFP-positive cells on day four, rising to 41.96% on
day seven). For the purpose of future experiments a five- or six-day period was
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FIGURE 3.6: Percentage of moDCs expressing GFP at different time-points after
transduction with a GFP-encoding lentivirus. The percentage of GFP-positive
moDCs was measured by flow cytometry. It increased steadily over several days post-
transduction. At the last time-point examined (seven days post-transduction) the highest
proportion of GFP-positive moDCs was observed (41.96%). Results from one
experiment are shown, and demonstrate the same trend of increasing transgene
expression as reported in the literature (Schroers et al., 2000; Dyall et al., 2001).140
selected as a suitable length of time for transduction of moDCs before using them in
further assays, as this represented a balance between achieving good transgene
expression (10.63% to 25.99% of GFP-positive cells) and optimal moDC viability.
In three further experiments, a mean transduction efficiency of 12.5 ± 2.5% GFP-
positive immature moDCs was observed at six-day’s post-transduction.
ii. Multiplicity of Infection
In order to determine the optimal multiplicity of infection (MOI) for lentiviral
transduction of moDCs, a titration experiment was performed. moDCs were
transduced with 0.05, 0.1, 0.3, 1.0 or 1.5 ml of a GFP-encoding lentivirus. On day
five post-transduction, the lentiviral copy number per cell for each transduction was
determined by qPCR and the percentage of GFP-expressing moDCs was assessed
by flow cytometry (Figure 3.7). Lentiviral copy number per moDC increased with
increasing volume of lentivirus used in transduction. At low MOIs, the percentage
of moDCs that were GFP-positive increased slightly from 10.6% GFP-positive
moDCs at 3.0 lentiviral copies per cell to 17.2% at 5.6 lentiviral copies per cell.
However, interestingly, at higher MOIs the proportion of GFP-positive moDCs
appeared to reach a plateau, and then declined slightly to 16.6% GFP-positive
moDCs at 16.9 lentiviral copies per cells and 13.2% GFP-positive cells at 30.1
lentiviral copies per cells. This may be due to a toxic effect of high MOIs on the
moDCs, as reported by other groups (Gruber et al., 2000; Dyall et al., 2001).
Therefore an optimal MOI of between three and eight lentiviral copies per moDC
was used for future experiments, as MOIs greater than this did not appear to
significantly increase that proportion of GFP–positive moDCs.141
iii. Characterisation of moDCs Transduced with a GFP-encoding Lentivirus
To investigate whether lentiviral transduction of moDCs affected their antigen-
presenting surface phenotype, MHC-I expression by GFP-transduced (MOI = 5.6)
and non-transduced moDCs was examined by flow cytometry. moDCs were stained
with an MHC-I antibody, and GFP-positive and GFP-negative moDCs from three
donors were compared for MHC-I expression (Figure 3.8.a and 3.8.c). LPS
stimulation resulted in a 1.7- or 1.9-fold increase in MHC-I mean fluorescence
intensity (MFI) in non-transduced and GFP-transduced moDCs respectively.
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FIGURE 3.7: Titration to determine optimal multiplicity of infection (MOI) for
transgene expression using the pSIN lentiviral vector. qPCR was used to determine
the lentiviral copy number per cell (grey bars) for moDCs transduced with different
volumes of GFP-encoding lentivirus. Means and standard deviations from two
experiments are shown. Flow cytometric analysis was used to determine the percentage
of moDCs that were GFP-positive (green diamonds) after transduction with different
volumes of lentivirus. Results from one experiment are shown.142
Stimulation with a ‘cytokine cocktail’ resulted in a 2.9- or 3.2- fold increase in
MHC-I MFI in non-transduced and GFP-transduced moDCs respectively.
Importantly, there was no significant difference (p>0.05; student T test) between the
MHC-I MFI of non-transduced and GFP-transduced moDCs from each individual,
and the fold increase in MHC-I MFI after exposure to either maturation stimuli was
equivalent for both non-transduced and GFP-transduced moDCs.
To confirm that lentiviral transduction did not affect maturation of moDCs, CD80
expression by GFP-transduced and non-transduced moDCs was examined by flow
cytometry. moDCs were stained with a CD80 antibody conjugated to PE and GFP-
positive and GFP-negative moDCs from three donors were compared for CD80
expression (Figure 3.8.b and 3.8.c). The CD80 MFIs of both non-transduced and
GFP-transduced moDCs were equivalent, and increased by 1.7- or 1.8-fold after
stimulation with LPS and 3.6- or 3.4-fold after stimulation with a ‘cytokine
cocktail’.
Interestingly, the proportion of moDCs that were GFP-positive decreased after
moDCs were exposed to maturation stimuli (Figure 3.9). GFP expression appeared
to be downregulated in correlation with the potency of the stimulus used to induce
moDC maturation. Stimulation with a ‘cytokine cocktail’ induced strong, uniform
maturation of immature moDCs (82% to 94% of moDCs double-positive for CD80
and HLA-DR, Figure 3.5) and resulted in a 37.1% (FCS-grown moDCs) to 38.5%
(AB-grown moDCs) decrease in the proportion of GFP-positive moDCs that was
statistically significant (student T test; see Figure 3.9). LPS, which at 20ng/ml gave
rise to around 73% to 79% of double-positive moDCs, caused a smaller decrease in143
FIGURE 3.8: Expression of MHC-I and CD80 by non-transduced and GFP-
transduced moDCs. a. and b. show examples of flow cytometry plots showing MHC-I
(a) and CD80 (b) surface expression by non-transduced (left-hand quadrants) and GFP-
transduced (right-hand quadrants) moDCs before and after maturation. Numbers in each
quadrant indicate the percentage of cells in the quadrant (top) and the MHC-I or CD80
MFI of the cells in that quadrant (bottom). c. shows fold change in MHC-I and CD80
surface expression by non-transduced (grey bars) and GFP-transduced (green bars)
before and after maturation by different stimuli. Mean and standard deviations from
three experiments are shown. In each experiment, MFIs were normalised to non-
transduced immature moDCs.
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the proportion of GFP-expressing cells that was not significantly different from the
proportion of GFP-positive immature moDCs.
3.2.d Transduction of moDCs with the KSHV Lentiviral Library
i. Confirmation of Viral Gene Expression by RT-PCR
To confirm that all the 31 different KSHV-ORF-encoding lentiviral vectors in the
KSHV lentiviral library (26 previously existing constructs and five newly
constructed as part of the work described in this thesis, section 3.3.1) successfully
transduced moDCs resulting in expression of the appropriate transgene insert,
moDCs were transduced with individual KSHV ORFs. On day six post-
FIGURE 3.9: Percentage of GFP-positive moDCs before and after exposure to
different maturation stimuli: immature (white bars); LPS-matured (pale grey
bars); cytokine matured (dark grey bars). Maturation induced downregulation of
GFP. Stimulating moDCs with a ‘cytokine cocktail’ resulted in a 37.1% – 38.5%
decrease in the proportion of GFP-positive cells compared to immature moDCs that was
statistically significant (paired student T test). LPS stimulation resulted in a lesser
decrease in the proportion of GFP-positive cells that was not statistically significant.
Means and standard deviations from three experiments are shown.
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transduction, moDCs were harvested, RNA was extracted and reverse-transcription
(RT)-PCR was used to confirm KSHV transgene expression (Figure 3.10).
ii. Titre of Lentivirus by qPCR
qPCR was used to determine the MOI of each KSHV-ORF-encoding lentiviral
vector. Three hundred thousand moDCs were transduced with 300μl of each
lentivirus preparation. On day six post-transduction, moDCs were harvested, DNA
was extracted and qPCR was used to determine the lentiviral copy number per cell.
Results are shown in Figure 3.11. Virus preparations had an MOI of between 1.9
and 8.9. In order to achieve a uniform MOI for all lentivirus preparations in future
FIGURE 3.10: KSHV transgene expression by moDCs after transduction with
individual KSHV-ORF-encoding lentiviral vectors. For each ORF, left-hand lane
shows PCR product and right-hand lane shows no reverse transcriptase control. moDCs
were transduced with 300μl of lentivirus encoding individual KSHV ORFs. On day six
post-transduction, moDCs were harvested, RNA was extracted, cDNA was synthesised
with and without reverse transcriptase, and the resulting product was used as a template
for RT-PCR to confirm viral gene expression. All viral genes were expressed. Faint
bands were sometimes seen in the no reverse-transcriptase controls, likely due to some
sample contamination, however the true RT-PCR product was always brightest,
indicating true transgene expression.
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experiments (particularly the screen for immunogenic ORFs) the volume of
lentivirus used for transduction was increased to 600μl for preparations with an
MOI of less than 3.4, and decreased to 150μl for preparations with an MOI greater
than 7.2. This achieves an MOI range of 3.4 to 7.2 for all preparations (median =
4.5; interquartile range = 3.9 to 5.4; mean = 4.75). With the GFP–encoding
lentivirus, an MOI in this range achieved good transgene expression (between
10.6% and 17.2% GFP-positive immature moDCs; see Figure 3.7) with no notable
improvement if the MOI was increased further. Furthermore, whilst there is a
consensus that lentiviral transduction of moDCs at MOIs of less than ten does not
affect moDC viability, immunophenotype or antigen-presenting function (Gruber et
al., 2000; Dyall et al., 2001; Koya et al., 2003; Dullaers et al., 2004), the evidence
regarding higher transduction with higher MOIs is less clear (Chen et al., 2004).
FIGURE 3.11: Lentiviral copy number per cell for moDCs after transduction with
300μl of different KSHV-ORF-encoding lentiviral vector preparations. qPCR was
used to determine the multiplicity of infection (MOI) by measuring the lentiviral copy
number and normalising to cell number by measuring the GAPDH copy number. Means
and standard deviations from two experiments are shown.
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iii. Multiple Transductions
As the KSHV lentiviral library consisted of 31 KSHV ORFs, it was decided to
perform the immunogenic screen with moDCs transduced with up to three KSHV
ORFs simultaneously, in order to make the experiment more manageable and to
make the best use of clinical samples. KSHV ORFs were grouped according to
expression profile to determine whether latent or immediate-early, early or late lytic
gene products elicit the strongest T-cell responses. To ensure moDCs could be
transduced with up to three ORFs, resulting in the co-expression of all three genes,
a multiple transduction experiment was performed (Figure 3.12). Briefly, moDCs
were transduced with one, two or three different KSHV-ORF-encoding lentiviral
vectors. Transduction was normalised to an MOI of approximately 6 for each
construct. On day six post-transduction, cells were harvested, RNA was extracted,
cDNA was synthesised and RT-PCR was used to confirm KSHV transgene
expression. All single, double and triple transductions showed the expected
transgene expression. No transgene expression was seen in RT-PCR products from
reactions performed on ‘no reverse transcriptase’ control preparations.
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FIGURE 3.12: Viral gene expression by moDCs transduced with one, two or three
KSHV-ORF-encoding lentiviral vectors. Electrophoresis gel showing KSHV gene
expression (K6, top panel; K11.1, middle panel; ORF72, bottom panel) by non-
transduced moDCs (lane c) and moDCs transduced with one (lanes 1, 2 and 3), two
(lanes 4, 5 and 6) or three (lane 7) different KSHV-gene-encoding lentiviral vectors.148
3.3 T-cell Response Assays
3.3.a T-cell Proliferation Responses Measured by CFSE
Fluorescence
Allogenic mixed lymphocyte cultures were used to refine methods for measuring T-
cell responses. moDCs were cultured for 10 days (as this is the length of time the
moDCs transduced to express KSHV genes were cultured for) and then harvested
and cocultured with allogenic CFSE-stained T cells.
T cells only
160 to 1 20 to 1 40 to 1 80 to 1
T cells cultured with allogenic mature moDCs at different ratios (T cells to moDCs)
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FIGURE 3.13: Flow cytometry dot plots showing progressive loss of CFSE
fluorescence by proliferating T cells in allogenic mixed lymphocyte reactions. Non-
proliferating T cells that are small in size and have high CFSE fluorescence are
represented in the top left quadrant. In response to stimulation by allogenic mature
moDCs, T cells proliferate, growing in size and losing CFSE fluorescence. Proliferating
T cells are represented in the bottom right quadrant. The barred pattern that can be seen
indicates the different generations of daughter cells – each bar is representative of each
new generation of cells. The strength of the response can be assessed by the proportion
of proliferating cells in the bottom right quadrant, as indicated by the percentage values
shown on each plot. Decreasing the ratio of T cells to moDCs increases the strength of
the response.149
CFSE is a fluorescent vital dye that is partitioned with high fidelity between
daughter cells, leading to serial halving of fluorescence down each new generation
of cells (Lyons and Parish, 1994; Lyons, 2000). T-cell proliferative responses can
therefore be measured by flow cytometry as the proportion of T cells that are
CFSE-low (Figure 3.13 shows representative results from one experiment). The
number of distinct populations with different levels of CFSE fluorescence indicates
the number of divisions.
In the experimental design for the screen for immunogenic KSHV ORFs, CD14-
negative PBMCs were cryopreserved at -80ºC whilst the autologous moDCs are
cultured from CD14-positive monocytes and transduced with KSHV-ORF-encoding
lentiviral vectors. T cells were then isolated from the frozen cells and cultured with
the transduced moDCs. Therefore, T cells isolated from cryogenically preserved
CD14-negative PBMCs were compared to T cells isolated from fresh blood for their
ability to mount a proliferation response in allogenic mixed lymphocyte reactions.
Results are shown in Figure 3.14.
In two experiments using different moDC donors, T cells isolated from frozen
CD14-negative PBMCs mounted slightly, though not significantly (p> 0.05; student
T test), stronger responses than T cells isolated from fresh blood. Different donors
provided the fresh and frozen T cells, and therefore the difference in the strength of
the response may be attributable to the degree of HLA-type mismatch between the
moDC donor and the T-cell donor. Nevertheless, T cells clearly remain capable of
mounting a proliferative response after cryopreservation.150
To test the stimulatory capacity of moDCs cultured in different serum supplements
and matured by exposure to different stimuli, four allogenic mixed lymphocyte
reactions were performed using moDCs from four different donors, each cultured
and matured under all of the different conditions. moDCs were cultured with
allogenic CFSE-stained T cells at four different ratios. After six days, the T-cell
proliferation response was measured as the proportion of cells that were CFSE low
using flow cytometry. Results are shown in Figure 3.15. Decreasing the ratio of T
cells to moDCs increased the strength of the proliferation response. There was
considerable variation in the size of responses between the different donor-matched
FIGURE 3.14: Proliferation response by fresh or frozen T cells in allogenic
mixed lymphocyte reactions. Mature moDCs were cultured with CFSE-stained
allogenic T cells isolated from either fresh blood or frozen CD14-negative PBMCs at
four different ratios of T cells to moDCs. The proliferation response was measured by
flow cytometry as the proportion of T cells that were CFSE-low. Decreasing the ratio
of T cells to moDCs increased the strength of the T cell proliferation response. For
each moDC donor, T cells from frozen PBMCs showed a slightly stronger
proliferative response than T cells from fresh blood.
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pairs as indicated by the error bars, but this is likely just a reflection of variation
between individuals as well as the degree of HLA-type mismatch between pairs.
As would be expected, mature moDCs were more stimulatory than immature
moDCs, as assessed by the strength of the T-cell proliferative response primed by
these cells. moDCs matured by stimulation with a ‘cytokine cocktail’ were more
stimulatory than LPS-matured moDCs (p<0.001; paired student T test). This was in
keeping with Figure 3.4, which showed that the ‘cytokine cocktail’ is a more potent
maturation stimulus than LPS at these working concentrations, resulting in a higher
proportion of mature (CD80-positive and HLA-DR-positive) moDCs, and thus
presumably a more stimulatory population of moDCs.
FIGURE 3.15: Allogenic stimulatory capacity of moDCs cultured in different
serum supplements and matured by exposure to different stimuli. moDCs from four
donors were cultured in either FCS (blue) or human AB serum (purple) and left either
immature (left) or matured by stimulation with either LPS (centre) or a ‘cytokine
cocktail’ (right). moDCs were then cultured with allogenic CFSE-stained T cells at four
different ratios of T cells to moDCs for six days. Mature moDCs were more stimulatory
than immature; and cytokine-matured moDCs were more stimulatory than LPS-matured
moDCs. moDCs cultured in FCS were more stimulatory than moDCs cultured in AB.
Means and standard deviations from four experiments are shown.
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moDCs cultured in FCS were slightly more stimulatory than moDCs cultured in
human AB serum (p<0.01; student T test), although the difference in the strength of
the response they elicit was greater between immature moDCs than for mature
moDCs. On average, immature moDCs cultured in FCS primed a 22.9% stronger
response than immature moDCs cultured in AB. However, there was little
difference in the strength of response primed by cytokine-matured moDCs cultured
in the two serum supplements – on average 6.3% more of the total T-cell population
proliferated in response to FCS-grown moDCs as compared to AB-grown moDCs –
although this was still statistically significant (p<0.05; student T test). Again, this
fitted with the maturation profile of the different populations of moDCs shown in
Figure 3.4. Immature moDCs cultured in different serum supplements had quite
different maturation profiles – 50% of immature moDCs cultured in FCS were
HLA-DR-positive and CD80-positive, compared to 28% of immature moDCs
cultured in AB serum. This was reflected in the stimulatory capacity of these moDC
populations. There was less difference in the maturation profile of the cytokine-
matured moDCs cultured in different serum supplements – 95% of cytokine-
matured moDCs cultured in FCS were double-positive, compared to 83% of
cytokine-matured moDCs cultured in AB serum. Again, this was reflected in the
stimulatory capacity of these moDC populations. When T cells were cocultured
with mature moDC populations (that showed more than 80% of moDCs displaying
a mature profile) at low ratios of T cells to moDCs (40 to 1 or 20 to 1), more than
70% of the T cells were stimulated into a proliferative response and appeared to
reach a threshold in the strength of the T-cell response.153
3.3.b Cell-surface Marker Expression and Intracellular Cytokine
Production
One of the advantages of using CFSE staining to measure T-cell responses is that it
can be used alongside immunostaining in order to characterise the proliferating
cells. Cell-surface marker staining for the expression of CD8 or CD4 can determine
whether the proliferating T cells are CD8-positive CTLs or CD4-positive helper T
cells or both. Staining for intracellular cytokine production can determine the
functional profile of proliferating CTLs, or whether proliferating helper T cells are
Th1 or Th2 cells. To refine techniques for cell-surface and intracellular
immunostaining in conjunction with CFSE-staining, allogenic mixed lymphocyte
assays were used. In the first instance, staining for the production of the
intracellular cytokines IFNγ and IL4 was used as an indication of whether
proliferating helper T cells were Th1 or Th2, respectively.
In order to stain for intracellular cytokine production, T cells were stimulated with
TPA and ionomycin. This stimulation results in downregulation of the CD4 cell-
surface molecule. Therefore, experiments were performed to determine whether
staining for CD8 expression alone was sufficient to distinguish between CD4 helper
T cells and CD8 CTLs. The proportions of CD4-positive or CD8-positive cells in
stimulated and non-stimulated T-cell populations were measured by flow
cytometry. In non-stimulated T cells, the mean proportion of CD4-positive cells
was 51% and the mean proportion of CD8-positive cells was 45% (n = 12). In a
student T Test there was no significant difference between the proportions of CD8-
negative T cells and the proportions of CD4-positive T cells. This indicates that the
proportion of CD8-negative T cells is approximately the same as the proportion of154
CD4-positive T cells, and thus staining for the CD8 cell surface marker alone, and
gating on either CD8-positive or CD8-negative T cells is sufficient to distinguish
helper T cells and CTLs. In stimulated T cells the mean proportion of CD4-positive
cells was 22% and the mean proportion of CD8-positive cells was 48% (n = 12).
There was no significant difference between the mean proportion of CD8-positive
cells in non-stimulated and stimulated T-cell populations. However, there was a
significant difference (p < 0.00001) between the mean proportion of CD4-positive
cells in non-stimulated and stimulated T-cell populations, illustrating that CD4 is
indeed downregulated by cells after stimulation with TPA and ionomycin.
CD8 cell-surface marker staining was therefore used in conjunction with CFSE
staining and staining for intracellular production of the cytokines IFNγ and IL4 to 
characterise the responding T cells in allogenic mixed lymphocyte reactions.
Different populations of moDCs were used to stimulate allogenic T cells in order to
investigate whether moDCs cultured in different serum supplements or matured by
exposure to different maturation stimuli primed polarised T-cell responses. This
was to determine the most appropriate conditions for the culture and maturation of
moDCs for use in an investigation into KSHV-specific T-cell responses, in order to
avoid masking the true polarisation of these memory responses. moDCs from four
different donors were cultured in media supplemented with either 10% FCS or 5%
human AB serum and were matured by stimulation with either LPS or a ‘cytokine
cocktail’ and then cocultured with allogenic T cells. Flow cytometry was used to
assess intracellular cytokine production by CD8-positive and CD8-negative (CD4)
T-cell fractions as illustrated in Figure 3.16. The results from the four experiments
are summarised in Figure 3.17.155
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FIGURE 3.16: Flow cytometry dot plots showing intracellular cytokine production
by T cells in an allogenic mixed lymphocyte reaction with moDCs cultured in FCS.
Numbers indicate % of total cells in that quartile (top) and MFI of those cells (bottom).
a. and b. Cytokine production by CD8 T cells in response to stimulation by LPS-
matured (a) or cytokine-matured (b) moDCs. c. and d. Cytokine production by CD8-
negative (CD4) T cells in response to stimulation by LPS-matured (c) or cytokine-
matured (d) moDCs.156
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FIGURE 3.17: IFNγ (navy bars) and IL4 (lilac bars) production by proliferating T
cells in allogenic mixed lymphocyte reactions with different populations of moDCs.
Means and standard deviations from four experiments are shown. a. Cytokine
production by CD8-positive T cells. Between 39% and 60% of proliferating CD8 cells
produced  IFNγ  and  5%  to  9%  produced IL4. There was no difference in cytokine
production by CD8 cells stimulated with moDCs cultured in different serum
supplements or matured by exposure to different stimuli. b. Cytokine production by
CD8-negative (CD4) T cells. Between 15% and 22% of proliferating CD8-negative cells
produced IL4 after stimulation with all four different moDC populations. Between 40%
and 42% of proliferating CD8- cells produced IFNγ after stimulation with LPS-matured
moDCs compared to 17% to 20% after stimulation with cytokine-matured moDCs,
although this did not reach statistical significance.157
Cytokine production by CD8-positive T cells was similar after stimulation with all
four different populations of moDCs (Figure 3.17.a). Between 39% and 60% of
proliferating CD8-positive  T  cells  produced  IFNγ,  whereas  only 5% to 9% of
proliferating CD8-positive T cells produced IL4. There was considerable variation
in levels of cytokine production between donors, as indicated by the error bars.
However, the serum supplement and maturation stimuli used in moDC culture did
not appear to affect moDC priming of CD8-positive T-cell cytokine production.
Cytokine production by CD8-negative T cells appeared slightly different depending
on the method used to mature the stimulating moDCs (Figure 3.17.b). Between 15%
and 22% of CD8-negative T cells responding to all four different populations of
moDCs produced IL4. However, between 40% and 42% of proliferating CD8-
negative T cells stimulated by LPS-matured moDCs produced IFNγ, compared to 
between 17% and 20% of proliferating CD8-negative T cells stimulated by
cytokine-matured moDCs. This did not, however, reach statistical significance in
these four experiments using a paired student T test (p=0.169 and p=0.0127 for
moDCs cultured in FCS or AB respectively). Again, there was considerable
variation in levels of cytokine production between donors, as indicated by the error
bars, but the serum supplement used in moDC culture did not appear to affect
moDC priming of cytokine production by CD8-negative T cells.158
3.4 Using Transduced moDCs to Investigate Antigen-
specific Memory T-cell Responses
Due to the lack of success cloning the immunodominant CMV gene phosphoprotein
65 (CMVpp65) into the pSIN lentiviral vector (section 3.1.b), moDCs transduced
with an adenovirus encoding CMVpp65 (Adpp65) were used to investigate the use
of transduced moDCs to prime an antigen-specific memory T-cell response.
Adpp65 was kindly provided by Dr Magnus Essand of Uppsala University, Sweden
(Carlsson et al., 2003).
3.4.a Transduction of moDCs with an Adenovirus Encoding the
CMV Gene Phosphoprotein 65
Expression of CMVpp65 by moDCs transduced with Adpp65 was confirmed by
reverse-transcription PCR (Figure 3.18).
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FIGURE 3.18: Electrophoresis gel of RT-PCR product showing expression of
CMVpp65 by moDCs transduced with Adpp65. No RT control = no reverse
transcriptase control.159
i. Immunophenotype of moDCs Transduced with Adpp65
To ensure that transduction with Adpp65 did not affect the immunophenotype of
moDCs, cell-surface marker expression by moDCs transduced with Adpp65 was
compared to that of non-transduced moDCs at 48 hours post-transduction. The
experiment was repeated twice for both moDCs cultured in FCS and moDCs
cultured in human AB serum, and the immunophenotypes of both immature moDCs
and moDCs matured by stimulation with a ‘cytokine cocktail’ were examined.
Representative results from one experiment are shown in Figure 3.19.
In summary, there was no difference observed in the expression of moDC markers
CD80 and HLA-DR between transduced and non-transduced moDCs, as assessed
by the proportion of marker-positive cells and the MFI of each marker.
Transduction with Adpp65 did not affect moDCs’ antigen-presenting phenotype,
and did not affect their maturation after exposure to an appropriate stimulus. In this
particular experiment, MFI values for moDCs cultured in AB serum were lower
than for moDCs cultured in FCS. However, the fold change in MFI after maturation
was comparable for moDCs cultured in the two different serum supplements.
ii. Allogenic Stimulatory Capacity of moDCs Transduced with Adpp65
To ensure that moDCs transduced with Adpp65 retained their allogenic stimulatory
capacity as well as their immunophenotype, allogenic mixed lymphocyte reactions
comparing non-transduced moDCs and Adpp65-transduced moDCs were carried
out. Stimulatory capacity was assessed by the strength of the T-cell proliferation
response to these cells, measured by loss of CFSE fluorescence (see section 3.3.a).160
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FIGURE 3.19: Marker expression profile of moDCs transduced with Adpp65.
Results from one representative experiment are shown. a. – c. Co-expression of CD80
and HLA-DR by mature moDCs cultured in FCS. There was no difference between the
immunogenic profiles of non-transduced moDCs (b; black dots) and moDCs transduced
with Adpp65 (c; blue dots). Both were highly homogenous populations of double-
positive cells. d. – g. Flow cytometry histograms showing mean fluorescence intensity
(MFI) of HLA-DR (d and e) and CD80 (f and g) in immature (d and f) and mature (e
and g) moDCs cultured in FCS. Marker expression is shown in black for non-transduced
moDCs and in blue for transduced moDCs. There is no difference in the expression of
either HLA-DR or CD80 between transduced and non-transduced immature moDCs.
Both transduced and non-transduced moDCs upregulated HLA-DR and CD80 in a
comparable manner after exposure to a maturation stimulus. h. – k. Flow cytometry
histograms showing MFI of HLA-DR (h and i) and CD80 (j and k) in immature (h and
j) and mature (i and k) moDCs cultured in human AB serum. Marker expression is
shown in black for non-transduced moDCs and in blue for transduced moDCs. As for
moDCs cultured in FCS, there is no difference in the expression of either HLA-DR or
CD80 between transduced and non-transduced, immature or mature moDCs.161
The experiment was repeated twice with two different donors. Representative
results from one experiment are shown in Figure 3.20. Briefly, there was no
difference between the allogenic T-cell response to transduced and non-transduced
moDCs cultured in FCS. In moDCs cultured in AB, the response to transduced
moDCs was slightly stronger than that to non-transduced moDCs (on average
7.65% more proliferation was seen to transduced moDCs; p < 0.05, student T test).
This could be due to the additional activation of memory T cells specific for CMV
antigens presented by the transduced moDCs. The transduced moDCs clearly retain
their capacity to simulate T cells.
FIGURE 3.20: Allogenic stimulatory capacity of non-transduced (black lines) and
Adpp65-transduced moDCs (blue lines) cultured in two different serum
supplements. Allogenic stimulatory capacity of non-transduced and transduced moDCs
was assessed by the strength of the T-cell response to these cells, as measured by the
loss of CFSE fluorescence. moDCs capacity to stimulate T cells is not impaired by
transduction with Adpp65. Results from one representative experiment are shown.
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3.4.b Antigen-specific Memory Responses to moDCs
Transduced with Adpp65
i. T-cell Proliferation Measured by CFSE Fluorescence
CFSE-stained T cells were cocultured with autologous moDCs that were either non-
transduced or transduced with Adpp65. After six days, the T-cell proliferation
response was assessed using CFSE fluorescence as outlined in section 3.3.a. Both
the proportion of CFSE-low T cells and the CFSE MFI of the total T-cell
population were used to determine the strength of the T-cell response. The
experiment was repeated with two different donors, and for each donor the
experiment was performed with moDCs that had been cultured in either human AB
serum or FCS, and left either immature or matured using a ‘cytokine cocktail’.
Representative results from one experiment are shown in Figures 3.21 and 3.22.
Figure 3.21 illustrates the clear detection of an antigen-specific memory T-cell
response by T cells cocultured with moDCs transduced with Adpp65 as compared
to T cells cocultured with non-transduced moDCs. There is a dramatic increase in
the proportion of CFSE-low T cells and a decrease in the CFSE MFI of the total T-
cell population in T cells exposed to the CMV antigen. Both these parameters
indicate a strong proliferation response. The strength of the response increased with
decreasing T cell to moDC ratio.
Figure 3.22 shows the different responses to moDCs cultured in different media
serum-supplements and left either immature or matured by stimulation with a
‘cytokine cocktail’. Mature moDCs cultured in FCS were the most potent163
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FIGURE 3.21: T-cell responses to non-transduced and Adpp65-transduced
autologous moDCs measured by CFSE fluorescence. Results from one representative
experiment are shown. a. Flow cytometry dot plots showing T-cell proliferation
response to autologous non-transduced (top) and transduced (bottom) moDCs measured
by the proportion of T cells that are proliferating (CFSE-low; indicated by the
percentages in the bottom right quadrants). b. Flow cytometry histograms showing T-
cell proliferation response to autologous non-transduced (top) and transduced (bottom)
moDCs measured by the CFSE MFI of the total T-cell population (indicated by the
numbers on each histogram). There is a distinct, strong response to the CMV antigen
that increases as the ratio of T cells to moDCs decreases.164
stimulators of an antigen-specific response to CMV pp65 (priming proliferation by
29.5% to 58.0% of total T cells, dependent on T cell to moDC ratio in culture).
However, these cells also primed a comparatively high background response to
non-transduced moDCs (6.5% to 33.7% proliferating T cells). Mature moDCs
cultured in human AB serum elicited very little background response when they
were non-transduced (0.5% to 7.0% proliferating T cells), but were potent
stimulators of an antigen-specific response when they were transduced with
Adpp65 (20.3% to 43.9% proliferating T cells).
Mature moDCs cultured in human AB serum were thus selected as the most
appropriate cells to use in the screen for immunogenic KSHV genes, although there
FIGURE 3.22: T-cell responses to non-transduced (black lines) and Adpp65-
transduced (blue lines), immature and mature autologous moDCs cultured in
different serum supplements. For all populations of moDCs, a strong response to the
CMV antigen was observed above the background response to non-transduced moDCs.
Mature moDCs were more potent stimulators than immature moDCs. moDCs cultured n
FCS were more potent stimulators than moDCs cultured in AB serum, but also primed a
higher background response to non-transduced moDCs. Results from one representative
experiment are shown.
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was the caveat that this was demonstrated using a different viral construct to the one
used in this screen.
Results in Figure 3.22 also indicated that the most appropriate ratio of T cells to
moDCs to use to investigate antigen-specific responses was 40 to 1. At this ratio,
when using mature moDCs cultured in AB serum, there was very little background
response to non-transduced moDCs (1.9% proliferating T cells), but a strong
response to Adpp65-transduced moDCs (39.1% proliferating T cells). The same
trend was seen when CFSE MFI values were used to analyse data instead of the
proportion of CFSE-low T cells.
ii. Cell-surface Marker Expression and Intracellular Cytokine Production
To investigate the type of helper T-cell response primed by moDCs transduced with
Adpp65, T cells that had been cocultured with these moDCs were stained for the
cell-surface molecule CD8, and for intracellular production of IFNγ and IL4 (see
section 3.3.b). The Adpp65-transduced moDCs used in this experiment were
cultured in AB serum and matured by exposure to a ‘cytokine cocktail’. The
experiment was repeated for each of the two donors with a similar outcome, and
representative results from one experiment are shown in Figure 3.23.
Seventy-seven percent of the CFSE-low, proliferating CD8-negative T cells
produced  IFNγ  in  response  to  stimulation  with  the  Adpp65-transduced moDCs,
whereas only 14% produced IL4. This strongly indicates that moDCs presenting
antigens derived from Adpp65 prime a Th1-type helper T response. This is
particularly evident when the cytokine production by these T cells is compared to166
cytokine production by T cells primed with non-transduced allogenic moDCs
cultured in the same way (in AB serum-supplemented media and matured by
stimulation with a ‘cytokine cocktail’). On average, only 17% of these proliferating
CD8-negative T cells produced IFNγ and 16% produced IL4, as shown in Figure
3.17.
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FIGURE 3.23: Intracellular cytokine production by proliferating CD8-negative T
cells stimulated with moDCs transduced with Adpp65. a. Sample flow cytometry dot
plots. T cells were gated on the CD8-negative fraction (left panel) and the % cells
producing IFNγ (middle panel) and IL4 (right panel) was assessed. In the middle and
right panels, the proliferating fraction of CD8-negative cells is represented by the
CFSE-low cells in the two left-hand quadrants, and the proportion of these that are
producing the cytokine of interest are represented by the top left quadrants. Numbers
indicate the % of total T cells in that quartile (top) and the IFNγ or IL4 MFI of the cells
in that quartile (bottom). b. Summarises the proportion of proliferating CD8-negative
cells producing either IFNγ or IL4, based on the results of the flow cytometry shown in
panel a. Nearly 80% of the CD8-negative T cells proliferating in response to stimulation
with moDCs transduced with Adpp65 produced IFNγ, which is strongly indicative of a 
Th1-type helper T response.167
3.5 Summary
In this chapter, experiments that were performed in order to prepare for and design
a protocol for a lentiviral-based system to investigate the KSHV-specific T-cell
response have been described.
Five putative or known immunogenic KSHV ORFs (ORF8, ORF57, ORF59,
ORF61, and ORF65) were cloned into the lentiviral vector for addition into a
previously existing library of lentiviral expression vectors encoding individual
KSHV ORFs. The resulting cumulative library contained 31 KSHV ORFs. The
proposed experimental design to screen these ORFs for immunogenicity was to
isolate moDCs from KSHV-seropositive individuals and transduce these moDCs
with each KSHV ORF. The moDCs would naturally process the KSHV gene
products and present the resulting optimal epitopes for that individual in the context
of MHC-I and MHC-II. The transduced moDCs would then be cocultured with
autologous T cells and a CFSE-dye based assay would be used to determine which
of the KSHV ORFs yielded epitopes that elicited a T-cell response. To this end,
protocols for the isolation, culture and transduction of moDCs were first
investigated and refined. T-cell response assays were then investigated and refined
in both an allogenic system and an autologous system that used moDCs transduced
with an adenovirus encoding CMVpp65 to stimulate antigen-specific memory
responses.
moDCs were derived from CD14+ monocytes, and different culture conditions were
investigated to identify the most suitable for use in the immunogenic screen. A168
culture media supplemented with 5% human AB serum and a ‘cytokine cocktail’
maturation stimulus were selected for use in the immunogenic screen, as moDCs
cultured using these conditions showed good viability and differentiated into a
homogeneous population of mature moDCs with strong stimulatory capacity. AB
serum was deemed preferable to FCS as moDCs cultured in a selected AB serum
primed a lower background response in autologous T-cell response assays. The
‘cytokine cocktail’ was selected in preference to LPS as it provided the most potent
moDC maturation stimulus. Furthermore, cytokine-matured moDCs did not prime
polarised Th responses so it seemed a more neutral maturation stimulus for use in
investigation of polarisation of Th responses by KSHV antigens.
A GFP-encoding lentivirus (pCSGW) was used to demonstrate that moDCs could
be successfully transduced using this lentiviral vector, and to determine the optimal
time-point and MOI for achieving good transgene expression with this vector.
pCSGW was additionally used to show that lentiviral transduction did not affect the
moDCs’ antigen-presenting surface phenotype or their maturation. Next, each of the
KSHV-ORF-encoding lentiviruses was demonstrated to transduce moDCs, resulting
in expression of the desired transgene and the MOI for each of the lentiviral
preparations was determined.
As the library of lentiviral expression vectors available for the immunogenic screen
consisted of 31 KSHV ORFs, it was decided to perform the screen with moDCs
transduced with up to three KSHV ORFs (grouped according to each ORF’s
expression profile during the viral life cycle). This was in order to make the
experiment more manageable; to make the best use of clinical samples; and to169
determine whether latent, immediate-early lytic, early lytic or late lytic ORFs are
the major targets of KSHV-specific T-cell response. Thus, it was demonstrated that
moDCs could be transduced with up to three KSHV ORFs simultaneously, resulting
in expression of all three transgenes.
Finally, a CFSE-dye based assay in conjunction with immunostaining for cell
surface markers and intracellular cytokine production was used to assess T-cell
responses to both allogenic moDCs and autologous moDCs transduced to express a
viral antigen. For future experiments, a ratio of T cells to moDCs of 40 to 1 was
selected, as this achieved a balance between a strong antigen-specific response to
transduced moDCs and a low background response to non-transduced moDCs in
autologous assays.
Based on these findings, a protocol for a screen for immunogenic KSHV ORFs was
established, and this screen was carried out as described in the following chapter.170
CHAPTER 4: Investigating the Targets of the CD8
and CD4 T-cell Responses against KSHV
4.1 Lentiviral-based Screen for Immunogenic KSHV ORFs
In Chapter 3 of this thesis, a pre-existing library of lentiviral expression vectors
encoding individual KSHV ORFs was extended to include a total of 31 KSHV
ORFs. Preparations of each of these lentiviruses were synthesised; they were each
shown to express their transgene in monocyte-derived dendritic cells (moDCs);
each MOI was determined; and simultaneous transduction of moDCs with up to
three KSHV genes was demonstrated. Lentiviral transduction of moDCs was shown
not to affect their immunophenotype, and the best serum supplement and
maturation stimulus for preparing moDCs to use in a screen for immunogenic
KSHV ORFs were decided. T-cell response assays for measuring antigen-specific
memory responses were refined. Based on this work, an experimental design for a
screen for immunogenic KSHV genes was decided, and is shown in Figure 4.1.
As the KSHV lentiviral library consisted of 31 KSHV ORFs, it was decided to
perform the immunogenic screen with moDCs transduced with up to three different
KSHV ORFs simultaneously, in order to make the experiment more manageable
and to make the best use of clinical samples. KSHV ORFs were grouped according
to expression profile to determine whether latent, immediate-early lytic, early lytic
or late lytic KSHV genes elicit the strongest T-cell responses. KSHV ORFs known171
to affect the expression of MHC-I [K3, K5, K9 and ORF 71; (Coscoy and Ganem,
2000; Lagos et al., 2007)] were used to singly transduce moDCs, since these genes’
functions may affect priming of T cells by moDCs thus skewing the results (see
Materials and Methods 2.4.b).
4.1.a Study Participants
For the screen, 14 KSHV-seropositive and seven KSHV-seronegative study
participants were recruited from the Chelsea and Westminster Hospital, London,
UK. All participants provided written, informed consent. Study protocols were
FIGURE 4.1: Schematic illustration of the experimental design for a screen for
immunogenic KSHV ORFs using lentiviral-transduced moDCs.
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approved by the Riverside Research Ethics Committee. Study participants were
classified into five groups based on their KSHV-serostatus, HIV-serostatus and
history of KSHV-related disease. These included two KSHV-seronegative control
groups and three KSHV-seropositive groups and were as follows:
1) HIV-negative, KSHV-seronegative individuals (n = 3).
2) HIV-positive, KSHV-seronegative individuals (n = 4).
3) HIV-positive, KSHV-seropositive individual with no history of KSHV-related
disease (asymptomatic carrier; n = 1).
This individual was originally intended for inclusion in the study as an HIV-
positive, KSHV-negative control participant, as they had no history of
KSHV-related disease and were considered to be at low risk of KSHV
infection, and so was assumed to be KSHV-negative. However, when the
KSHV immunogenic screen was performed in this individual, strong T-cell
responses to several pools of KSHV ORFs were observed. The individual’s
KSHV-serostatus was thus retrospectively tested using plasma frozen at the
time of venesection, which proved to be positive (see section 4.1.b).
4) HIV-positive, KSHV-seropositive individuals with a history of KSHV-related
disease (KS; KS and MCD; or PEL) but in remission at the time of venesection and
on HAART (n = 11).
Individuals in this group were the original target cohort of KSHV-positive
individuals, as this cohort have been shown to have comparatively high173
levels of KSHV-specific T cells (Bihl et al., 2007a; Bourboulia et al., 2004),
and have the additional advantages that they are easily identifiable and
continue to attend clinics regularly after entering remission.
5) HIV-negative, KSHV-seropositive individuals with active KSHV-related disease
(KS), in regression at the time of venesection (n = 2).
I was eager to take any opportunities that arose to perform the screen in
HIV-negative, KSHV-seropositive individuals, to see what results were
obtained in individuals who didn’t have the complication of a background of
immunosuppression. Unfortunately, classic KS is rare in the UK and blood
samples from individuals with no active neoplasm are difficult to obtain as
these individuals do not regularly attend clinics after entering remission. I
was able to collect two samples from individuals with classic KS, although
these were collected at the time of their final hospital visit, when their KS
was regressing but minor lesions were still present.
All study participants were male apart from one HIV-positive, KSHV-seronegative
female. Study participants’ age at venesection ranged from 30 to 74 years. All HIV-
positive individuals were on HAART and had an HIV viral load of <50 copies per
ml. CD4 counts ranged from 171 to 785 cells/mm
3. Individual characteristics of
HIV-positive participants are shown in Table 2.6. Summarised characteristics of
each group of study participants are shown in Table 4.1. The different groups of
study participants were well matched for age and HIV+ groups were well matched
for CD4 count.174
Group Group Description Number Male/
Female
Mean
Age
(Range)
KSHV status HIV status Mean CD4
Count
(Range)
1 HIV-/KSHV-
Healthy Controls
3 3/0 37
(30 to 45)
Seronegative Negative ND
2 HIV+/KSHV-
Controls
4 3/1 48
(32 to 70)
Seronegative Positive
On HAART
HIV viral load suppressed
345
(174 to 652)
3 HIV+/KSHV+;
asymptomatic
carriers of KSHV
1 1/0 56 Seropositive
Asymptomatic
Positive
On HAART
HIV viral load suppressed
373
4 HIV+/KSHV+;
history of KSHV-
related neoplasia
11 11/0 47
(36 to 74)
Seropositive*
KSHV-related
disease in
remission
Positive
On HAART
HIV viral load suppressed
389
(171 to 785)
5 HIV-/KSHV+;
history of KSHV-
related neoplasia
2 2/0 37, 41 Seropositive
Active KS,
regressing
Negative 550, ND
TABLE 4.1: Summary of characteristics of study participants in the screen for immunogenic KSHV ORFs. * indicates except for two
individuals (K058 and B625) for whom plasma were unavailable for serological testing; ND indicates not determined. Detailed individual
characteristics of HIV-positive participants can be seen in Table 2.6.
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4.1.b KSHV Serostatus of Study Participants
All study participants had their KSHV serostatus at the time of venesection assessed
by multi-antigenic ELISA, except for two individuals who had a history KSHV-
related disease (K058 and B625) for whom plasma samples were unavailable for
serological testing. Results are shown in Table 4.2.
KSHV Serostatus Participant
ID
Positive Negative
Comments
HC1 N
HC2 N
HIV-negative, no
history of KSHV-
related disease HC3 N
D919 N
C122 N
S810 N
D403 (N) Borderline negative
HIV-positive, no
history of KSHV-
related disease
H419 P Asymptomatic Carrier
D208 P
S079 P
K058 Not Tested
P940 P
B625 Not Tested
M620 P
V689 P
A556 P
B196 P
T541 P
HIV-positive,
KSHV-related
disease in remission
T328 P
S346 P HIV-negative,
active KS W946 P
TABLE 4.2: KSHV serostatus of study participants at the time of venesection for
the screen for immunogenic KSHV ORFs. P = positive; N = negative; (N) =
borderline negative.176
All participants had very clear serostatus, with the exception of D403, an HIV-
positive individual with no history of KSHV-related neoplasm who was KSHV
seronegative but had a fairly high antibody titre (0.129 ± 0.02) only just below the
cut-off for positivity (0.145). It is possible, therefore, that D403 had either a very
low level of latent KSHV infection or had been exposed to KSHV in the past but
infection had been abortive.
4.1.c Antigen-presenting Surface Phenotype of Transduced
moDCs Expressing KSHV ORFs
moDCs from each study participant and transduced with each KSHV ORF or group
of ORFs were checked for their expression of HLA-DR and CD80 by flow
cytometric analysis. This was to ensure that no KSHV ORF (or group) significantly
affected the antigen-presenting surface phenotype of the moDCs or their maturation
in such a way that would skew the results of T-cell response assays using the
transduced moDCs. Figure 4.2 shows the mean proportion of HLA-DR-positive and
CD80-positive moDCs after transduction with each KSHV ORF or group of ORFs
across all 21 study participants included in the screen for immunogenic KSHV
ORFs. On average, 92.8% of non-transduced control moDCs had a mature
phenotype (i.e. were double-positive for these markers). Control moDCs transduced
with the empty vector alone (pSIN) were on average 89.2% double-positive. This
slight reduction in the proportion of double-positive moDCs reached statistical
significance (p<0.001; paired student T test) across this large number of samples (n
= 21). This was in contrast to what we observed when comparing the phenotypes of
non-transduced moDCs with moDCs transduced with a GFP-encoding lentivirus in177
Chapter 3 (section 3.2.c). It may be that lentiviral transduction has some subtle
affect on moDCs – either mild toxicity or triggering or blocking of moDC
differentiation pathways – that only becomes apparent when examining a large
number of samples. Nonetheless, the effect was very slight and did not interfere
with the capacity of transduced moDCs to stimulate T-cell responses (see below,
sections 4.1.d – f).
Eight different populations of moDCs transduced with KSHV ORFs showed a
maturation profile that was statistically significantly different from moDCs
FIGURE 4.2: Maturation profile of moDCs transduced with different KSHV ORFs
or groups of ORFs. Maturation profile measured as the proportion of moDCs [non-
transduced (white bar); transduced with the pSIN empty lentiviral vector (red bar); or
transduced with KSHV ORFs or groups of ORFs (grey bars)] that were both HLA-DR-
positive and CD80-positive using flow cytometry. Means and standard deviations across
all study participants (n = 21) are shown. Stars indicate proportion of double-positive
moDCs significantly different from that in moDCs transduced with empty pSIN. **
indicates p<0.01; * indicates p<0.05 (paired student T test).
0.0
20.0
40.0
60.0
80.0
100.0
No virus pSIN ORF71 ORF72
ORF73
K11.1
K12 K15
ORF45
ORF50
ORF58
ORF74
K2 K4
K6 K8
K14
ORF57 K5 ORF8
ORF49
ORF61
ORF59
ORF65
K4.1
K3 K9 ORF28
ORF36
ORF37
ORF33
K1 K8.1
%
C
e
l
l
s
C
D
8
0
+
a
n
d
H
L
A
D
R
+
%
m
o
D
C
s
t
h
a
t
a
r
e
C
D
8
0
+
a
n
d
H
L
A
D
R
+
No virus pSIN ORF71 ORF72
ORF73
K11.1
K12
K15
ORF45
ORF50
ORF58
ORF74
K2
K4
K6
K8
K14
ORF57 K5 ORF8
ORF49
ORF61
ORF59
ORF65
K4.1
K3 K9 ORF28
ORF36
ORF37
ORF33
K1
K8.1
Controls Latent Immediate-Early Lytic Early Lytic Late Lytic
**
** ** **
** * * *
p<0.001178
transduced with the empty pSIN vector (paired student T test; Figure 4.2).
However, none of these differences were numerically large, and all were within 5%
of the proportion of double-positive moDCs transduced with pSIN alone (89.2%).
The range across all transduction conditions was 85.1% to 93.5%; the inter-quartile
range was 86.6% to 91.7%; the median was 89.0%; and the mean was 89.2%.
Populations of moDCs with 85.1% to 93.5% HLA-DR/CD80 double-positive cells
can be considered to represent effectively homogenous populations of mature,
highly stimulatory moDCs. This level of variation would not be expected to affect
the stimulatory capacity of moDCs in T-cell response assays (and, indeed, was
demonstrated not to; sections 4.1.d – 4.1.f).
Interestingly, moDCs transduced with ORF71, K5 or K9 (ORFs known to affect
MHC-I expression) showed a modest but statistically significant increase in the
proportion of double-positive cells as compared to moDCs transduced with pSIN
alone (93.5%, 92.5% and 91.5%, respectively compared to 89.2%). ORF71 (which
codes for the latency protein vFLIP) upregulates MHC-I expression at the
translational level by activating the NFκB pathway (Lagos et al., 2007) and has 
recently been shown to promote the upregulation of CD80 and other costimulatory
molecules and to drive moDC maturation through the same pathway (Rowe et al.,
2009). Paradoxically, both K5 (MIR2) and K9 (vIRF1) downregulate MHC-I
expression. K9/vIRF1 downregulates MHC-I by binding to the transcriptional co-
activator p300 in competition with IRF1 and IRF3 and thereby blocking type I and
II IFN-mediated activation of MHC-I transcription (Lagos et al., 2007). K5/MIR2
downregulates MHC-I by enhancing its endocytosis from the cell surface. The
internalised MHC-I molecules are delivered to endolysosomal vesicles where they179
are degraded (Coscoy and Ganem, 2000). It is thus surprising that moDCs
transduced with these ORFs showed an increase (albeit very slight) in the
proportion of HLA-DR/CD80 double-positive cells.
moDCs transduced with [ORF72/ORF73], [ORF45/ORF50/ORF58],
[ORF59/ORF61/K4.1], [ORF28/ORF36/ORF37] and [ORF33,K1/K8.1] all showed
a modest but statistically significant decrease in the proportion of double-positive
cells compared to moDCs transduced with pSIN alone (85.6%, 86.5%, 85.1%,
88.9% and 86.7% respectively compared to 89.2%). Infection of CD14-positive
monocytes with KSHV has been shown to inhibit their differentiation into moDCs,
and to reduce the moDCs allogenic stimulatory capacity both before and after
maturation. In particular, a strong reduction in the expression of CD80 on the cell
surface of KSHV-infected mature moDCs was reported (Cirone et al., 2007).
Further investigation of the effect of the ORFs above on moDC maturation and
CD80 expression may therefore be warranted, in particular those groups of ORFs in
which the greatest reduction in double-positive cells was seen ([ORF72/ORF73]
and [ORF59/ORF61/K4.1]).
4.1.d T-cell Proliferation Responses to Lentiviral-transduced
moDCs Expressing KSHV ORFs
CFSE-stained T cells were cultured with autologous moDCs transduced to express
up to three KSHV ORFs grouped according to their expression profile. After six
days, T cells were harvested and flow cytometry was used to assess the CD8-
positive cytotoxic lymphocyte (CTL) response and the CD8-negative (CD4) helper180
T-cell response to each KSHV ORF or pool, as measured by the proportion of
CFSE-low proliferating cells. Gating strategy is shown in Figure 4.3. See section
3.3.b for the rationale behind staining for CD8 only.
An example of CD8 and CD4 responses by one HIV-positive, KSHV-seropositive
individual (V689; group 4) are shown in Figures 4.4.a and 4.4.b, respectively. Strict
criteria were used to designate positive and borderline positive responses (see
section 2.4.d) to ensure that no false positives were recorded as a result of the slight
variation observed in individuals’ background response to moDCs transduced with
the empty vector alone. This may mean that some weak T-cell responses were not
identified in some or all KSHV-seropositive individuals. However, it allows us to
observe patterns of immunodominant T-cell responses against KSHV.
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FIGURE 4.3: Gating strategy for T-cell proliferation responses to moDCs expressing
KSHV ORFs. Live T lymphocyte gate was set according to forward scatter and side
scatter. Gates were then set on either the CD8-high or CD8-low (CD4) T-cell population.
The proportion of proliferating CD8 or CD4 T cells was measured by the proportion of
CFSE-low cells within each population.181
FIGURE 4.4: Example of CD8 (a) and CD4 (b) responses to moDCs transduced
with each KSHV ORF or pool of ORFs by T cells from one study participant
(V689; HIV+, KSHV+, history of KSHV-related neoplasm, in remission). Bar
graphs show the proportion of CFSE-low cells in response to each ORF or pool of ORFs
(with the background response to moDCs transduced with the empty pSIN vector
subtracted). Mean of triplicates and standard deviations are shown. Two stars indicate a
response that was considered to be positive; one star indicates a response that was
considered to be borderline positive according to the criteria described in section 2.4.d.
Flow cytometry histograms show examples of strong (top), medium (middle) and
negative (bottom) CD8 (a) or CD4 (b) responses to different KSHV antigens from the
same study participant (V689). In all histograms, grey shading represents CD8 or CD4
T cells cultured with moDCs transduced with the empty pSIN vector and black open
lines represent CD8 or CD4 T cells cultured with moDCs transduced with different
KSHV antigens.
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CD8 and CD4 responses by all participants to all KSHV ORFs or pools are
summarised in Figure 4.5.a and Figure 4.5.b, respectively. A single borderline CD8
response (participant C122 to [ORF74/K2/K4]) and two borderline CD4 responses
(participant HC3 to [ORF59/ORF65/K4.1]; and participant D403 to
[ORF28/ORF36/ORF37]) were observed in KSHV seronegative individuals
compared to 32 CD8 responses and 21 CD4 responses by KSHV seropositive
individuals. This gives us confidence that the responses observed to KSHV ORFs
are indeed KSHV-specific. Interestingly, one of the borderline CD4 responses
observed in a KSHV seronegative individual was in D403, who had a KSHV
antibody titre only just below the cut-off value for seropositivity (0.129 ± 0.02
compared to 0.145; see section 4.1.b). It is possible that this weak T-cell response
against KSHV and relatively high KSHV antibody titre both result from previous
abortive exposure to KSHV.
One of the two participants with active classic KS (W962) did not respond to any of
the KSHV ORFs (CD8 or CD4) and the other (S346) gave only one borderline CD4
response (against [ORF8/ORF49/ORF61]). The asymptomatic carrier of KSHV
(H419) gave six strong positive CD8 responses and one borderline and four strong
CD4 responses to different KSHV ORFs. Of the 11 HIV+ individuals with a history
of KSHV-related disease, six (D208, S079, K058, B625, T514 and T328) gave one
or no responses (total of CD8 and CD4), and were classified as poor responders.
There were no notable differences in the ages, CD4 counts or years in remission
from KSHV-related disease between the poor responders and good responders (i.e.
those that gave one or more total CD8- and CD4-mediated responses). However,
interestingly, one poor responder (D208) suffered a relapse of KS within a year of183
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K058 nd nd 0
P940 3
B625 0
M620 4(5)
V689 1(3)
A556 8
B196 5(6)
T541 0(1)
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T328 0
S346 0 HIV-, KSHV+, Active KS
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Total responses in KSHV+ individuals 1 2 1 0 2 4 0 0 5(6) 4(5) 0 0 5(7) 3(4) 27(32)
FIGURE 4.5.a: Summary of CD8 T-cell responses to KSHV ORFs by all study participants. Dark blue boxes represent positive responses; light blue
boxes represent borderline responses; unfilled boxes represent no response. Nd indicates experiment not done due to insufficient numbers of PBMCs.
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S079 1
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Total responses in KSHV+ individuals 0 1(2) 0(1) 0 1 1 0 0 4(6) 3(4) 0 0 2 3(4) 15(21)
FIGURE 4.5.b: Summary of CD4 T-cell responses to KSHV ORFs by all study participants. Dark green boxes represent positive responses; light
green boxes represent borderline responses; unfilled boxes represent no response. Nd indicates experiment not done due to insufficient numbers of
PBMCs.
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venesection for this experiment. Three other poor responders (S079, B625 and T328)
had received no cancer-specific chemotherapy treatment in addition to their
antiretroviral therapy, whereas all good responders received HAART in combination
with cancer chemotherapy. All poor responders had a history of KS alone, except for
K058, who had been treated for PEL. Of the good responders, three (M620, A556 and
B196) had a history of KS alone and two (P940 and V689) had a history of KS and
MCD. These study participant characteristics are summarised in Table 4.3.
moDCs transduced with an adenovirus encoding the immunodominant CMV gene
phosphoprotein 65 were used as a positive control to demonstrate that T cells from
KSHV seronegative individuals were capable of responding to transduced autologous
moDCs. All seven KSHV seronegative individuals mounted strong positive CD8
responses and five out of seven gave positive CD4 responses (and a further one gave a
borderline CD4 response) to Adpp65-transduced moDCs (Figure 4.6). The T-cell
responses, in particular CD8 responses, to Adpp65-transduced moDCs were much
stronger (an average of 52.6 ± 16.0 % proliferating CD8 T cells) than responses to
moDCs transduced with KSHV ORFs (an average of 15.7 ± 4.9% proliferating CD8 T
cells). This may be due to a number of factors. The T-cell responses against KSHV
recorded to date have been consistently lower in both frequency and magnitude than
responses to other viruses (Bihl et al., 2007b; Brander et al., 2001). Thus, circulating
CMV-specific T cells may be of higher frequency than KSHV-specific T cells and
may hence mount a stronger proliferation response to stimulation. However, it is
likely that the different expression vectors used (adenoviral versus lentiviral) result in
different transduction efficiencies as well as differences in levels of antigen
processing and presentation and so differences between CMV-specific and186
Participant
ID
Age CD4
Count
KSHV-related
disease history
Treatment for KSHV-related disease Approximate years
between active disease
and venesection
D208 46 785 KS HAART + chemotherapy + radiotherapy <1, since relapsed
S079 74 183 KS HAART only 2
K058 46 565 PEL HAART + chemotherapy 3.5
B625 39 406 KS HAART only <1
T541 51 171 KS HAART + chemotherapy 5
T328 40 308 KS HAART only <1
Poor
Responders
Mean 49 403 2
P940 36 645 KS and MCD HAART + chemotherapy <1
M620 38 496 KS HAART + chemotherapy + radiotherapy 8.5
V689 53 281 KS and MCD HAART + chemotherapy 1.5
A556 49 226 KS HAART + chemotherapy 3.5
B196 49 209 KS HAART + chemotherapy <1
Good
responders
Mean 45 371 3
Table 4.3: Characteristics of HIV-positive study participants in remission from KSHV-related disease.
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FIGURE 4.6: T-cell responses by KSHV-seronegative controls to autologous
moDCs transduced with Adpp65. a. Example flow cytometry histograms showing
CD8 (left) and CD4 (right) responses to Adpp65-transduced moDCs by one individual
(S810; HIV+, KSHV-seronegative). Grey shading represents T cells cultured with non-
transduced autologous moDCs; black open lines represent T cells cultured with
Adpp65-transduced autologous moDCs. b. and c. Summary of CD8 (b) and CD4 (c)
responses to Adpp65 by all KSHV-seronegative controls (with the background response
to non-transduced moDCs subtracted). Means and standard deviations of triplicate
experiments are shown. ** indicates positive response above background; * indicates
borderline positive response above background.188
KSHV-specific responses could not be quantitatively compared using the results
from this experiment. Furthermore, an empty adenoviral vector was not available as
a control, and thus the measured T-cell responses to Adpp65 represent the
combined responses to the CMV antigen as well as any antigens derived from the
adenoviral vector. With responses to moDCs transduced with KSHV ORFs, vector-
specific response was controlled for by subtracting the background response to
moDCs transduced with the empty lentiviral vector alone. Vector-specific responses
are reportedly stronger to adenoviral vectors than to lentiviral vectors, partly due to
inherent differences in the host immune response to the viruses from which they are
derived, and partly due to differences in the construction of the vectors [(Collins
and Cerundolo, 2004; Palmowski et al., 2004); see section 1.4.b Antigen Delivery to
Dendritic Cells].
4.1.e Targets of the KSHV-specific CD8 CTL T-cell Response
CD8 responses to KSHV ORFs by all responsive KSHV-seropositive individuals
showed a bias towards early lytic and late lytic gene products (Figure 4.5.a.). Out of
a total of 32 CD8 responses observed, four were directed against latent ORFs; six
against immediate-early lytic ORFs; 11 against early lytic ORFs; and 11 against late
lytic ORFs. Two pools of early lytic ORFs were frequently recognised CD8 targets:
[ORF8/ORF49/ORF61] was recognised by six individuals and
[ORF59/ORF65/K4.1] was recognised by five individuals. ORF8 codes for
glycoprotein B, which contains a well-described CD8 epitope, aa492-500
[LMWYELSKI; (Wang et al., 2002b)]. ORF61 codes for a large ribonucleotide
reductase essential for DNA synthesis and also contains a previously documented189
CD8 epitope, aa505-513 [GLADVFAEL; (Lambert et al., 2006)]. ORF65 codes for
the minor capsid protein which has also been identified as a target of the KSHV-
specific CD8 T-cell response, and contains one identified CD8 epitope [aa35-43;
NMSQAEYLV; (Lambert et al., 2006)]. One pool of late lytic ORFs –
[ORF28/ORF36/ORF37] – was recognised by seven individuals, and thus was the
most frequently recognised target of CD8 T cells by this study cohort. This was of
particular interest to us as none of the gene products in this pool have been
previously investigated for immunogenicity. For the same reason, a pool of
immediate-early ORFs – [K6/K8/K14] – that was recognised by four individuals
was also of interest.
4.1.f Targets of the KSHV-specific CD4 T-cell Response
CD4 responses to KSHV ORFs by all KSHV-seropositive individuals also showed
a bias towards early lytic and late lytic gene products (Figure 4.5.b). Out of a total
of 21 CD4 responses observed, three were directed against latent ORFs; two against
immediate-early lytic ORFs; 10 against early lytic ORFs; and six against late lytic
ORFs. The most frequently recognised CD4 targets were the pool
[ORF8/ORF49/ORF61], comprised of early lytic antigens, which was recognised by
six individuals; and the pools [ORF59/ORF65/K4.1] (early lytic antigens) and
[ORF33/K1/K8.1] (late lytic antigens), which were each recognised by four
individuals. Out of these pools, the K8.1 gene product has previously been
identified as a target of the KSHV-specific CD4 T-cell response, although no
specific epitope was identified (Barozzi et al., 2008), but none of the remaining190
ORFs have been previously investigated as potential CD4 antigens. Interestingly,
the only pool which contained ORFs in which CD4 epitopes have been previously
identified ([K11.1/K12/K15]) was only recognised by CD4 T cells from one
individual (H419; HIV-positive, KSHV-seropositive asymptomatic carrier of
KSHV). This pool contains K12 and K15, both ORFs in which CD4 epitopes were
previously identified that elicited a response in one HIV-positive, asymptomatic
carrier of KSHV out of 52 KSHV-positive individuals (35 of which HIV-positive)
tested (Guihot et al., 2006).
4.2 Asymptomatic Carriers of KSHV
The strong CD8 and CD4 responses mounted by the asymptomatic carrier of KSHV
(H419) and the often weak or lack of responses seen in individuals with a history of
KSHV-related disease prompted me to look for further asymptomatic carriers of
KSHV in which to perform the immunogenic screen.
4.2.a KSHV Seroprevalence in HIV-positive Individuals
Regular attendees to an HIV-clinic at Chelsea and Westminster Hospital were tested
for KSHV seropositivity by multi-antigenic ELISA. Results are shown in Table 4.4.
Out of 27 individuals tested, eight were KSHV seropositive giving a 30%
seroprevalence of KSHV in this cohort of HIV-positive individuals. Seroprevalence
was higher in men (seven out of 22; 32%) than in women (one out of five; 20%).191
No particular association was observed between an individual’s KSHV serostatus
and whether or not they originated from a country where KSHV is endemic (Ghana,
Italy, Nigeria, Uganda, Zimbabwe). Two men from Italy were seronegative; one
man and one woman from Nigeria were both seronegative; two women from Sub-
Saharan Africa (one from Uganda and one from Zimbabwe) were also seronegative.
Only one of the eight KSHV-seropositive individuals was born in a country where
KSHV Serostatus Participant
ID
Negative Positive
Gender Ethnicity Country
of Birth
V245 N M White – British UK
I418 N M Black – African Nigeria
H850 P M White – British UK
F692 N M White – Other Italy
C971 P M White – Other Uruguay
W864 N M White – British UK
K305 N M Black – Caribbean Jamaica
E176 P M White – Other France
G020 N M White – Other Portugal
W688 P M White British UK
T378 P M White – Other Germany
M582 N M White – Irish Ireland
C329 N M White – Irish Ireland
D786 N M Mixed Ethiopia
B661 N M White – British UK
J145 P M White – British UK
T407 P M White – British UK
P722 N M White – British UK
V340 N M White – Other Italy
B084 N M White – British UK
S577 N M White – Other Portugal
L451 N M Chinese China
S562 N F Mixed White/Black UK
G781 P F Black African Ghana
O763 N F Mixed White/Black Uganda
A266 N F Black African Nigeria
K081 N F Black African Zimbabwe
TABLE 4.4: Prevalence of asymptomatic KSHV infection in an HIV-positive cohort.
P = positive; N = negative; M = male; F = female.192
KSHV is endemic (G781; a woman born in Ghana). Seven of the eight KSHV-
seropositive individuals were ‘White – British’ or ‘White – Other’ males, and six of
these were born in Western Europe in countries where KSHV seroprevalence in the
general population is low (UK, France or Germany). It thus seems likely that the
majority of KSHV prevalence observed in this cohort is associated with
homosexual practices, although this information was not available.
4.2.b Screen for Immunogenic KSHV ORFs in Three
Asymptomatic Carriers of KSHV
Of the eight HIV-positive individuals with no history of KSHV-related disease who
were identified as KSHV seropositive, I was able to collect further peripheral blood
samples from three individuals (E176, G781, H850) for use in the screen for
immunogenic KSHV ORFs. However, disappointingly, no CD8 or CD4 responses
were observed to any of the KSHV ORFs or pools of ORFs in any of these
individuals. Furthermore, none of the three individuals mounted CD4 responses to
moDCs transduced with Adpp65 (used as a positive control), and CD8 responses to
Adpp65-transduced moDCs were absent in individual H850 and greatly reduced in
individual G781 (16.6% proliferating T cells) compared to CMV-specific CD8
responses observed in the seven KSHV-seronegative controls (mean 52.6%
proliferating T cells; see section 4.1.d and Figure 4.6). Only CD8 T cells isolated
from E176 responded significantly to Adpp65-transduced moDCs, with 63.9% of
CD8 T cells proliferating in response to stimulation.193
On further consultation with the physicians treating these individuals, I discovered
that each of these individuals were receiving chemotherapy for other types of
cancer (E176 had anal cancer; G781 had ovarian cancer; and H850 had Hodgkin’s
lymphoma) as well as drugs to suppress opportunistic infections at the time of
venesection. It seems likely that the chemotherapy drugs taken by these individuals
suppressed either the ability of their moDCs to process and present antigens or the
ability of their T cells to proliferate in response to stimulation in this culture system,
or had substantially depleted the individuals’ memory T cells, thus explaining these
negative results. Although CD8 T cells from individual E176 responded to Adpp65
transduced moDCs, CD8 responses to KSHV ORFs by this individual were still not
observed. This may yet be a suppressive effect of the individual’s chemotherapy
regime, damping down the weaker responses to KSHV ORFs but still allowing
stronger responses to Adpp65-transduced moDCs to be observed (see section 4.1.d).
The cell-surface expression of HLA-DR and CD80 by moDCs from these
individuals was not notably reduced as compared to the other participants in this
study (see section 4.1.c). Across all three individuals and all different transduction
conditions the mean proportion of HLA-DR and CD80 double-positive cells was
90.0 ± 6.3% compared to a mean proportion of 89.2 ± 9.5% double-positive cells
seen across all transduction conditions in all 21 participants included in the
previously described immunogenic screen (Figure 4.2).
It thus seemed that although moDCs from individuals with non-KSHV-related
cancers and undergoing chemotherapy were not notably lacking in the expression of
antigen-presenting cell-surface markers, these individuals were still not appropriate194
for use in this model system for investigating KSHV-specific T-cell responses. It
seems likely that disease- or therapy-related damage to the cells of their immune
system reduced their ability to prime, recognise or respond to antigens, or had
caused substantial loss of the individuals’ memory T-cell compartment.
Unfortunately, I found that comparatively healthy asymptomatic carriers of KSHV
attended clinics too infrequently for follow-up collection of peripheral blood
samples to be practical. Thus, the original target cohort of individuals with a history
of KSHV-related neoplasia attending follow-up clinics after treatment does indeed
seem to be the most appropriate for further immunological studies.
4.3 Summary
The experimental method of using lentiviral-transduced moDCs expressing KSHV
ORFs to investigate the targets of the KSHV-specific T-cell response had several
advantages as a system for performing a broad screen for immunogenic KSHV
ORFs. In particular, no prior knowledge of the optimal epitope or HLA-restriction
was required, and far more ORFs could be investigated for immunogenicity than
would be possible using artificial peptides. The use of overlapping peptides to test
the immunogenicity of the 31 KSHV gene products included in this screen would
be impractical, and even the use of epitope prediction software (Immune Epitope
Database; www.immuneepitope.org.uk) yielded over 1000 potential nine-mer
epitopes (IC50 value less than 5000 nM; see sections 2.5.c and 5.1.e) from these 31
genes for HLA-A*0201 alone (data not shown). The lentiviral library system
offered a good overview of the immunogenic profile of KSHV, and enabled the
identification of antigenic hotspots within the KSHV genome. Unexpectedly, the195
results indicated that early lytic and late lytic gene products are the major targets of
the KSHV-specific immune response.
However, the lentiviral system also had limitations. The experiments were very
long and time-consuming. The variable background response to moDCs transduced
with the empty pSIN vector meant that strict criteria were applied to designate
positive and borderline positive responses (see Materials and Methods section
2.4.d) in order to ensure that no false positives were recorded. Thus the system may
not have been very sensitive, and some weak T-cell responses may not have been
identified in some or all KSHV-seropositive individuals. Moreover, the long
duration of each experiment, coupled with the background response to the empty
vector, made the system unsuitable for further functional characterisation of the
KSHV-specific T-cell response, for example by using intracellular staining
techniques such as those described in section 3.3.b. It was thus decided to use the
information that had been gathered using the lentiviral system to embark on an
epitope discovery project to identify new late lytic KSHV epitope(s) and to
investigate alternative protocols for the exploration of the functional properties of
KSHV-specific T cells. This work is described in Chapter 5.196
CHAPTER 5: Identification of an Immunodominant
Late Lytic KSHV Epitope; Pentamers as Tools to
Explore Phenotypes and Functions of Virus-Specific
T cells; T-cell Memory Phenotypes in KSHV Infection
Although several HLA-restricted, KSHV-specific CD8 epitopes have been
identified, the frequency of recognition of these epitopes is low and the responses
they elicit appear weak compared with responses to known epitopes from other
viruses such as HIV-1 and EBV (Bihl et al., 2007b; Brander et al., 2001). For
example, Table 5.1 shows all published HLA-A*0201-restricted KSHV epitopes
with an accumulated tally of the number of responses observed to each of these
epitopes by all individuals (from all publications) in which the epitope has been
tested. Strikingly, only three of these 21 epitopes have been confirmed by more than
one study (LLNGWRWRL from K12; LMWYELSKI from ORF8; and
FLNWQNLLNV from ORF22), and less than half (10 out of 21 epitopes) have
been tested in more than 10 individuals. Of these 10 epitopes, only six elicited
responses in more than five percent of individuals tested (LLNGWRWRL from
K12; VLGDEVLSL from ORF6; LMWYELSKI from ORF8; GLADVFAEL from
ORF61; NMSQAEYLV from ORF65; and FLNWQNLLNV from ORF22). For
these six epitopes, the percentage of responders to each epitope ranged from 16% to
46% of all individuals (HIV-negative and HIV-positive) tested, and 13% to 32% of
all HIV-positive individuals tested. The two most frequently recognised epitopes (of
those tested in more than 10 individuals) appear to be LLNGWRWRL from K12197
Viral Gene
Expression
KSHV ORF Peptide Total HIV+ and HIV-
Responders (Percentage)
Total HIV+ Responders
(Percentage)
References
FTSGLAPAFV 1 of 52 (2) 1 of 35 (3) Guihot et al., 2006
WATESPIYV 2 of 52 (4) 2 of 35 (6) Guihot et al., 2006
ORF73
QMARLAWEA 2 of 52 (4) 2 of 35 (6) Guihot et al., 2006
*LLNGWRWRL 23 of 61 (38) 12 of 37 (32) Brander et al., 2001
Bourboulia et al., 2004
Lambert et al., 2006
K12
VLLNGWRWRL 2 of 4 (50) 1 of 3 (30) Micheletti et al., 2002
Latent
K15 ILFTSTFAV 1 of 52 (2) 1 of 35 (3) Guihot et al., 2006
K5 *ALYAANNTRV 4 of 7 (57) Nt Ribechini et al., 2006 Immediate-
Early Lytic ORF6 *VLGDEVLSL 18 of 46 (39) 4 of 23 (17) Lambert et al., 2006
GLAAATWVWL 4 of 8 (50) Nt Ribechini et al., 2006 K3
FVFYQLFVV 1 of 8 (13) Nt Ribechini et al., 2006
ORF8 **LMWYELSKI 33 of 131 (25) 16 of 85 (19) Wang et al., 2002b
Bourboulia et al., 2004
Guihot et al., 2006
Lambert et al., 2006
Guihot et al., 2008
ORF61 *GLADVFAEL 13 of 46 (28) 3 of 23 (13) Lambert et al., 2006
ORF65 *NMSQAEYLV 22 of 48 (46) 6 of 24 (25) Lambert et al., 2006
VVQELLWFL 2 of 5 (40) Nt Ribechini et al., 2006
SLLTYMLAHV 1 of 5 (20) Nt Ribechini et al., 2006
Early Lytic
ORF70
*YMLAHVTGL 5 of 5 (100) Nt Ribechini et al., 2006
K8.1 *LVLILYLCV 4 of 8 (50) 4 of 8 (50) Bourboulia et al., 2004
ORF22 *FLNWQNLLNV 14 of 85 (16) 13 of 67 (19) Micheletti et al., 2002
Bourboulia et al., 2004
Guihot et al., 2006
Guihot et al., 2008
FQWDSNTQL 3 of 6 (50) Nt Ribechini et al., 2006
IVLESNGFDL 3 of 6 (50) Nt Ribechini et al., 2006
Late Lytic
ORF26
VLDDLSMYL 4 of 6 (67) Nt Ribechini et al., 2006
TABLE 5.1: Frequency of recognition of all published A*0201-restricted KSHV CD8 epitopes. * indicates epitopes tested for recognition by
ex vivo T cells from A*0201-positive, KSHV-positive individuals (section 5.2); ** indicates epitope included in HLA-binding and off-rate assays
and in silico analysis (section 5.1) as well as in later ex vivo assays.
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(recognised by 38% of all individuals tested and 32% of all HIV+ individuals
tested) and NMSQAEYLV from ORF65 (recognised by 46% of all individuals
tested and 25% of all HIV+ individuals tested). However, it seems reasonable to
conclude that there is no immunodominant HLA-A*0201 epitope evident from the
compiled data from these studies (see Table 5.1).
From the work described in Chapter 4 of this thesis, a search for new epitopes
derived from within the late lytic KSHV antigens ORF28, ORF36 and ORF37 (the
three ORFs in the pool that elicited the most responses in the lentivirus-based
screen) seemed warranted. MHC binding assays and computer algorithms were
used to identify potential HLA-A*0201 epitopes from within ORF28, ORF36 and
ORF37. These potential epitopes were then tested in clinical samples alongside nine
of the most frequently recognised known HLA-A*0201-restricted epitopes
(indicated in Table 5.1) in order to investigate further the patterns of recognition of
these epitopes, and in an attempt to identify an immunodominant epitope(s).
Identification of such an epitope would be a useful tool for further exploration of
the KSHV-specific T-cell response. In particular the functions and memory
phenotypes of KSHV-specific CD8 T cells remain largely unexplored, but novel
technology may allow better investigation and understanding of this field. Since
their introduction 13 years ago (Altman et al., 1996), tetrameric moieties
(‘tetramers’) have been useful tools for investigating the memory phenotypes and
functions of T cells specific for viruses such as CMV and HIV-1 (Appay et al.,
2000; Chen et al., 2001). Tetramers are synthetic T-cell receptor (TCR) ligands
comprised of four MHC-peptide complexes conjugated to a fluorescent tag via a199
streptavidin moiety, thus allowing fluorescent labelling of T cells specific for a
known epitope. More recently, pentamers have been developed with the goal of
improving TCR labelling. Such pentamers are pentavalent (and so have five MHC-
peptide complexes available for TCR binding) and also have a higher number of
fluorescent tags, designed to increase the brightness of fluorescence. However, with
KSHV, a limitation to such investigations has been the paucity of known
immunodominant epitopes to target.
Such an epitope would also be a useful tool for tracking changes in the KSHV-
specific T-cell response during chronic infection and disease. Furthermore, it could
have a potential clinical application, for example, in vaccine design.
5.1 Identification of Potential CD8 Epitopes from Late Lytic
KSHV Gene Products
5.1.a Target HLA-restriction
Before embarking on a search for potential new late lytic epitopes, a target HLA-
restriction needed to be selected. The seven individuals who mounted CD8
responses against the late lytic KSHV gene pool [ORF28/ORF36/ORF37] were
HLA typed. Results are shown in Table 5.2. The most frequently arising HLA
alleles amongst these seven individuals were A*0201 (four out of six typed);
B*0702 (three out of six typed); Cw*0702 (three out of seven); and DRB1*1501
(four out of seven).200
High Resolution HLA Types Participant
HIV/KSHV Status
Participant
ID
A B Cw DRB1
P940 *0201
*2902
*0702
*4403
*0702
*1601
*0701
*1501
M620 *2402
*2902
*5101
*1402
*0802
*1502
*0402
*1302
V689 *0201
*0301
*0702
*3501
*0702
*0401
*0101
*1501
A556 *0201
*2402
*1302
*4402
*0602
*0501
*0401
*1501
B196 nd nd *0602
*1601
*0701
*1102
HIV+, KSHV-related
neoplasia in remission
T541 *0201
*2601
*0801
*1801
*0701
*1203
*0301
*1103
HIV+, Asymptomatic H419 *0301 *0702
*1501
*0702
*0304
*0401
*1501
It was decided to focus on HLA-A*0201-restricted epitopes, as this was the most
common MHC-I allele in the seven responders to the late lytic ORF pool.
Moreover, HLA-A*0201 is recognised to be one of the most common alleles in the
general population. For example, in the population of North America, HLA-A*0201
is the most common HLA allele carried by Caucasians and Hispanics, found in
45.6% and 37.1% of individuals respectively. HLA-A*0201 is also the fourth most-
common HLA allele amongst African-Americans, carried by 22.3%; and the eighth
most-common HLA allele in those of South-East Asian origin, carried by 18.1%
(source: HLA matchmaker; http:tpis.upmc.edu/tpis/HLAMatchmaker/). Thus HLA-
Table 5.2: High resolution HLA types of all individuals who showed CD8 T-cell
responses to the [ORF 28/ORF 36/ORF37] KSHV gene pool.201
A*0201-restricted epitopes are likely to be useful for future immunological
investigations or the development of vaccines or immunotherapies.
5.1.b Target Immunogenic KSHV Open Reading Frame
As discussed in section 4.1.e, the gene pool most frequently recognised by CD8 T
cells from KSHV+ individuals was the late lytic pool [ORF28/ORF36/ORF37]
(recognised by seven out of 14 individuals) and none of the gene products from this
pool have been previously investigated for immunogenicity. Thus a search for novel
KSHV CD8 epitopes from within this pool seemed warranted.
To narrow down this search, the likelihood of each of the gene products in the
[ORF28/ORF36/ORF37] pool being immunogenic was considered. Firstly, the
function of each of these proteins was examined. ORF28 has been classified as an
envelope glycoprotein based on positional and structural similarities to EBV
BDLF3 (Zhu et al., 2005), which encodes the EBV glycoprotein gp150. Viral
glycoproteins are often targets of anti-viral T-cell responses (Torseth et al., 1987;
Wallace et al., 1999). Three other KSHV glycoproteins (glycoprotein B, encoded by
ORF8; glycoprotein H, encoded by ORF22; and glycoprotein 35/37 encoded by
K8.1) are documented targets of the KSHV-specific CD8 T-cell response
(Micheletti et al., 2002; Wang et al., 2002b; Wilkinson et al., 2002). KSHV ORF36
encodes a serine protein kinase (Hamza et al., 2004) and ORF37 a modified DNA
exonuclease involved in host mRNA shut off (Glaunsinger and Ganem, 2004).
There is no evidence to indicate that either of these gene products is likely to be
immunogenic.202
Secondly, the amino acid (aa) sequence of each of the three ORFs was examined. In
the search for immunodominant virus-specific epitopes it seems logical to focus on
viral gene products with aa sequences that share the least similarity with proteins
from other pathogens, as epitopes derived from such proteins are the most likely to
be biologically relevant in terms of effective host control of viral infection. This is
supported by observations of the EBV-specific T-cell response (personal
communication with Professor Alan Rickinson). The NCBI BLAST ‘blastp’ tool
was used to search for proteins that shared regions of aa sequence with each of the
three KSHV ORFs of interest. Results are shown in Figure 5.1.
The results for ORF28 returned a match to two identical published aa sequences for
the KSHV ORF28 gene product. Other than this, there was no sequence similarity
between ORF28 and any other known proteins from other viruses. The only
matches returned were occasional loose similarity between the ORF28 aa sequence
and proteins from thermal bacteria, yeast and rice. This confirmed reports that
although KSHV ORF28 is the positional equivalent of EBV BDLF3, its gene
product shares no aa sequence similarity to EBV gp150 (Zhu et al., 2005).
The results for ORF36 and ORF37 showed considerable sequence similarity
between these gene products and their equivalent proteins in a host of other
herpesviruses that infect a range of animal species. Of particular significance,
KSHV ORF36 shares several aa residues with its EBV homologue BGLF4 and
KSHV ORF37 shares several aa residues with its EBV homologue BGLF5. It was
thus decided to focus initially on KSHV ORF28 in a search for new epitopes.203
FIGURE 5.1: Sequence similarity between KSHV ORF28, ORF36 and ORF37 and
genes from other viruses. Results from an NCBI ‘BLAST’ search for sequences that
align to ORF28 (top panel), ORF36 (middle panel) and ORF37 (bottom panel). Each
ORF’s sequence is indicated by the red line with base pair graduations at the top of each
panel. The lines below represent genes with sequence similarity. The degree of sequence
alignment is indicated by the colour of the line (colour key at top). Colour-coordinated
labels at the side show the origins of the genes represented by each line.
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5.1.c Binding Affinities of KSHV ORF28-derived Peptides to HLA-
A*0201
REVEAL™ assays (ProImmune Ltd., Oxford, UK), which measure MHC-peptide
binding affinity and denaturation rates (section 5.1.d), were used to identify putative
candidate HLA-A*0201-restricted epitopes from within ORF28.
Ninety-four overlapping nine-mer peptides, off-set by one amino-acid residue, were
synthesised spanning the entire amino acid sequence of ORF28 and numbered P1 to
P94 sequentially (see Materials and Methods Table 2.8 for peptide sequences). One
of the best documented KSHV HLA-A*0201-restricted epitopes, LMWYELSKI
(aa492-500 from glycoprotein B/ORF8 [Gb492-500]; indicated on Table 5.1), was
also included in the screen for comparison, and was designated P95. The
REVEAL™ binding assay measured the ability of each peptide to bind to HLA-
A*0201, and compared this to the binding affinity of a known high-affinity
A*0201-restricted T-cell epitope (the influenza matrix protein epitope,
GILGFVFTL) in order to identify putative immunogenic peptides. An intermediate-
affinity control (whose identity was undisclosed by the manufacturer, but was
described as: ‘a known T-cell epitope of marginal binding’) was also included in the
assay for comparison. Results are shown in Figure 5.2 and Table 5.3.
Each peptide was given a binding score as a percentage relative to the binding of
the high-affinity positive control, GILGFVFTL. A ‘pass’ rate was set at 45%. This
was a fairly arbitrary cut-off score, designed to identify the best peptide binders to
prioritise in future experiments. Twelve peptides qualified as ‘passed’ using this
scoring system. Significantly, the ‘pass’ score was higher than the binding score of205
the known intermediate-affinity control (17.54 ± 2.7%). Five further peptides (P31,
P47, P42, P79 and P39) had binding scores above that of the intermediate control
(38.34%, 28.84%, 27.42%, 26.72%, and 20.29% respectively), and so may also be
weaker-binding T-cell epitopes and may warrant further investigation in the future.
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FIGURE 5.2: Binding affinity of ORF28-derived peptides to HLA-A*0201. Binding
shown as a percentage relative to the binding of the known high-affinity HLA-A*0201-
restricted epitope, GILGFVFTL (from the influenza matrix protein; ‘positive control’;
green bars). Dashed line indicates the ‘pass’ rate of 45%, designated to identify the best
binders for use in future assays. Yellow bars indicate the intermediate-affinity control
epitope and the lilac bar indicates the KSHV control epitope (Gb492-500).206
Peptide ID Binding Affinity Peptide ID Binding Affinity
12* 103.49* 53 0.47
Positive Control* 100 ± 2.0* 19 0.42
51* 97.95* 17 0.42
36* 81.20* 11 0.41
30* 79.09* 3 0.41
21* 76.27* 87 0.30
95* 76.25* 8 0.30
55* 71.89* 7 0.30
29* 57.52* 33 0.27
34* 55.69* 73 0.25
45* 55.20* 61 0.25
38* 52.35* 49 0.23
2* 49.80* 43 0.23
31 38.34 9 0.20
47 28.84 93 0.15
42 27.42 86 0.15
79 26.72 57 0.13
39 20.29 26 0.13
Intermediate Control 17.54 ± 2.7 24 0.13
46 15.90 16 0.13
54 13.29 48 0.12
75 12.61 40 0.12
5 11.71 14 0.10
28 3.23 13 0.09
27 2.66 10 0.09
37 2.60 91 0.00
44 2.01 90 0.00
82 1.95 89 0.00
64 1.64 88 0.00
35 1.53 83 0.00
63 1.51 80 0.00
4 1.35 78 0.00
69 1.13 74 0.00
92 1.05 72 0.00
81 1.05 71 0.00
67 1.01 70 0.00
20 0.97 68 0.00
1 0.93 66 0.00
6 0.83 65 0.00
84 0.75 60 0.00
41 0.70 59 0.00
18 0.70 58 0.00
23 0.69 56 0.00
94 0.60 52 0.00
85 0.60 32 0.00
77 0.60 25 0.00
50 0.58 22 0.00
62 0.50 15 0.00
TABLE 5.3: HLA-A*0201 binding affinity of ORF28-derived peptides as a
percentage relative to positive control (highlighted green). KSHV control epitope
(Gb492-500) highlighted lilac; intermediate-affinity epitope highlighted yellow. * indicates
peptides that scored above the ‘pass’ rate of 45%.207
Of the 12 ‘passed’ peptides, one peptide (P12) had a higher binding score than the
positive control, showing 103.49% binding relative to the positive control.
Importantly, the KSHV control epitope, P95, qualified as a passed peptide with a
binding score of 76.25%, indicating that the results of the assay concur with the
results from previous ex vivo studies used to identify KSHV epitopes. However,
five of the peptides from within ORF28 (P12, P51, P36, P30 and P21) were better
binders than the P95 KSHV control peptide epitope, with binding scores of
103.49%, 97.95%, 81.20%, 79.09% and 76.27% respectively.
5.1.d Stability of KSHV ORF28 Peptides in the Context of HLA-
A*0201
For each of the 12 highest-scoring (‘passed’) peptides in the binding assay, the off-
rates for peptide binding to HLA-A*0201 were measured to assess how long each
individual peptide could be presented to T cells to help identify the most useful
epitope. The rate of dissociation for each A*0201-peptide complex was measured at
0 hours (hr), 2 hr and 24 hr at 37ºC (Figure 5.3), and A*0201-peptide complex half-
life values, t1/2 (h), were calculated for each peptide (Figure 5.4 and Table 5.4).
One of the peptides, P30, had an estimated A*0201-binding half-life (40.49h) that
was greater than the positive control (40.37 ± 3.1 hr). Two further peptides (P21
and P51) had estimated A*0201-binding half-lives (24.98hr and 17.89hr
respectively) that were greater than that of the intermediate control (13.54 ± 1.0 hr).
Interestingly, the five peptides (P12, P51, P36, P30, P21; marked with a * on Table
5.4) that scored highest in the REVEAL™ binding assay (section 5.2.a), were also208
FIGURE 5.3: Rate of dissociation of ORF28-derived peptides from HLA-A*0201.
Denaturation of peptide-HLA-A*0201 complexes were measured at 0 hours (hr), 2 hr
and 24 hr at 37ºC and compared to the denaturation rates of positive and intermediate
controls (top two panels) and the KSHV control peptide (P95; bottom right panel).
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Peptide ID Peptide Sequence Half-life (hr)
Binding
Affinity
2 SMTSPSPVT 2.42 49.80
12* GMVDGSVLV 7.10 103.49
21* RMATKPPVI 24.98‡ 76.27
29 IGLITVLFL 0.59 57.52
30* GLITVLFLL 40.49‡ 79.09
34 VLFLLVIGA 2.10 55.69
36* FLLVIGACV 11.81 81.20
38 LVIGACVYC 1.45 52.35
45 YCCIRVFLA 2.68 55.20
51* FLAARLWRA 17.89 97.95
55 RLWRATPLG 1.19 71.89
95 LMWYELSKI 1.40 76.25
Intermediate Control ~ 13.54 ± 1.0 17.54
Positive Control ~ 40.37‡ ± 3.1 100.00
FIGURE 5.4: Estimated half-lives of peptide-HLA-A*0201 complexes for ORF28-
derived peptides, KSHV control peptide (P95; lilac bar) and positive (green bar)
and intermediate (yellow bar) controls. Half-lives were calculated based on the rate of
dissociation of each peptide from HLA-A*0201 at 37ºC.
TABLE 5.4: Estimated half-lives of peptide-HLA-A*0201 complexes for ORF28-
derived peptides; KSHV control peptide (P95; highlighted lilac); and intermediate
(highlighted yellow) and positive (highlighted green) controls. * indicates the five
peptides that scored highest in the binding assay – these were also the five highest-
scorers in the off-rate assay. ‡ indicates that the measurement interval of 24 hr was too
short to calculate this value accurately.
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the five peptides with the longest A*0201-peptide complex half-lives in the
REVEAL™ off-rate assay. Also of interest was that P95, the KSHV control
peptide, was one of the poorest scorers in the off-rate assay with an estimated
A*0201-peptide complex half-life of 1.40h, despite being a middle-ranking scorer
out of the 12 ‘passed’ peptides in the binding assay and despite being previously
identified as an epitope in ex vivo experiments by other groups (Table 5.1).
5.1.e Further In Silico Analysis of ORF28 Peptides
For the 12 ‘passed’ peptides, further in silico analysis was performed. First, each
peptide’s sequence was examined for known A*0201-binding ‘motif’ aa residues.
Each peptide’s binding score and off-rate score (A*0201-peptide complex half-life)
were then compared. Finally, each peptide was run through three ‘epitope-
prediction’ computer algorithms to see how highly they scored in these. Three
known very high-affinity A*0201-restricted T-cell epitopes (GILGFVFTL, the
high-affinity control used in the binding and off-rate assays from the influenza
matrix protein; SLYNTVATL from HIV GAG; and NLVPMVATV from CMV
pp65) were included in these analyses for comparison. All these results are
summarised in Table 5.5. The three algorithms used were Immune Epitope
Database (IEDB; www.immuneepitope.org); SYFPEITHI (www.syfpeithi.de); and
HLA_BIND (www-bimas.cit.nih.gov/molbio/hla_bind/). Each of the ORF28
peptide sequences was also entered into the NCBI PubMed search engine
(www.ncbi.nlm.nih.gov/sites/entrez?db=pubmed) to ensure that none of these
peptides had been previously used in a published study. No publications were found
for any of the ORF28 peptides.211
Amino Acid Residue
Peptide
1 2 3 4 5 6 7 8 9
REVEAL™
Binding
Assay
Ranking
REVEAL™
Off-rate
Assay
Ranking
Immune
Epitope
Database
Score
SYFPEITHI
Score
HLA_BIND
Score
Combined
Algorithm
Score
L L
M V
Optimal HLA-
A*0201
‘Motif’
Residues V
Influenza G I L G F V F T L 2 2 18.8 30 550.9 +++
HIV gag S L Y N T V A T L Nt Nt 16.0 31 157.2 +++
CMV pp65 N L V P M V A T V Nt Nt 32.1 30 160.0 +++
ORF28 P12 G M V D G S V L V 1 6 23.4 24 206.0 +++
ORF28 P51 F L A A R L W R A 3 4 3.7 21 394.2 +++
ORF28 P36 F L L V I G A C V 4 5 10.8 25 1183.8 +++
ORF28 P30 G L I T V L F L L 5 1 11.2 27 285.0 +++
ORF28 P21 R M A T K P P V I 6 3 257.8 20 <10 ++
ORF8 P95 L M W Y E L S K I 7 11 18.6 24 244.5 +++
ORF28 P55 R L W R A T P L G 8 12 >5000.0 <15 <10
ORF28 P29 I G L I T V L F L 9 13 >5000.0 19 11.1 ++
ORF28 P34 V L F L L V I G A 10 9 93.9 22 71.9 +++
ORF28 P45 Y C C I R V F L A 11 7 3854.3 <15 <10 +
ORF28 P38 L V I G A C V Y C 12 10 >5000.0 <15 <10
ORF28 P2 S M T S P S P V T 13 8 >5000.0 15 <10 +
TABLE 5.5: Amino-acid sequences, ranks in binding and denaturation assays, and computer algorithm scores of ORF28-derived peptides
with high affinity for HLA-A*0201.
2
1
1212
Although binding ‘motifs’ are neither sufficient nor necessary for an epitope to be
presented in vivo, they are an indication of the best peptide binders to a specific
HLA allele and thus help to identify candidate epitopes. For A*0201, a leucine (L)
or a methionine (M) residue at the second position in conjunction with an L or a
valine (V) residue at the ninth position creates an optimal binding motif, and a V at
the sixth position also promotes binding (Table 5.5). HIV SLYNTVATL and CMV
NLVPMVATV both contained an optimal A*0201-binding motif [an L at the
second position with an L (SLYNTVATL) or a V (NLVPMVATV) at the ninth
position], as well as both having a V at the sixth position. Influenza GILGFVFTL
contained a V at the sixth position and an L at the ninth position, and also had an
isoleucine (I) residue at the second position. Isoleucine is very similar in chemical
formula and structure to leucine, and there is little change in protein structure or
folding if these aa residues are substituted. Thus the presence of an I residue at the
second or ninth position (where an L contributes to an optimal binding ‘motif’) may
also improve a peptide’s A*0201-binding affinity.
Three out of the 12 ‘passed’ peptides contained an optimal binding ‘motif’. P12 had
an M at the second position and a V at the ninth position and was the highest scorer
in the binding assay. P30 had two L residues at the second and ninth positions and
was the highest scorer in the off-rate assay. P36 had an L at the second position and
a V at the ninth position, and was within the top-five highest scorers in both the
binding and the off-rate assay. Three peptides (P29, P34 and P45) contained a V at
the sixth position. A further seven peptides (P51, P21, P29, P28, P34, P55 and P95)
contained one residue from a binding ‘motif’. Two peptides (P21 and P95) also213
contained an isoleucine (I) residue at the ninth residue. The only peptide that did not
contain any binding ‘motif’ residues was P38.
The three ‘epitope-prediction’ computer algorithms used for analysis each have
different methods for scoring potential peptides and different cut-off points are used
to distinguish peptides ‘unlikely’ to be epitopes. With IEDB, a low score is best and
a commonly used cut-off score of greater than 5000 eliminates unlikely peptides
(Westrop et al., 2009). With SYFPEITHI, a high score is best, and a common cut-
off score is less than 15 (Rammensee et al., 1999). With HLA_BIND a high score is
best and a commonly used cut-off score is less than 10 (Parker et al., 1994). Each
peptide was given a combined algorithm score to indicate how many of the three
algorithms scored the peptide within their ‘likely’ epitope range.
GILGFVFTL, SLYNTVATL, NLVPMATV and the P95 control KSHV peptide all
performed well in all three computer algorithms. This is to be expected, as such
algorithms are written based on documented peptide sequences. Only five of the 11
‘passed’ ORF28 peptides (P12, P51, P36, P30 and P34) were classed as ‘likely’
epitopes by all three algorithms. Four of these (P12, P51, P36 and P30) were also
among the five peptides that scored most highly in both the binding and off-rate
assays. The other peptide that scored in the top five in the binding assays, P21, was
designated a ‘likely’ epitope by two of the three algorithms. Two of the 11 ‘passed’
ORF28 peptides (P55 and P38) were not classified as likely epitopes by any of the
three algorithms, and a further two (P45 and P2) were only classed as likely by one
of the three algorithms.214
The entire ORF28 aa sequence was also run through each of the algorithms to see if
they identified any peptides likely to be epitopes that did not bind well to A*0201 in
the binding assay. All peptides identified by one or more algorithms as being
putative epitopes are shown in Table 5.6. Only two of the peptides (P31 and P32)
eliminated by the binding assay were flagged as candidate epitopes by more than
one algorithm. Of these, P32 was identified by two algorithms but performed very
poorly in the binding assay. P31, however, was classed as a likely epitope by all
three algorithms, and also performed quite well in the binding assay, with a relative
binding score of 38.34% that was greater than that of the intermediate control
(17.54% ± 2.7) although just under the pass score of 45%. P31 may well thus
represent a weaker binding A*0201-restricted epitope and may warrant further
investigation in the future.
Of the 14 peptides identified by one or more algorithms as a potential epitope but
eliminated by the binding assay, one (P23) had a V at the sixth position (an optimal
A*0201-binding residue), and also had one residue from within an optimal A*0201
binding ‘motif’ (an L at the ninth position) A further nine peptides also contained a
single residue from within an optimal A*0201-binding ‘motif’ (P59, P67, P31, P27,
P71, P26, P79, P1, P42).
The twelve peptides indicated as candidate epitopes by the binding and off-rate
assays (including the KSHV control peptide, P95 [LMWYELSKI from ORF8])
were synthesised for use in further assays to test the recognition of these peptides
by T cells from KSHV-positive individuals. Results are presented in section 5.2.215
Amino Acid Residue
Peptide
1 2 3 4 5 6 7 8 9
REVEAL™
Binding Assay
Score
Immune
Epitope
Database
Score
SYFPEITHI
Score
HLA_BIND
Score
Combined
Algorithm
Score
L L
M V
Optimal
HLA-A*0201
‘Motif’ Residues
V
Influenza G I L G F V F T L 100.00 18.8 30 550.9 +++
HIV gag S L Y N T V A T L Nt 16.0 31 157.2 +++
CMVpp65 N L V P M V A T V Nt 32.1 30 160.0 +++
ORF28 P23 A T K P P V I G L 0.69 >5000.0 23 <10 +
ORF28 P59 A T P L G R A T V 0.00 >5000.0 22 <10 +
ORF28 P67 V A Y Q V L R T L 1.01 >5000.0 22 <10 +
ORF28 P31 L I T V L F L L V 38.34 308.0 21 30.9 +++
ORF28 P32 I T V L F L L V I 0.00 2560.8 20 <10 ++
ORF28 P27 P V I G L I T V L 2.66 >5000.0 20 <10 +
ORF28 P81 S H A P P T V G I 1.05 >5000.0 20 <10 +
ORF28 P90 A T Q E P Y R T I 0.00 >5000.0 19 <10 +
ORF28 P71 V L R T L G P Q A 0.00 >5000.0 17 <10 +
ORF28 P47 C I R V F L A A R 28.84 >5000.0 16 <10 +
ORF28 P26 P P V I G L I T V 0.13 >5000.0 15 <10 +
ORF28 P79 A G S H A P P T V 26.72 >5000.0 15 <10 +
ORF28 P1 M S M T S P S P V 0.93 1856.8 <15 <10 +
ORF28 P42 A C V Y C C I R V 27.42 4259.8 <15 <10 +
TABLE 5.6: Amino-acid sequences, ranks in the binding assay, and computer algorithm scores of ORF28-derived peptides with
low affinity for HLA-A*0201.
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5.2 Recognition of KSHV Epitopes by T cells from A*0201-
positive, KSHV-positive Individuals
5.2.a Identification of HLA-A*0201-positive, KSHV-positive
Individuals
In the experiment investigating KSHV T-cell responses with lentiviral-transduced
moDCs described in Chapter 4 of this thesis, HIV-positive individuals who had a
history of KSHV-related neoplasia but were in remission were found to be the most
useful available cohort for such immunological studies. This is because they are
easily identifiable; attend clinics regularly; and showed comparatively high levels
of KSHV-specific T-cell responses (see sections 4.1.a and 4.2.b). Thus this cohort
was again selected to test the recognition of the candidate ORF28 peptides
identified in section 5.1, and to investigate patterns of immunodominance in a
selection of previously identified A*0201-restricted, KSHV-specific epitopes
(indicated in Table 5.1). To do this, it was first necessary to identify further a
number of HLA-A*0201-positive individuals that fitted this specification.
Small peripheral blood samples (3ml) were collected from 59 HIV-positive
individuals attending an HIV/oncology clinic at Chelsea and Westminster Hospital
for DNA extraction and HLA-typing. Samples were collected from those who either
had a history of, or who currently had, a KSHV-related neoplasia (KS or MCD), so
that those identified as HLA-A*0201-positive could be followed-up at a later date
(preferably when in complete remission) by taking a larger blood sample for use in
the proposed functional studies.217
Of the 59 individuals HLA-typed, 27 were HLA-A*0201-positive. Thus 45.8% of
this patient cohort are A*0201-positive. Within this cohort, 24 out of 47 individuals
(51.2%) of Caucasian origin were A*0201-positive – a close match to the reported
prevalence of A*0201 in the Caucasian population of North America (45.6%;
source: HLA matchmaker; http:tpis.upmc.edu/tpis/HLAMatchmaker/). Only four
out of 12 individuals (25.0%) of mixed, non-Caucasian origin were A*0201-
positive, but this again fitted observations of HLA-type prevalence between
different ethnic groups in North America (see section 5.1.a).
Further blood samples were obtained from 18 of these 27 HLA-A*0201-positive
individuals for use in ex vivo assays to assess the recognition of KSHV-derived
peptides.
5.2.b Study Participants
Individual characteristics of the 18 HIV-positive participants can be seen in Table
2.9 (Materials and Methods section 2.6.a). In summary, all participants were male,
and their age at venesection ranged from 29 to 67 years. CD4 counts ranged from
48 to 1467 cells/mm
3 and HIV viral loads ranged from undetectable (<50 copies per
ml) to 11164. Three individuals had active KS at the time of venesection (B257,
B792 and S314), the rest were either in remission from KSHV-related neoplasia, or
had quiescent (regressing) KS. In addition to the 18 HIV-positive individuals with a
history of KSHV-related neoplasia, four HIV-negative, KSHV-negative healthy
controls were included in the study to ensure the peptides did not show any cross-218
reactivity with other antigens. All study participants’ KSHV serostatus at the time
of venesection was tested by ELISA. Results are shown in Table 5.7.
KSHV Serostatus Participant
ID
Positive Negative
Comments
HC-A N
HC-B N
HC-C N
HIV-negative
healthy controls
HC-D N
B042 (N) Borderline negative
B066 P
B257 P
B792 P
C448 P
D592 P
D850 P
G386 P
H501 P
H980 P
J228 P
K331 P
M907 P
P896 P
P940 P
S314 P
S929 P
HIV-positive
individuals with a
history of KSHV-
related neoplasia
T541 P
Seventeen of the 18 HIV-positive participants were KSHV-seropositive, as would
be expected given that they all had a history of KSHV-related neoplasia. However,
one HIV-positive individual (B042) had an antibody titre that was borderline
negative for KSHV seropositivity (0.055 ± 0.001 compared to a cut-off value for
positivity of 0.060). This individual had entered remission from KS after
TABLE 5.7: KSHV serostatus of study participants at time of venesection for
testing recognition of HLA-A*0201-restricted KSHV peptides. P = positive; N =
negative; (N) = borderline negative.219
completing a course of systemic chemotherapy less than six months prior to
venesection. Thus it was decided to include the individual in the study as a KSHV-
positive individual, regardless of this serology result. Such serological assays are
recognised to be limited in their sensitivity, particularly in HIV-positive individuals,
whose B cells and helper T cells may be severely compromised thus affecting their
antibody production. All four HIV-negative, healthy-control individuals were very
clearly KSHV-seronegative.
5.2.c T-cell Responses to KSHV CD8 Peptides by IFNγ ELISpot
The 11 ORF28-derived peptides identified as potential HLA-A*0201-restricted
epitopes in section 5.1 (see Table 5.3) and nine previously described HLA-A*0201-
restricted KSHV CD8 epitopes (including the KSHV control peptide used in the
binding assays, Gb492-500; indicated in Table 5.1) were tested for recognition by T
cells in ex vivo IFNγ ELISpot assays. Results are shown in Figure 5.5.a, 5.5.b and
5.5.c. A positive response was designated as a response that was greater than 20
spot-forming cells (SFC) per million PBMCs above the background response to
media alone and greater than five times the background response. Background
responses ranged from 0.0 to 5.0 SFC per million PBMCs.
For the first five individuals tested (B257, B792, H980, K331 and P869; Figure
5.5.a), all KSHV peptides, control peptides [FEC (a pool of influenza EBV and
CMV peptides), HIV SLYNTVATL and CMV NLVPMVATV] and a PHA control
were used at a final concentration of 5μg/ml. Responses to PHA and FEC were
observed in all individuals, a response to SLYNTVATL was seen in one individual220
(B257) and responses to NLVPMVATV were observed in three (B257, K331 and
P869) out of the four individuals tested (B792 did not respond and H980 was not
tested). None of the KSHV peptides (new or previously identified) elicited
responses in any of the study participants. KSHV-specific responses are reportedly
weak compared to those against antigens from other viruses, and so the
concentration of KSHV peptides was increased to 10μg/ml for the next individual
tested (P940; Figure 5.5.a) while controls were kept at the same concentration. P940
responded to PHA and FEC, but not to SLYNTVATL, and there were still no
responses observed to any of the KSHV peptides. Therefore, for the next 12
individuals tested (B042, B066, C448, D592, D850, G386, H501, J228, M907,
S314, S929, T541; Figure 5.5.b.), KSHV peptides were used at 20μg/ml whilst
controls were kept at the same concentration.
All 12 of these individuals responded to PHA, FEC and NLVPMVATV. One
(G386) out of 11 tested gave a weak response to SLYNTVATL (30.0 SFC per
million). Significantly, at this increased peptide concentration, nine of the 12
individuals (B042, B066, C448, D850, G386, H501, M907, S929, and T541)
responded to one of the KSHV peptides – the previously identified peptide
LVLILYLCV, derived from the late lytic ORF K8.1 that encodes glycoprotein
35/37. No responses were observed to any of the other KSHV peptides by any of
the individuals tested. Responses to the K8.1 peptide were weak (21.7 to 113.3 SFC
per million; mean = 47.6; median = 36.7), especially compared to responses to
CMV NLVPMVATV by these 12 individuals, which ranged from 68.3 to 1383.3
SFC per million (mean = 640.4; median = 635.0). Nonetheless, these data clearly
indicate that K8.1 LVLILYLCV represents an immunodominant HLA-A*0201-221
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FIGURE 5.5.a: CD8 T-cell responses to A*0201-restricted peptides by HIV-positive, KSHV-positive individuals. PHA, control peptides (FEC,
SLY, NLV) and KSHV peptides were all used at 5μg/ml (except for P940; KSHV peptides = 10μg/ml). Responses shown as SFC per million PBMCs
with background response to T-cell media (Tcm) alone subtracted. Responses below 1.0 were set to 1.0 to enable plotting of data on a logarithmic
scale. Dashed line indicates positive response cut-off value of 20 SFC per million PBMCs.
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FIGURE 5.5.b: CD8 T-cell responses to A*0201-restricted peptides by HIV-positive, KSHV-positive individuals. PHA and control peptides
(FEC, SLY and NLV) and were used at 5μg/ml and KSHV peptides were used at 20μg/ml. Responses shown as SFC per million PBMCs with
background response to T-cell media alone (Tcm) subtracted. Responses below 1.0 are set to 1.0 to enable plotting of data on a logarithmic scale.
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FIGURE 5.5.c: CD8 T-cell responses to A*0201-restricted peptides by HIV-negative, KSHV-negative healthy controls. PHA and control
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background response to T-cell media (Tcm) alone subtracted. Responses below 1.0 are set to 1.0 to enable plotting of data on a logarithmic scale.
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restricted KSHV CD8 epitope as, at a concentration of 20μg/ml, it was recognised
by T cells from 75.0% of HIV-positive, KSHV-positive, HLA-A*0201-positive
individuals.
Three HIV-negative, KSHV-negative individuals (HC-A, HC-B, and HC-C) were
tested for responses to all peptides (control peptides at 5μg/ml and KSHV peptides
at 20μg/ml) to ensure there was no cross-reactivity of peptides with other antigens
(Figure 5.5.c). The exact HLA-types of these individuals were unknown, although
they were all Caucasian and were anecdotally reported to be A*0201-positive from
participation in previous immunological studies. All three individuals responded to
PHA, and two (HC-A and HC-B) responded to FEC. One (HC-A) responded to
CMV NLVPMVATV (108.3 SFC per million PBMCs), confirming that this
individual was indeed A*0201-positive. No responses were seen to any of the
KSHV peptides by T cells from any of these three individuals, although one (HC-B)
had a response to one peptide (ORF28 - P45) that was just below the cut-off value
for positivity (19.0 SFC per million PBMCs).
5.2.d Enhancing Responses to KSHV Peptides by using Peptide-
pulsed Autologous moDCs as Stimulants in ELISpots
The lack of responses observed in the above ELISpot assays, particularly to
published KSHV peptides that have reportedly been recognised by 13% to 32% of
HIV-positive individuals in other studies (Table 5.1), was somewhat surprising.
However, several other groups have reported difficulty in detecting weak KSHV-
specific T-cell responses to peptides using such IFNγ ELISpot assays, particularly 225
in HIV-positive individuals (Guihot et al., 2006; Wang et al., 2002b). Autologous
moDCs pulsed with KSHV peptides have thus been used previously as stimulants in
place of peptide solutions to facilitate detection of elusive weak responses (Wang et
al., 2002b). This technique was therefore tried with a selection of peptides [ORF28
- P36; ORF28 - P51; ORF8 - LMW (P95); and K8.1 – LVL] to see if any additional
responses could be detected. ORF28 - P36 and ORF28 - P51 were selected as these
were two of the highest-scoring ORF28 peptides in the MHC binding and off-rate
assays. ORF8 - LMW was included as the best-documented A*0201-restricted
KSHV epitope, and also as others have detected responses to this peptide using
peptide-pulsed moDCs in a similar protocol to this one (Wang et al., 2002b). K8.1 -
LVL was selected to examine whether weak responses observed to this peptide in
solution could be replicated and enhanced using this protocol. Results from six
individuals (D850, J228, M907, S314, T514 and HC-A) are shown in Figure 5.6.
Three of the six individuals (D850, M907, and T514) had shown weak positive
responses to the K8.1 peptide in peptide-stimulated ELISpots (21.7, 31.7 and 25.0
SFC per million PBMCs, respectively). Using peptide-pulsed autologous moDCs as
stimulants enhanced these responses to 78.3, 111.7 and 138.3 SFC per million
PBMCs, respectively. The other three individuals (J228, S314 and HC-A) had not
responded to the K8.1 peptide in the original assay, and did not respond to
autologous moDCs pulsed with the K8.1 peptide. Likewise, none of the six
individuals responded to any of the other peptides (ORF28 - P36, ORF28 - P51,
ORF8 - LMW) in the original assay and they did not respond to moDCs pulsed with
these peptides. This gives confidence that using this technique does not generate
false positive responses. It was thus concluded that pulsing moDCs is a useful way226
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FIGURE 5.6: T-cell responses to HLA-A*0201-restricted  peptides  in  IFNγ 
ELISpot assays using peptide solutions (pale blue bars) or peptide-pulsed
autologous moDCs (dark blue bars) as stimulants. Responses shown are SFC per
million PBMCs after the background response to T-cell media alone (peptide solution
assays) or moDCs alone (peptide-pulsed moDC assays) had been subtracted. Dashed red
line indicates positive cut-off value of 20 SFC per million PBMCs.227
to enhance weak responses, and can confirm the validity of low positive responses
(for example, those below 50 SFC per million PBMCs) observed in peptide-
stimulated assays.
A limitation of this technique is, however, that far fewer peptides can be
investigated in this manner, due to the number of PBMCs needed to generate
sufficient numbers of moDCs for use with each different peptide. It is thus possible
that, had it been feasible to test a broader range of peptides, some of those that
elicited responses close to the positive cut-off value of 20 SFC per million may
have proved to be positive. For example 16.7 and 15.0 SFC per million PBMCs
were observed in response to ORF28 - P38 in D850 and B066 respectively, and
ORF61 - GLA elicited a response of 15.0 SFC per million in P940.
5.2.e Peptides Derived from KSHV ORF36 and ORF37
As, disappointingly, no responses were observed to any of the ORF28 peptides in
any of the individuals tested, it was decided to test a selection of additional peptides
derived from ORF36 and ORF37, the other two ORFs within the late lytic gene
pool that was frequently recognised in the lentivirus-based screen for immunogenic
KSHV ORFs. The size and complexity of these two ORFs meant that performing
MHC binding and denaturation assays on peptides spanning the entire ORF
sequences (as was done for ORF28 in section 5.1) would have been impractical.
The data and in silico analysis described in section 5.1 indicated that the use of
computer algorithms to identify candidate T-cell epitopes from within an ORF is
still very much a technology in its infancy, with different algorithms often returning228
different results and no one algorithm providing definitive solutions. However,
when multiple algorithms were used and potential epitopes were selected based on a
consensus of results from all algorithms, this seemed to correlate well with peptides
that performed well in MHC-binding and denaturation assays. Thus a combination
of three computer algorithms (IEDB; SYFPEITHI and HLA_BIND; see section
5.1.e) was used to identify three good candidate HLA-A*0201-restricted epitopes
from within ORF36 and ORF37. Because neither ORF36 nor ORF37 encode unique
viral proteins with respect to their amino acid sequence, each potential epitope was
also run through NCBI’s ‘blastp’ tool, to ensure there was no sequence similarity to
potential antigens from other viruses. The six selected candidate epitopes are
shown in Table 5.8 with their scores from the three computer algorithms.
The six additional peptide were tested at a concentration of 20μg/ml for responses
by T cells from nine of the HIV-positive, KSHV-positive, HLA-A*0201-positive
individuals recruited to this study (B792, C448, D592, D850, G386, K331, P869,
S314 and S929) and three HIV-negative, KSHV-negative healthy controls (HC-A,
HC-C and HC-D). Results are shown in Figure 5.7. No responses were observed to
any of the new peptides by any of the controls. Disappointingly, neither were any
responses observed to any of the peptides by any of the KSHV-positive individuals.229
Amino Acid Residue
Peptide
1 2 3 4 5 6 7 8 9
Immune
Epitope
Database
Score
SYFPEITHI
Score
HLA_BIND
Score
Combined
Algorithm
Score
L L
M V
Optimal
HLA-A*0201
‘Motif’ Residues
V
Influenza G I L G F V F T L 18.8 30 550.9 +++
HIV gag S L Y N T V A T L 16.0 31 157.2 +++
CMVpp65 N L V P M V A T V 32.1 30 160.0 +++
ORF36 - YLG Y L G F M I P R V 5.8 26 735.9 +++
ORF36 - GLM G L M A A V S F L 10.9 26 999.9 +++
ORF36 - VMT V M T Q I L S A V 34.3 23 196.4 +++
ORF37 - YLV Y L V D T L D G L 6.7 28 454.1 +++
ORF37 - ALK A L K D F F Y S I 14.0 24 10.8 +++
ORF37 - RLG R L G S P K Y Y I 211.3 20 57.4 +++
TABLE 5.8: Candidate HLA-A*0201-restricted CD8 epitopes from within ORF36 and ORF37 identified using
the combined results of three computer algorithms for epitope prediction.
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FIGURE 5.7: CD8 T-cell responses to ORF36 and ORF37 A*0201-restricted peptides by HIV-positive, KSHV-positive individuals and
HIV-negative, KSHV-negative healthy controls. Control peptides FEC (* indicates that for HC-C, PHA was used in place of FEC as this
individual did not respond to FEC in previous assays) and NLV were used at 5μg/ml and KSHV peptides were used at 20μg/ml. Responses shown
as SFC per million PBMCs with background response to T-cell media (Tcm) alone subtracted. Responses below 1.0 are set to 1.0 to enable plotting
of data on a logarithmic scale. Dashed line indicates positive response cut-off value of 20 SFC per million PBMCs.
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5.3 The Use of Pentamers to Determine the Memory
Phenotypes and Functions of Virus-specific T cells
One of the main goals of the studies described in sections 5.1 and 5.2 was to
identify an immunodominant epitope (either a novel late lytic epitope, or one of
several previously described epitopes) that would be a suitable target for
investigations utilising pentamers to enumerate KSHV-specific T cells and to
determine their memory phenotypes and functional properties. The results of these
studies identified one clear immunodominant epitope: LVLILYLCV from the late
lytic ORF, K8.1. Disappointingly, when synthesis of a pentamer containing this
peptide was attempted, the peptide proved to be too hydrophobic for the pentamer
to be synthesised. Unfortunately, as none of the other KSHV-derived peptides
included in this study had elicited responses in any of the study participants, there
were no other suitable KSHV peptides against which to attempt the synthesis of a
corresponding pentamer. It was thus not possible to explore the phenotypes and
functions of KSHV-specific CD8 T cells as had been hoped, although much work
had been done to refine the technique and to establish suitable protocols using
control pentamers directed against HIV SLYNTVATL and CMV NLVPMVATV.
This work is briefly described below.
5.3.a Memory Phenotypes of Virus-specific CD8 T cells
Pentamers specific for the immunodominant HLA-A*0201-restricted CMV peptide
NLVPMVATV (NLV) were used in conjunction with antibodies against the T-cell232
differentiation markers CCR7 and CD45RA to enumerate NVL-specific cells and to
determine the memory phenotype of NLV-specific CD8 T cells. An example of
staining and gating strategy are shown in Figure 5.8.
Enumeration and phenotyping of NLV-specific CD8 T cells was performed using
PBMCs from seven individuals who responded to the NLV peptide in the ELISpot
assays described in section 5.2. Six of these were HIV-positive (B257, C448, J228,
K331, M907 and P869) and one was HIV-negative (HC-A). Results are summarised
in Table 5.9.
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FIGURE 5.8: Example of pentamer staining used in conjunction with staining for
cell-surface markers to elucidate the memory phenotype of virus-specific CD8 T
cells. Shows staining performed on PBMCs from an HIV-positive individual (C448).
Gates are set on the live lymphocyte population, then the CD3-positive and CD8-
positive T cells, and finally on the NLV pentamer-specific population. Staining with
antibodies against the lymphoid homing marker CCR7 and the ‘RA’ isoform of CD45
allows different CD8 T-cell memory sub-populations to be identified.233
% NLV-specific T cells that
are
Participant
ID
% CD8 T
cells that are
NLV-specific TEM TEMRA
B257 0.30 43.8 55.3
C448 0.86 51.9 47.5
J228 0.43 79.3 19.8
K331 0.11 78.6 19.6
M907 0.72 7.0 92.0
HIV-positive
P869 1.19 33.0 66.8
HIV-negative HC-A 0.23 60.6 39.4
Mean 0.55 50.6 48.6
Median 0.43 51.9 47.5
The proportion of CD8 T cells that were NLV-positive ranged from 0.23% to
1.19%, with a mean of 0.55%. These values are similar to those reported by other
groups (Stone et al., 2005). Although there was some variation between individuals,
on average, 50.6% of NLV-specific T cells had a TEM phenotype and 48.6% had a
TEMRA phenotype. Again, this is in keeping with observations by other groups
(Champagne et al., 2001).
One of these seven individuals (B257) also showed responses to the
immunodominant HLA-A*0201-resricted HIV epitope SLYNTVATL in the
ELISpot assays described in section 5.2. It was therefore possible to make a
comparison of the memory phenotypes of CMV- and HIV-specific CD8 T cells
from this individual using pentamers directed against NLVPMVATV and
SLYNTVATL. Results from this experiment are shown in Figure 5.9.
TABLE 5.9: Enumeration of CD8 T cells specific for CMV NLVPMVATV and
determination of memory phenotype of CMV-specific T cells.234
In this individual, CMV-specific CD8 T cells were 43.8% TEM cells and 55.3%
TEMRA cells, whereas HIV-specific T cells were 97.5% TEM cells and 1.3% TEMRA
cells. This is in keeping with reports that HIV-specific CD8 T cells show defective
differentiation from TEM cells to TEMRA cells, a phenotype that is thought to
contribute towards the pathogenesis of HIV (Champagne et al., 2001).
5.3.b Functions of Virus-specific CD8 T cells
The first step towards using pentamers to investigate the functions of virus-specific
CD8 T cells was to establish a suitable antibody panel. A six-colour flow cytometer
allowed  simultaneous  investigation  of  three  cytokines  (IFNγ,  TNFα  and  IL2). 
FIGURE 5.9: Comparison of memory phenotypes of CD8 T cells specific for CMV
or for HIV. Results shown are from one individual, B257.
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However, as antibodies against these cytokines are only commercially available
conjugated to a limited number of fluorochromes (FITC, PE, APC and PeCy7) it
was first necessary to find CD3 and CD8 antibodies conjugated to APCCy7 and
PerCP that could be used in conjunction with the pentamers. Certain CD3 and CD8
antibody clones inhibit pentamer binding and none that had previously been tested
were available conjugated to the correct fluorochromes. Thus an experiment was
performed to ensure that the antibodies CD3-APCCy7 (clone SK7; BD
Biosciences) and CD8-PerCP (clone HIT3; Abcam) did not inhibit pentamer
binding. Results are shown in Figure 5.10.
With a suitable antibody panel established, several attempts were made at
performing pentamer staining in conjunction with staining for the production of the
FIGURE 5.10: Identification of antibodies against CD3 and CD8 that were suitable
for use in conjunction with intracellular staining and did not inhibit pentamer
binding.
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intracellular  cytokines  IFNγ,  TNFα  and  IL2.  However,  in  each  case  no  cells 
positive for the pentamer were observed after the 16-hour intracellular staining
protocol, despite pentamer-positive cells being detectable at 0 hours using the
standard cell-surface staining protocol. By sequentially omitting each of the steps
involved in the intracellular protocol, it was established that the pentamer staining
was lost upon permeabilisation of the cells, after the overnight stimulation for
cytokine production and before staining for the expression of the cytokines. On the
manufacturer’s recommendation the permeabilisation and fixation steps were split
from one step (using a Cytofix/Cytoperm kit available from BD) to two steps, using
manually prepared fixation and permeabilisation buffers (see Materials and
Methods section 2.8.b). Nonetheless, the same loss of pentamer staining was
observed. An example is shown in Figure 5.11.
FIGURE 5.11: Loss of pentamer staining upon permeabilisation of PBMCs for
intracellular staining.
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It was thus concluded that, in my hands, this protocol for pentamer staining in
conjunction with staining for the production of intracellular cytokines did not
appear to be a very robust method for investigating the functions of virus-specific
CD8 T cells.
5.4 T-cell Memory Phenotypes in KSHV Infection
In addition to different virus-specific T cells displaying distinct patterns of memory
phenotype, different viral infections are also associated with varying representation
of memory T-cell phenotypes (i.e. naïve, central memory, effector memory and
terminally differentiated effector memory) in the whole circulating T-cell
population. In some viral infections this varies further during the course of chronic
infection and manifestation of disease. Thus, the phenotypes of the whole
circulating T-cell population in individuals at different stages of KSHV infection
were investigated using whole-blood staining.
5.4.a Study Participants
The representation of T-cell memory subsets in circulating T-cell populations was
examined in 15 HIV-positive individuals in remission from KSHV-related
neoplasm and nine HIV-positive individuals with active KS, and compared to
representation of T-cell memory subsets in 11 HIV-negative, KSHV-negative
control individuals. All individuals tested were male and aged between 24 and 73
years-old at venesection, with a mean age of 42 years. HIV-positive individuals had238
CD4 counts from 159 to 811, with a mean of 484. Mean CD4 counts were lower in
those with active KS than those in remission (397 compared to 537, respectively)
although this did not reach statistical significance (p = 0.08; student T test). All
HIV-positive individuals were on HAART, apart from one individual with active
KS. HIV viral loads were generally undetectable with the exception of one
individual in remission from KS and two with active KS who had HIV viral loads
between 50 and 150, and two further individuals with active KS who had higher
HIV viral loads of 384 and 12599. HIV-positive individuals in remission from
KSHV-related neoplasm had had either KS (n = 8) or MCD (n = 7). None of the
study participants were receiving chemotherapy at the time of venesection.
Characteristics of HIV-positive individuals are shown in detail in Table 2.13 and
are summarised in Table 5.10.
Group Group
Description
Number Mean
Age
(Range)
Mean CD4
Count
(Range)
HIV Viral
Load Range
1 HIV-/KSHV-
Healthy Controls
11 32
(24 – 60)
Nt Nt
2 HIV+/KSHV+;
history of KSHV-
related neoplasia,
in remission
15 47
(30 – 74)
555
(188 – 811)
<50 – 69
3 HIV+/KSHV+;
Active KS
9 46
(34 – 71)
397
(159 – 575)
<50 – 12599
TABLE 5.10: Summary of characteristics of groups of study participants for
whole-blood T-cell phenotyping. Nt = not tested.239
5.4.b Differentiation of T-cell Memory Subsets in the Whole
Circulating T-cell Population
The lymphoid homing marker, CCR7, and the ‘RA’ isoform of CD45 were used to
distinguish naïve, central memory (TCM) and effector memory (TEM) CD8 and CD4
T-cell subpopulations, and the terminally differentiated effector memory CD8 T-
cell subpopulation (TEMRA). The representation of each of these subpopulations was
assessed in each group of study participants. Gating strategy is shown in Figure
5.12.
FIGURE 5.12: Gating strategy for whole-blood T-cell phenotyping. The lymphoid
homing marker CCR7 and the RA isoform of CD45 were used to distinguish CD8 and
CD4 memory T-cell subpopulations.
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5.4.c Representation of T-cell Memory Subsets During Chronic
KSHV Infection and KS
Figures 5.13.a and 5.13.b show the representation of CD8 and CD4 T-cell memory
subsets in each group of study participants respectively. The proportion of naïve
CD8 T cells was dramatically reduced in HIV-positive individuals compared to
HIV-negative individuals (means of 12.3% and 38.2%, respectively; p<0.05; Mann-
Whitney test; Figure 5.13.a), as has been described elsewhere (Chen et al., 2001).
No differences were observed between the proportion of TCM CD8 T cells between
HIV-positive individuals and HIV-negative individuals. However, there was a slight
enrichment in the proportion of TCM CD8 T cells in HIV-positive individuals in
remission from KSHV-related neoplasm (mean = 13.2%) as compared to those with
active KS (mean = 6.7%) that reached statistical significance (p<0.05; Mann-
Whitney Test; Figure 5.13.a). A small study of iatrogenic KS patients has
previously shown that conversion of their immunosuppressive drug regime from
calcineurin inhibitors to sirolimus led to increased proportions of circulating TCM
CD8 T cells, concurrent with KS regression [(Barozzi et al., 2008); see Introduction
section 1.3.a The CD8 T-cell Response Against KSHV]. Thus, the restoration of a
central memory CD8 T-cell subpopulation may play a role in control of KSHV
infection in both individuals with HIV and transplant recipients on
immunosuppressive drugs. No significant differences were observed in the
representation of TEM and TEMRA CD8 T-cell subpopulations between any of the
three groups of individuals (Figure 5.13.a).241
FIGURE 5.13: Representation of memory subsets in the whole circulating CD8 (a.)
and CD4 (b.) T-cell populations in healthy controls (yellow bars), individuals with
chronic KSHV infection (green bars) and individuals with KS (blue bars). Medians,
inter-quartile range, and 10
th and 90
th percentiles are shown. Dots indicate out-liers.
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The proportion of naïve CD4 T cells was also dramatically reduced in HIV-positive
individuals as compared to HIV-negative individuals (means of 20.4% and 45.4%,
respectively; p<0.05, Mann-Whitney test; Figure 5.13.b.), as has been previously
described (Roederer et al., 1995). There was also a concurrent enrichment in the
proportion of TEM CD4 T cells in HIV-positive individuals (mean = 35.2%) as
compared to HIV-negative individuals (mean = 16.1; p<0.05, Mann-Whitney test;
Figure 5.13.b.), as described elsewhere (Roederer et al., 1995). No significant
differences were observed in the proportion of TCM CD4 T cells between any of the
three groups of individuals. No significant differences were observed in the
representation of any of the CD4 T-cell memory subsets in individuals in remission
from KSHV-related neoplasm compared to individuals with KS (Figure 5.13.b.).
CD4 effector memory T cells do not generally reexpress CD45RA (Sallusto et al.,
2004), and so no CD4 TEMRA population was observed.
5.5 Summary
MHC binding assays and computer algorithms were used to identify potential new
HLA-A*0201-restricted epitopes from within the late lytic KSHV ORFs, ORF28,
ORF36 and ORF37. These were then tested for recognition by T cells from 18 HIV-
positive, KSHV-positive, HLA-A*0201-positive individuals alongside nine
previously identified A*0201-restricted KSHV epitopes from ORFs expressed
across the spectrum of the KSHV replication cycle. The immunodominant A*0201-
restricted epitopes from HIV GAG (SLYNTVATL) and CMV pp65
(NLVPMVATV) were also included in the assays for comparison. Only two out of
the 17 individuals tested (11.8%) responded to HIV SLYNTVATL, a result that243
may be unexpected for an epitope widely classified as ‘immunodominant’.
However, other groups have reported similarly low frequencies of recognition for
this epitope, particularly among individuals who have been receiving HAART for
extended periods of time (Lambert et al., 2006). A more robust immunodominant
response was observed for CMV NLVPMVATV, which was recognised by 15 of
the 16 individuals tested (93.8%), in keeping with reports by other groups (Lambert
et al., 2006).
Disappointingly, none of the potential new A*0201 epitopes identified from within
ORF28, ORF36 and ORF37 were recognised by T cells from any of the 18
individuals tested. Of note, however, no other responses were observed by any of
these individuals to eight out of nine previously described KSHV epitopes, all of
which could be expected to elicit responses in 13% to 32% of HIV-positive
individuals based on findings from previous studies (Table 5.1). This was a
surprising result, and is perhaps indicative of the difficulties associated with
searching for T-cell responses to a virus know to elicit comparatively weak
responses in individuals with compromised immune systems.
Interestingly one peptide – LVLILYLCV, from the late lytic, glycoprotein-encoding
ORF, K8.1 – did elicit a response by T cells from nine of the 12 individuals tested
(75.0%) when used at a concentration of 20μg/ml. This concurs with the original
data collected by Bourboulia et al. which indicated that LVLILYLCV could be the
most frequently recognised of all known A*0201-restricted KSHV epitopes, with
responses seen in 50% of individuals tested [(Bourboulia et al., 2004); Table 5.1].
The limitations of this original study were a small sample number (eight244
individuals), and a lack of comparison to responses to other known KSHV CD8
epitopes by the same individuals. The new data described in this thesis thus
provides further evidence for K8.1 LVLILYLCV representing an immunodominant
A*0201-restricted KSHV epitope, arguably the first such epitope to be described.
This information may have important implications for future immunological studies
of KSHV, and may have a clinical application, for example in the design of
immunotherapies for KSHV-related malignancies or potentially even a KSHV
vaccine.
Disappointingly, this one peptide that consistently and reliably elicited responses in
KSHV-positive individuals proved to be too hydrophobic for a pentamer to be
synthesised that would enable fluorescent labelling of KSHV-specific T cells. It
was thus not possible to use pentamer technology to enumerate KSHV-specific T
cells and to elucidate their memory phenotypes and functional properties, as had
been initially proposed. Experiments that were performed to establish such assays
are however described. Pentamers directed against CMV NLVPMVATV- and HIV
SLYNTVATL-specific T cells were used in conjunction with staining for cell-
surface markers to demonstrate a dramatic difference in the memory phenotypes of
CMV- and HIV-specific CD8 T cells. NLVPMVATV-specific T cells were
predominantly TEM or TEMRA cells and were, on the whole, fairly evenly distributed
between these two subpopulations. By contrast, SLYNTVATL-specific T cells were
overwhelmingly of a TEM phenotype, illustrating the defective differentiation of
HIV-specific T cells towards a TEMRA phenotype that has been previously described
(Champagne et al., 2001). Pentamer staining in conjunction with staining for
intracellular cytokine production was less successful, as the permeabilisation step245
required for this protocol appeared to interfere with either pentamer binding or
stability. Thus this may not be the most useful technique for investigations into the
functional properties of virus-specific T cells.
In the absence of a suitable pentamer for investigating the memory phenotypes of
KSHV-specific T cells, the representation of T-cell memory subsets by the whole
circulating T-cell population was examined in chronic KSHV infection and KS. No
differences were observed in the representation of CD4 T-cell memory
subpopulations. However, the central memory CD8 T-cell subpopulation was
slightly reduced in individuals with KS compared with those in remission,
indicating that restoration of this T-cell subpopulation may be important for the
control of KSHV infection.246
CHAPTER 6: Discussion
The aim of this thesis was to achieve a better understanding of the T-cell response
against KSHV. To this end, a novel methodological approach was developed to
investigate the targets of CD4 and CD8 KSHV-specific T cells. Monocyte-derived
dendritic cells were transduced with a library of lentiviral expression vectors
encoding KSHV ORFs and then cocultured with CFSE-stained autologous T cells.
In this way, pools of KSHV ORFs that elicited T-cell proliferation responses were
identified. Experiments were then performed to identify potential epitopes from
within these ORFs and these potential epitopes were tested for recognition by T
cells from KSHV-positive individuals alongside nine previously described KSHV
epitopes in order to investigate patterns of immunodominance. Finally, the use of
pentamers as tools for the elucidation of the memory phenotypes and functional
properties of virus-specific T cells was investigated.
On embarking on this project, my hypothesis was that the KSHV gene products that
elicit the strongest T-cell responses were those that are expressed early in the viral
lytic cycle, as the T-cell response against EBV (the most closely related human
herpesvirus to KSHV) is skewed towards immediate-early EBV gene products
(Rickinson and Moss, 1997; Landais et al., 2005a; Pudney et al., 2005). It has been
suggested that this pattern observed in the T-cell response against EBV is
attributable to the fact that early in the viral lytic cycle is the time when it is most
important for the host to keep the virus in check in order to prevent uncontrolled247
viral replication. It seemed reasonable to hypothesise that the KSHV-specific T-cell
response might display a similar pattern.
Preparation for and Design of a Lentiviral-Based Screen for
Immunogenic KSHV ORFs
To test my hypothesis, a novel approach using a pre-existing library of lentiviral
expression vectors to transduce moDCs and then stimulate autologous T cells was
proposed. This approach offered a number of advantages. Lentiviral vectors have
been shown to efficiently transduce moDCs and to integrate into the cellular
genome resulting in sustained transgene (Chinnasamy et al., 2000; Schroers et al.,
2000; Dyall et al., 2001). Lentiviral-transduced moDCs endogenously process the
antigenic protein, and so no prior knowledge of the optimal epitope or HLA-
restriction was required. Furthermore, the pre-existing library already included 26
KSHV ORFs, representing approximately 30% of the entire KSHV genome. This
system therefore enabled simultaneous screening of a large number of KSHV ORFs
for immunogenicity– far more than would have been possible using artificial
peptides.
By including both known immunogenic ORFs and ORFs that had not been
previously investigated for immunogenicity in the screen, it was hoped to determine
the relative importance of documented antigens and also to identify some novel
targets of both the CD8 and CD4 T-cell responses against KSHV. Therefore, it was
decided first to clone five additional known or putative immunogenic KSHV ORFs
into the pSIN lentiviral vector for inclusion in the screen alongside the 26 ORFs248
already in the pre-existing library. The novel genes that were selected were ORF8,
ORF57, ORF59, ORF61 and ORF65.
ORF8, ORF57, ORF61 and ORF65 are all documented targets of the KSHV-
specific CD8 T-cell response (Wang et al., 2000; Wang et al., 2001b; Wang et al.,
2002b; Bourboulia et al., 2004; Woodberry et al., 2005; Guihot et al., 2006;
Lambert et al., 2006; Bihl et al., 2007b; Guihot et al., 2008). Thus, they were cloned
in to the lentiviral vector and included in the library in order to investigate the
immunodominance of these CD8 antigens and also to discover whether they
additionally yielded CD4 T-cell epitopes.
ORF57 is an immediate-early lytic gene that is involved in controlling viral gene
expression through post-transcriptional regulation (Gupta et al., 2000). It is a
homologue of the EBV gene BMLF1, although the amino-acid sequences of these
genes share only minimal sequence similarity. BMLF1 is one of the
immunodominant targets of the EBV-specific CD8 T-cell response and has also
been shown to elicit CD4 T-cell responses (Landais et al., 2005a; Hislop et al.,
2007). ORF61 is an early lytic gene that codes for the large ribonucleotide
reductase that is required for DNA replication. It is a homologue of the ORF61 gene
of the mouse γ2-herpesvirus, murine herpesvirus 68 (MHV68), which is a target of
the MHV68-specific T-cell response (Stevenson et al., 1999). ORF65 is also an
early lytic gene that codes for the small capsomer-interacting protein that decorates
the outside of KSHV capsids and is essential for capsid assembly (Nealon et al.,
2001; Perkins et al., 2008). It lacks sequence similarity with its structural
counterparts from other herpesviruses (Nealon et al., 2001) and is highly antigenic,249
eliciting strong antibody responses frequently used in serological assays for the
detection of KSHV infection (Simpson et al., 1996; Pau et al., 1998). ORF57,
ORF61 and ORF65 were all successfully cloned into the lentiviral vector without
the incorporation of any amino-acid-substituting mutations.
ORF8 is an early lytic gene that codes for glycoprotein B (gB). It is a homologue of
gBs from other herpesviruses, including EBV and MHV68. However, KSHV gB
has several unique features. Unlike EBV and MHV68 gBs, it is incorporated into
both the virion envelope and the membrane of infected cells (Akula et al., 2001).
KSHV gB also contains a unique arginine-glycine-aspartate (RGD) motif, which
binds to the cell surface and promotes cell entry by activating intracellular
signalling pathways involved in endocytosis and cytoskeleton restructuring (Wang
et al., 2003; Sharma-Walia et al., 2004). The expression pattern and function of
KSHV gB makes it an attractive target for host immunosurveillance, identifying
infected cells and flagging up resurgences in active viral lytic replication. ORF8
was successfully cloned into the lentiviral vector, but contained a single point
mutation that resulted in an amino acid substitution. This was at base pair 1199 and
converted amino acid 400 from a valine to an alanine. This was carefully noted, but
as it lay outside of the well-documented gB CD8 epitope (see Tables 1.2 and 5.1)
and the RGD motif, and did not result in a truncated protein, it was considered to be
acceptable for use in the proposed screen.
ORF59 is an early lytic gene that codes for the processivity factor of the viral DNA
polymerase, and is required for extension during DNA replication (Lin et al., 1998).
It is a homologue of the EBV gene BMRF1, which is an immunodominant target of250
the EBV-specific CD8 T-cell response (Landais et al., 2005a; Hislop et al., 2007).
To the best of my knowledge, T-cell responses against KSHV ORF59 have not
been investigated, and so it was included in the screen as an unknown potential
immunogen. ORF59 was successfully cloned into the lentiviral vector with
complete sequence fidelity.
At this time, cloning of the CMV gene phosphoprotein 65 (pp65) into the lentiviral
vector was also attempted, as this was proposed for use in experiments to refine the
protocol for the screen for immunogenic KSHV ORFs, and also for subsequent use
as a positive control in the screen. CMV is a β-herpesvirus that is found in 50% to
90% of immunocompetent individuals from different populations (Staras et al.,
2006) and is a common opportunistic infection in individuals with AIDS. It is
distinct enough from KSHV to ensure minimal cross-reactivity of T-cell responses.
The tegument protein pp65 is the immunodominant protein target of the CD8
response against CMV (Wills et al., 1996), and a major target of the CD4 response
against CMV (Kern et al., 2002). Unfortunately, despite extensive efforts
CMVpp65 could not be inserted into the lentiviral vector, and so an alternative
approach had to be found.
Preparations of an adenoviral vector encoding CMVpp65 (Adpp65) were a kind gift
from Dr Magnus Essand of Uppsala University, Sweden. moDCs transduced with
this construct were previously used to stimulate and promote proliferation of both
CD8 and CD4 CMV-specific T cells from CMV-infected individuals (Carlsson et
al., 2003). Adpp65 was therefore used in preliminary experiments to refine the
protocol for the immunogenic screen and was also used later as a positive control,251
with the caveat that transgene expression was through a different vector and
therefore responses were not directly comparable to responses elicited by
transgenes expressed through the lentiviral vector.
Another important step in the preparation for the immunogenic screen was to refine
techniques for the culture and lentiviral transduction of primary moDCs. moDCs
were derived from monocytes by an established method of CD14-positive
monocyte isolation from peripheral blood followed by culture in the presence of
IL4 and GMCSF (Sallusto and Lanzavecchia, 1994). A suitable serum supplement
and maturation stimulus for the culture of moDCs for use in the proposed screen
had to be selected. Early protocols for culturing moDCs used RPMI media
supplemented with foetal calf serum (FCS). FCS is not, however, suitable for use in
moDC preparations intended for clinical applications. A variety of alternative
supplements have thus been investigated, including human plasma, serum albumin
or various serum-free medias but these reportedly give rise to lower yields of
moDCs and larger numbers of adherent cells (Jeras et al., 2005). For the purpose of
the proposed immunogenic screen, FCS was also not suitable for moDC culture, as
moDCs cultured in FCS prime a background response to bovine-derived antigens
when cultured with autologous T cells (Jonuleit et al., 2001). Therefore, human AB
serum was investigated as alternative media supplement for culturing moDCs.
Different maturation stimuli have also been found to affect the phenotype of
moDCs, for example, by polarising moDCs to prime either Th1- or Th2-type CD4
T-cell responses (Jeras et al., 2005). It was proposed to not only use the lentiviral
system to identify KSHV T-cell antigens but also to investigate cytokine release by252
KSHV-specific T cells (for example, to determine the type of helper T-cell response
elicited by KSHV CD4 antigens). Thus it was important to find a method for
deriving moDCs that were not polarised, in order to have a neutral background in
which to perform the immunogenic screen. Two different maturation stimuli were
investigated: lipopolysaccharides (LPS) or a mixture of inflammatory cytokines
comprising TNFα, IL1β, IL6 and PGE2 (referred to as a ‘cytokine cocktail’).
moDCs matured by stimulation with LPS produce IL12 and prime Th1-type CD4
T-cell responses. The ‘cytokine cocktail’ was trialled in the hope it would not
polarise moDCs in this way. There has been concern that PGE2-treated moDCs
promote a Th2-polarised response, as PGE2 inhibits bioactive IL12 production by
moDCs (Schuler et al., 2003; Jeras et al., 2005). However, there is also evidence to
dispute this, demonstrating that PGE2-treated moDCs are equally capable of
promoting a Th1-type response (Jonuleit et al., 1997; Schuler-Thurner et al., 2002;
Schuler et al., 2003).
Therefore, the viability, immunophenotype and allogenic stimulatory capacity of
moDCs cultured in different serum supplements and matured by exposure to
different stimuli were compared. A batch of AB serum (027K0432) was identified
in which moDCs showed good viability, comparable to moDCs cultured
conventionally in FCS. moDCs cultured under all conditions showed the expected
expression of markers including the major histocompatibility complexes I (MHC-I)
and II (HLA-DR); the costimulatory molecules CD40, CD80 and CD86; and the
DC maturation marker CD83. As has been previously described (Jeras et al., 2005),
moDCs cultured in AB serum were more phenotypically heterogeneous than those
cultured in FCS, but this was less apparent after maturation. The ‘cytokine cocktail’253
was the most potent maturation stimulus, in terms of both the immunophenotype of
the mature moDCs and the allogenic stimulatory capacity of these moDCs. After
stimulation with the ‘cytokine cocktail’, moDCs cultured in AB serum were more
than 80% double-positive for HLA-DR and CD80 (indicative of a mature
phenotype), and showed comparable stimulatory capacity to mature moDCs
cultured in FCS, especially when cultured at high ratios of moDCs to allogenic T
cells (1 to 20 or 1 to 40). Furthermore, CD4 T cells stimulated by allogenic
cytokine-matured moDCs appeared  to  produce  less  IFNγ  than  CD4  T  cells 
stimulated by allogenic LPS-matured moDCs. This indicated that cytokine-matured
moDCs do not prime polarised Th responses, although it must be noted that the
difference  in  proportion  of  IFNγ-producing CD4 T cells after stimulation with
either LPS- or cytokine-matured moDCs did not reach statistical significance.
Nevertheless, the ‘cytokine-cocktail’ was selected as the best suited maturation
stimulus for use in the proposed screen, as it was the most potent stimulus and,
taken together, my data and the literature indicated that it would provide the most
neutral background for the investigation of polarisation of Th responses to antigens.
With appropriate culture conditions for moDCs established, the transduction of
moDCs using the lentiviral vector was investigated. A lentivirus encoding GFP
(pCSGW) was used to demonstrate that moDCs could be successfully transduced
with this lentiviral vector and to investigate the kinetics of transgene expression and
the optimal multiplicity of infection (MOI) for this vector (Robey et al., 2009). In
keeping with findings by other groups (Schroers et al., 2000; Dyall et al., 2001),
GFP transgene expression was found to increase steadily over each day post-
transduction. A six-day period was selected as a suitable length of time for culture254
of transduced moDCs for the screen, representing a balance between good
transgene expression and optimal moDC viability (since these primary cells are not
suited to extended periods of culture). After six days, a transduction efficiency of
12.25 ± 2.5% was observed (mean ± s.d.). The MOI after transduction with
different volumes of pCSGW was also investigated and compared to levels of GFP
transgene expression. An optimal MOI of between three and eight for each
transduction was selected for the screen, as with the GFP construct this achieved
good transgene expression, with no notable improvement if the MOI was increased
further. Furthermore, whilst there is a consensus that lentiviral transduction of
moDCs at MOIs of less than 10 does not affect moDC viability, immunophenotype
or antigen presenting function (Gruber et al., 2000; Dyall et al., 2001; Koya et al.,
2003; Dullaers et al., 2004), the evidence regarding transduction of moDCs with
higher MOIs is less clear (Chen et al., 2004). In keeping with this, transduction of
moDCs with the lentiviral vector at an MOI of between three and eight was
demonstrated not to affect the moDCs’ immunophenotype or maturation, as
demonstrated by expression of MHC-I and CD80.
Interestingly, a slight downregulation of GFP transgene expression was observed
after maturation of moDCs. Other groups have reported that mature moDCs are
harder to transduce than immature moDCs (Gruber et al., 2000; Schroers et al.,
2000), but to the best of my knowledge there has been no previous documentation
of decreased transgene expression when maturation is induced after transduction.
This downregulation may be the result of the terminal differentiation of mature
moDCs and the concurrent changes in cellular gene expression and promoter
activity. Importantly, even after maturation with the ‘cytokine cocktail’ an average255
of 7.5 ± 1.7% GFP-positive cells was achieved, a level comparable to those
reported by other groups using a similar protocol (Gruber et al., 2000; Schroers et
al., 2000; Dyall et al., 2001; Esslinger et al., 2002; Lizee et al., 2004).
Following the experiments with pCSGW, RT-PCR was used to ensure that all
KSHV ORFs were expressed by moDCs after transduction and quantitative PCR
was performed to titre all KSHV-ORF-encoding lentivirus preparations.
Additionally, the transduction of moDCs with up to three different KSHV-ORF-
encoding lentiviruses simultaneously was demonstrated to result in the expression
of all three transgenes (Robey et al., 2009). Thus it was decided to perform the
screen with pools of ORFs grouped according to their expression in PEL cell lines
(Jenner et al., 2001; Jenner and Boshoff, 2002) in order to make the best use of
clinical samples and to determine whether latent, immediate-early, early or late lytic
gene products elicit the strongest T-cell responses.
Finally, an adenovirus encoding the immunodominant CMV gene pp65 (Adpp65)
was used to refine methods for investigating antigen-specific memory T-cell
responses. The protocol for transduction of moDCs with Adpp65 (including MOI
and length of time for transduction) was performed as previously described
(Carlsson et al., 2003). In cultures with autologous T cells, cytokine-matured,
Adpp65-transduced moDCs elicited strong proliferative responses. These were
assumed to be antigen-specific, as non-transduced moDCs did not elicit similar
responses. Non-transduced moDCs cultured in FCS did, however, stimulate a
substantial background response, presumably directed against bovine-derived
antigens as has been previously reported (Jonuleit et al., 2001). There was little256
response to non-transduced moDCs cultured in AB serum, confirming that this was
the most appropriate serum supplement for culturing moDCs for use in the screen
for immunogenic KSHV ORFs. A ratio of moDCs to T cells of 1 to 40 was
selected, representing a balance between a strong antigen-specific response to
transduced moDCs and a low background response to non-transduced moDCs.
Unfortunately, an empty adenoviral vector was not available for comparison, so it
was not possible to determine whether the antigen-specific responses was to the
CMV transgene or to adenoviral proteins encoded in the vector. However, the paper
in which the use of Adpp65-transduced moDCs was originally described provided
substantial evidence that they stimulated both CD8 and CD4 CMV-specific
memory T cells (Carlsson et al., 2003). CD4 T cells stimulated with cytokine-
matured, Adpp65-transduced moDCs produced cytokines indicative of a Th1-
polarised response, in keeping with the expected response elicited by pp65
(Gamadia et al., 2004). This was also dramatically different to cytokine production
by CD4 T cells stimulated with allogenic cytokine-matured, non-transduced
moDCs, further indicating that the ‘cytokine cocktail’ was an appropriate stimulus
for use in experiments investigating cytokine secretion in response to antigen
stimulation.
Based on the results discussed above, a protocol for a lentiviral-based screen to
investigate the targets of CD8 and CD4 KSHV-specific T cells was established, and
is shown schematically in Figure 4.1.257
Investigation of the Targets of the CD8 and CD4 T-cell
Responses against KSHV Using a Lentiviral-Based Screen
The screen for immunogenic KSHV ORFs was performed in 14 KSHV-seropositive
(12 HIV-positive) and seven KSHV-seronegative (four HIV-positive) individuals.
Out of the 14 KSHV-seropositive individuals tested, six responded to more than one
pool of KSHV ORFs (total of CD8- and CD4-mediated responses) and were
classified as ‘good responders’, and eight were classified as ‘poor responders’ (i.e.
gave one or no total CD8 and CD4 responses). Although this study was too small to
draw definite conclusions regarding the differences in phenotypes of KSHV-
seropositive individuals who made several responses to KSHV antigens using this
protocol and those who did not, some interesting observations were made.
Significantly, one HIV-positive individual with no history of KSHV-related
neoplasia (H419) who was originally intended for inclusion in the screen as an
HIV-positive, KSHV-negative control (as he was considered to be at low risk of
KSHV infection) gave several strong CD8 and CD4 responses to KSHV antigens. It
was only upon retrospective analysis of the individual’s KSHV-serostatus using
plasma frozen at the time of venesection that the individual was discovered to be
KSHV-seropositive and therefore an asymptomatic carrier of KSHV. This finding
gave extra confidence in the specificity of the KSHV responses observed using this
assay, as it was the presence of these responses that first indicated this individual
was a carrier of KSHV. Furthermore, the number and strength of responses seen in
this individual fitted with previous reports that KSHV T-cell responses are of
greater frequency and magnitude in asymptomatic carriers of the virus than in those258
with KS (Guihot et al., 2006; Lambert et al., 2006). Likewise, two individuals with
active KS at the time of venesection (S346 and W692) were poor responders.
Interestingly, although the screen was not performed in any individuals with active
MCD, the two individuals that were in remission from MCD (P940 and V689) were
both good responders, in line with previous reports that individuals with active
MCD show strong CD8 T-cell responses to KSHV antigens (Guihot et al., 2008;
Barozzi et al., 2009) that, in one study, were comparable to those seen in
asymptomatic carriers of KSHV (Guihot et al., 2008). Finally, all individuals who
had received HAART alone as treatment for their KS were poor responders,
whereas all good responders had received HAART in combination with cancer-
specific cytotoxic therapy. This was surprising, as individuals whose KS regresses
spontaneously on initiation of HAART might be expected to have higher levels of
KSHV-specific T cells than individuals who require chemotherapy in addition to
HAART to treat their KS. Furthermore, some forms of chemotherapy may cause
collateral damage to cells of the immune system, including T cells. A study of 33
HIV clade C-infected individuals with KS randomised to two treatment arms
(HAART alone versus combined HAART and chemotherapy) observed no
differences in the levels of T-cell responses between the two groups at five and 11
months after the initiation of therapy (Bihl et al., 2007a). The authors did, however,
observe reduced KSHV viraemia and better clinical outcome in those treated with
combined HAART and chemotherapy. This indicates that chemotherapy may not,
in the short term, inhibit reconstitution of KSHV-specific T-cell responses and it
may be that, in the long run, dissemination of KS lesions by chemotherapy259
increases systemic exposure to KSHV antigens, thus enhancing the generation of a
memory T-cell response against KSHV.
Overall, in this cohort of 14 KSHV-seropositive individuals, a distinct skewing of
both CD8 and CD4 responses towards early lytic and late lytic gene products was
observed (Robey et al., 2009). This was an unexpected result as it appears to
contrast with observations of the T-cell response against EBV, which preferentially
targets immediate-early lytic EBV gene products. It has been suggested that
immediate-early gene products might be frequent targets of herpesvirus-specific T-
cell responses as this enables the activation of the host immune response before the
expression of viral genes involved in immune evasion strategies. However, it has
recently been reported that the CD8 T-cell  response  against  the  murine  γ2-
herpesvirus, MHV68, is also directed against early lytic and late lytic gene products
(Gredmark-Russ et al., 2008). A broad repertoire of epitopes derived from late lytic
structural proteins and early lytic proteins involved in DNA replication were
identified in MHV68, but no epitopes derived from immediate-early proteins were
found. Similarly, 86% of CD8 and 90% of CD4 T-cell responses against CMV were
reported to target early lytic and late lytic gene products (Sylwester et al., 2005).
Thus, protein abundance and, to a lesser degree, function, may be important factors
affecting the immunogenicity of a gene product. Furthermore, a possible
explanation for the immunodominance of early lytic and late lytic KSHV (and other
herpesvirus) antigens may be the role they play in the establishment of homeostasis
between host and virus. The activation of viral immune evasion strategies such as
the downregulation of MHC molecules before the expression of immunodominant
antigens may result in a blunting of the immune response, enabling the virus to260
avoid elimination and to establish controlled chronic infection. Such persistent,
asymptomatic infection is a hallmark of herpesvirus infections and is the usual
manifestation of KSHV infection in immunocompetent individuals.
The three gene pools that were most frequently recognised by CD8 T cells from
KSHV-seropositive individuals were [ORF8/ORF49/ORF61];
[ORF59/ORF65/K4.1]; and [ORF28/ORF36/ORF37]. As discussed above, ORF8,
ORF61 and ORF65 are all documented CD8 antigens (Wang et al., 2000; Wang et
al., 2001b; Wang et al., 2002b; Bourboulia et al., 2004; Woodberry et al., 2005;
Guihot et al., 2006; Lambert et al., 2006; Guihot et al., 2008), and thus the data
from the screen corroborated these findings as well as indicating for the first time
the relative importance of these antigens compared to other documented latent and
immediate-early lytic antigens included in the screen (for example K12, ORF73, K5
and ORF57; see Table 1.2). Interestingly, however, none of the gene products
within the most frequently recognised CD8 target pool ([ORF28/ORF36/ORF37],
which was recognised by seven out of 14 individuals) have previously been
investigated for immunogenicity. The three ORFs within this late lytic gene pool
are therefore good candidates for further investigations into the dominant antigens
of the KSHV-specific CD8 T-cell response.
Overall, less CD4 T-cell responses were observed to KSHV antigens than CD8 T-
cell responses. This may be due to preferential processing and presentation of
endogenously expressed antigens (i.e. lentiviral transgenes) through the MHC-I
pathway. Lentiviral-transduced moDCs have been demonstrated by others to
present MHC-II-restricted epitopes and to elicit CD4 T-cell responses, although261
presentation was less efficient than that observed in moDCs pulsed with MHC-II-
restricted peptide epitopes (He et al., 2005). This is likely the result of decreased
access of endogenously processed antigens to the MHC-II processing pathway. In
future experiments, KSHV-ORF-encoding lentiviral vectors could be specifically
designed with the addition of signals that target expression of transgenes to
endosomal or lysosomal compartments in order to increase processing of antigens
through the MHC-II pathway and thereby enhance presentation of endogenously
expressed MHC-II-restricted epitopes (Wu et al., 1995; Dullaers et al., 2004).
Interestingly, two of the most common CD8 targets, [ORF8/ORF49/ORF61] and
[ORF59/ORF65/K4.1], were also two of the most common CD4 targets (recognised
by six and four out of 14 individuals respectively) alongside another pool of late
lytic KSHV ORFs [ORF33/K1/K8.1] (which was recognised by CD4 T cells from
four individuals). As discussed in section 1.3.b The CD4 T-cell Response Against
KSHV, very little is known about the CD4 response against KSHV. Three KSHV
CD4 antigens have been previously identified: two peptides have been identified,
one from within K12 and one from within K15, which each elicited a response in
one KSHV-positive individual out of 52 tested (Guihot et al., 2006); and
overlapping peptides spanning the entire sequences of K12 and K8.1 were shown to
elicit CD4 responses in one and two out of three iatrogenic KS patients respectively
(Barozzi et al., 2008). The data from the present study also indicate that K8.1 could
be an important CD4 antigen. The [K11.1/K12/K15] gene pool, however, was only
recognised by CD4 T cells from one individual tested using this methodological
approach (H419; HIV-positive asymptomatic carrier of KSHV). This is perhaps not
surprising given the low number of individuals that gave CD4 responses to K12 and262
K15 in the studies discussed above, and may indicate that these are not important
targets of the KSHV-specific CD4 response. Overall, the data from the screen
indicate that the major targets of the KSHV-specific CD4 response are likely to lie
within the same early lytic and late lytic gene products that elicit the strongest CD8
T-cell responses. This fits with observations in other herpesviruses, for example, in
the T-cell response against CMV, 53% of the most recognised ORFs are common to
both the CD8 and CD4 response (Sylwester et al., 2005). Similarly, the major EBV
CD8 targets BZLF1 and BMLF1 (immediate-early lytic) and EBNA1, EBNA2,
EBNA3A, EBNA3B, EBNA3C and LMP2 (latent) also elicit CD4 responses
(Landais et al., 2005a; Hislop et al., 2007).
Thus the lentiviral-based screen proved to be a useful system for achieving a broad
overview of the targets of the CD8 and CD4 T-cell responses against KSHV and
identifying antigenic hotspots within the KSHV genome. In particular, these data
showed a clear skewing of responses towards viral proteins expressed later in the
viral lytic cycle than was hypothesised, and identified some candidate ORFs in
which to focus future immunological investigations. However, this methodological
approach was also found to have limitations. In particular, a relatively high
background response was observed in T cells from some individuals to autologous
moDCs transduced with the empty lentiviral vector alone. This was a surprising
result, as lentiviral vectors are generally held to be the least immunogenic of
available viral vectors and reportedly do not elicit significant background responses
(Collins and Cerundolo, 2004; Palmowski et al., 2004). This is largely due to the
‘gutless’ structure of lentiviral vectors, whereby the vector does not encode, and
therefore does not express, any HIV-derived genes (it is only the physical structure263
of the vector that is comprised of HIV-derived proteins). However, one group has
reported the induction of primary CD8 and CD4 T-cell responses against HIV using
moDCs transduced with such gutless, self-inactivating lentiviral vectors at very
high MOIs (50 to 100 – more than 10 times the MOIs used in the present screen)
(Chen et al., 2006). It is possible, therefore, that in this HIV-positive cohort, some
of the background response to moDCs transduced with the empty lentiviral vector
was directed against HIV proteins contained within the vector, such as HIV-GAG.
Notably, however, a background response of comparable magnitude to moDCs
transduced with the empty lentiviral vector was observed in T cells from both HIV-
positive and HIV-negative individuals. One explanation could be cross-reactivity
with endogenous retroviruses. Alternatively, these responses could be due to
contamination of the lentiviral preparations from two possible sources. Lentiviral
preparations were prepared from filtered supernatant harvested from transfected
293T cells. By necessity, this supernatant contained FCS as 293T cells were found
not to survive sufficiently in human AB serum for the preparation of lentivirus (data
not shown). Although the volume of lentivirus preparations used for transduction of
moDCs was small in comparison to the total volume of moDC media, it is none the
less possible that, despite filtering, some bovine antigens were present in the
lentiviral preparations and were taken up and presented by moDCs. The data
presented in Chapter 3 of this thesis and by others (Jonuleit et al., 2001) have shown
that bovine antigens can elicit background responses in systems such as this one.
Secondly, the 293T cell line is derived from the 293 cell line, which was originally
derived from human embryonic kidney cells by transformation of the cells through
exposure to fragments of adenovirus type-5 (Ad5) DNA (Graham et al., 1977).264
Subsequent analysis revealed that the transformation had been brought about by the
insertion of 4.5 kilobases of Ad5 DNA (as a single linear insertion of viral DNA
with no rearrangements) into human chromosome 19 (Louis et al., 1997). 293T
cells therefore express Ad5 proteins which may additionally be present in the
lentiviral preparations. Given the high levels of pre-existing immunity to Ad5 in the
general population (Kostense et al., 2004), it seems likely that the T-cell responses
observed to moDCs transduced with the empty lentiviral vector were, at least in
part, directed against Ad5 antigens. In future experiments using lentiviral vectors
for such immunological investigations, prior purification of the preparations should
be considered, for example through a sucrose gradient. This procedure has been
shown to greatly reduce the immunogenicity of lentiviral preparations; however, it
is a cumbersome process and has also been shown to greatly reduce lentivirus titres
(Baekelandt et al., 2003).
The major significance of the observed background response was that strict criteria
had to be used to designate positive responses, which may have resulted in weaker
responses not being detected. This might partly explain why one or no responses
were detected in the ‘poor responders’. Furthermore, it was felt that the background
response would be difficult to distinguish from KSHV-specific responses when
examining cytokine production, and thus this system was not appropriate for the
investigation of the functional properties of KSHV-specific T cells. Therefore, an
alternative strategy was proposed, to use pentamer technology to elucidate the
memory phenotypes and functions of virus-specific T cells.265
Identification of an Immunodominant Late Lytic KSHV Epitope
Pentamer technology requires the prior identification of an immunodominant (or at
least a frequently recognised) epitope which can be targeted. From the findings in
the lentiviral-based screen for immunogenic KSHV ORFs, a search for novel
epitopes from within the late lytic pool of ORFs [ORF28/ORF36/ORF37] seemed
warranted. It was decided to focus on HLA*0201-restricted epitopes, since
HLA*0201 is one of the most common HLA-types in people of all ethnic
backgrounds, and so such epitopes were felt to have the greatest relevance for
future immunological studies as well as in the potential design of immunotherapies
and vaccines. MHC binding assays and computer algorithms were used to identify
candidate epitopes from within ORF28, ORF36 and ORF37. These peptides were
then tested for recognition by T cells from 18 HIV-positive, KSHV-positive, HLA-
A*0201-positive individuals alongside nine previously described HLA-A*0201-
restricted KSHV epitopes (Brander et al., 2001; Micheletti et al., 2002; Wang et al.,
2002b; Bourboulia et al., 2004; Lambert et al., 2006; Ribechini et al., 2006).
Disappointingly, none of our candidate epitopes were recognised by any individual.
This could mean that the responses observed to this pool of ORFs in the lentiviral-
based screen were not HLA-A*0201-restricted, or that the candidate epitopes
identified by the MHC binding assays and computer algorithms were not the HLA-
A*0201 epitopes that were endogenously processed and presented by the moDCs in
the screen. Of note, however, eight of the nine previously identified KSHV epitopes
were also not recognised by any of the 18 KSHV-positive individuals. This was
surprising, as reports in the literature indicated that these eight epitopes were
recognised by 16% to 100% of all individuals tested (total of HIV-positive and266
HIV-negative) or 13% to 32% of HIV-positive individuals tested in previous studies
(see Table 5.1).
Two of these epitopes (K5 - ALY and ORF70 - YML) had not previously been
tested in HIV-positive individuals, but only in one study of HIV-negative,
asymptomatic carriers of KSHV where they were tested in seven and five
individuals respectively (Ribechini et al., 2006). Responses to these epitopes were
detected by chromium-release and ELISpot assays after 14- or 21-day stimulations
with peptide-pulsed T2 cells in the presence of IL2 (Ribechini et al., 2006). Three
further epitopes (K12 - LLN, ORF8 - LMW and ORF22 - FLN) were also originally
identified using similar protocols for memory T-cell expansion (several weeks of
culture with peptide-pulsed antigen-presenting cells in the presence of IL2) before
detection of T-cell responses by cytotoxicity, lysis or ELISpot assays (Brander et
al., 2001; Micheletti et al., 2002; Wang et al., 2002b). Recognition of these three
epitopes (K12 - LLN, ORF8 - LMW and ORF22 - FLN) have been confirmed by
additional studies using ex vivo ELISpot protocols similar to the ones used in this
thesis (Bourboulia et al., 2004; Guihot et al., 2006; Guihot et al., 2008). However,
the vast majority of HIV-positive, KSHV-positive individuals used in these studies
were either asymptomatic carriers of KSHV or were individuals with MCD [who
reportedly show KSHV-specific CD8 responses equivalent to asymptomatic carriers
(Guihot et al., 2008)]. In fact, responses to these three epitopes have only been
detected ex vivo by ELISpot in four HIV-positive individuals with a history of KS:
three with quiescent KS or KS in remission (Bourboulia et al., 2004) and one with
active KS (Guihot et al., 2006).267
The three remaining epitopes (ORF6 - VLG; ORF61 - NMS; and ORF65 - NMS)
had been previously identified by one study only (Lambert et al., 2006), although
with a large cohort of study participants (46 to 48 individuals for each epitope,
including 23 or 24 HIV-positive individuals). Responses to these epitopes were
detected by tetramer staining, using the mean frequency + 2 s.d. of tetramer-positive
cells in 18 HLA-A2-negative, KSHV-positive individuals as a cut-off value for
positivity (Lambert et al., 2006).
The differences in techniques and study participants used by these studies and in
this thesis may help to explain my inability to detect responses to these previously
documented KSHV epitopes. In particular, the frequent use of prolonged cultures to
expand memory T cells before responses against peptides can be detected reflects
the extremely low frequency of cells specific for these epitopes in vivo and,
arguably, the limited biological relevance of these epitopes in the control of KSHV
infection. One attempt was made at replicating one of these memory T-cell
expansion protocols (Wang et al., 2002b) during the course of this thesis, in the
hope of detecting elusive weak responses to these peptides. However, the
background response observed to non-peptide-pulsed autologous moDCs by T cells
expanded in the same way (in the presence of IL2) was so high that distinguishing
peptide-specific responses to peptide-pulsed moDCs was deemed not possible (data
not shown).
Additionally, the lack of responses observed in this cohort of HIV-positive, KSHV-
positive individuals with a history of KSHV-related neoplasia could be an
indication of the limitation of this cohort for detection of such weak T-cell268
responses by ex vivo ELISpot. Although restoration of KSHV-specific T-cell
responses have been documented in HIV-positive individuals in remission from KS
(Bourboulia et al., 2004; Bihl et al., 2007a), it seems that these are not equivalent to
responses observed in true controllers of KSHV infection, i.e. asymptomatic
carriers of KSHV (either HIV-positive or HIV-negative). It is therefore possible
that, if further investigations were performed in an asymptomatic cohort of KSHV-
positive individuals, then one or more of the candidate epitopes identified from the
late lytic ORF pool may yet prove to be a weak T-cell epitope that elicits responses
equivalent to responses to most of the epitopes that have already been identified.
Significantly, just one of the nine previously identified KSHV epitopes (K8.1 -
LVL) elicited responses in this cohort of KSHV-positive individuals. When used at
a concentration of 20μg/ml, this late lytic epitope elicited responses in nine of the
12 individuals tested (75%). This was the only epitope that had been originally
identified using an ex vivo ELISpot assay similar to the one used in this thesis
(Bourboulia et al., 2004). In this original paper, Bourboulia et al. observed
responses to K8.I - LVL by T cells from four out of eight KSHV-positive
individuals who had been on HAART for more than two years at the time of
venesection. Together, this data and the data from the present study provide
evidence of an immunodominant role for this epitope. In the present study, three
individuals who had active KS at the time of venesection (B257, B792, and S314)
did not respond to the K8.1 - LVL peptide (although two of these, B257 and B792,
were tested at a lower concentration of 5μg/ml), which may further indicate a
protective effect for CD8 T cells specific for this peptide in the control of KSHV
infection.269
The finding that, out of nine known KSHV epitopes derived from proteins
expressed at various stages of the virus life cycle, one late lytic peptide displayed a
clear pattern of immunodominance is in keeping with the findings from the
lentiviral-based screen for immunogenic KSHV ORFs, which also indicated that
KSHV-specific T-cell responses are skewed towards early lytic and late lytic
antigens. The results from the two methodological approaches can not be easily
compared. The lentiviral system allows endogenous processing of an antigenic
protein and requires no prior knowledge of an optimal epitope or HLA-restriction
and therefore the responses observed in this system can not be considered
equivalent to responses observed to pre-determined artificial peptides. Nonetheless,
it is worth noting that the gene pool containing K8.1 ([ORF33/K1/K8.1]) was
recognised by CD8 T cells from four out of 14 KSHV-seropositive individuals,
making it the fourth most frequently recognised CD8 target in the screen. Out of the
four participants in the screen who were known to be A*0201-postive (P940, V689,
A556 and T541), one (A556) responded to [ORF33/K1/K8.1]. Of the remaining
three, two (P940 and T541) were tested for responses to peptides in the ELISpot
assay. P940 did not respond to the K8.1 peptide, in keeping with the results from
the screen. T541 did respond to the K8.1 peptide, but only very weakly (25 spot-
forming cells per million PBMCs). Thus this weak response may have been missed
in the lentiviral-based screen due to the strict criteria that were necessary to
distinguish a positive response.
Disappointingly, the K8.1 peptide proved to be too hydrophobic for the synthesis of
a pentamer directed against T cells specific for this peptide, and so the proposed
experiments to use pentamers as tools to investigate the memory phenotypes and270
functions of KSHV-specific T cells could not be performed. Preliminary
experiments using pentamers directed against CMV- and HIV-specific T cells
demonstrated their use for enumerating and determining the memory phenotypes of
virus-specific T cells. However, I was not able to use these pentamers to investigate
the functional properties of virus-specific CD8 T cells, as I found that pentamer
staining was lost upon permeabilisation of PBMCs during the protocol for staining
for intracellular cytokine production.
Conclusions and Future Directions
The major finding of the work described in this thesis was that, in contrast to my
hypothesis, the KSHV-specific CD8 and CD4 T-cell responses are skewed towards
early lytic and late lytic KSHV antigens. Evidence for this was provided by a
lentiviral-based screen for immunogenic KSHV ORFs, and also through ex vivo
ELISpot assays testing recognition of known KSHV epitopes. Although this finding
was unexpected, it was supported by findings reported during the course of the
research for this thesis that the CD8 T-cell response against the murine  γ2-
herpesvirus MHV68 also preferentially targets early lytic and late lytic antigens
(Gredmark-Russ et al., 2008). This information may have important implications
for future immunological investigations of KSHV, and potentially the development
of immunotherapies for KSHV-related malignancies or even a vaccine against
KSHV.
This thesis has also provided the first evidence of an immunodominant late lytic
CD8 KSHV epitope. It would have been interesting to explore the memory271
phenotypes and functional properties of CD8 T cells specific for this epitope
through the use of pentamer technology. Unfortunately, this was not possible due to
the hydrophobic nature of this peptide epitope. Furthermore, as discussed, I
experienced severe technical difficulties when using pentamer staining in
conjunction with staining for intracellular cytokines. Thus, an alternative strategy to
investigate the functional properties of KSHV-specific CD8 T cells could be to use
moDCs pulsed with the K8.1-derived peptide epitope LVLILYLCV as stimulants in
ELISpot assays to detect release of other cytokines such as TNFα, IL4 or IL2. This
may reveal more about the role of T-cells specific for this epitope in the control of
KSHV infection.
A major challenge in the research presented in this thesis was finding an appropriate
methodological approach for the investigation of the KSHV-specific T-cell
response, particularly in the available cohort of KSHV-positive individuals, who
were also HIV-coinfected and had a history of KSHV-related neoplasia. This cohort
clearly had disadvantages, with respect to eliciting sub-optimal KSHV-specific T-
cell responses. Nonetheless, it could be argued that with a long-term goal of
developing better treatments for, or a prophylaxis against, symptomatic KSHV
infection, investigations in this cohort of individuals remain the most relevant. With
this in mind, the major philosophy behind the lentiviral-based screen remains intact
– that using antigen-loaded moDCs to detect responses to endogenously processed
antigenic proteins offers several advantages over the use of pre-determined artificial
peptides. This was highlighted by the lack of responses observed to either candidate
late lytic epitopes or known KSHV epitopes in peptide-based ELISpot assays.
Furthermore, the use of moDCs to maximise responses to antigens was272
demonstrated by both the lentiviral-based screen as well as in ELISpot assays that
compared the use of peptide-pulsed moDCs or peptide solutions as stimulants.
However, the major disadvantage of the lentiviral-based system was that
preparations of the empty lentiviral vector proved to be immunogenic, highlighting
some of the unknown entities and complications associated with the use of these
vectors.
For future investigations, I suggest that the use of antigen-loaded moDCs still seems
to be a powerful tool, although an alternative antigen-delivery strategy needs to be
found. Novel, non-viral delivery methods may provide an efficient solution and
could circumvent many of the problems associated with the lentiviral vectors. One
such delivery method is the recently described SMoC technology (Okuyama et al.,
2007). SMoCs are artificially synthesized small-molecule mimics of the alpha-
helical peptide protein transduction domain (PTD) of the HIV TAT protein. SMoCs
have been shown to efficiently deliver dye molecules and functional proteins to a
variety of cell types (including those of a haematopoietic lineage) and to various
subcellular locations. If SMoCs proved to be efficient at delivering cargo to
moDCs, they could be extremely useful. Late lytic ORFs could be delivered to the
nucleus for further investigation of the KSHV-specific CD8 T-cell response (for
example which of ORF28, ORF36 and ORF37 is the most immunogenic). This may
also enable exploration of cytokine release by proliferating cells in response to
antigen-presenting moDCs, as was originally proposed for the lentiviral-based
experiments. For further investigation of the CD4 response, an alternative strategy
delivering recombinant early lytic and late lytic proteins instead of ORFs to moDCs
could be investigated, with SMoCs targeting these proteins to endosomal or273
lysosomal compartments for processing and presentation through the MHC-II
pathway. Since the uptake of SMoCs by cells appears to be via the clathrin-
mediated endocytotic pathway (Okuyama et al., 2007), it is possible that using this
technology to deliver proteins to antigen-presenting cells may prove to be ideal for
optimal antigen presentation through MHC-II and stimulation of CD4 T-cell
responses. Furthermore, SMoCs would be easier to translate to a clinical setting, as
they are likely to pose less safety concerns than the use of lentiviral vectors.
In light of recent advances in the development of dendritic-cell-based
immunotherapies and vaccines for a variety of tumours (Ballestrero et al., 2008), it
is tempting to speculate that such therapies may one day be realised for the
treatment of KSHV infection and its related malignancies – even if this is a long
way in the future, and first requires a yet deeper understanding of the KSHV-
specific T-cell response.274
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SUPPLEMENTARY INFORMATION
S1: Summary of All Study Participants
Table S1 below summarises all study participants who contributed blood samples for
use in the research described in this thesis. Each participant is cross-referenced to all
the assays in which their samples were used, as well as each of the Tables in the main
body of the thesis text in which the participant appears. Each participant’s KSHV
serostatus and HIV serostatus is summarised, along with their KSHV-related disease
history and their KSHV-related disease status at the time of venesection. Further
clinical phenotypes of participants can be found in Tables 2.6, 2.9, 2.13, 4.1 and 5.10,
as indicated. Those participants for whom full low- and high-resolution HLA-types
were determined are also indicated in Table S1 below.300
Code KSHV
serostatus
HIV
serostatus
KSHV-related
Disease History
KSHV-related
Disease Status
Assays Table(s) HLA-
Typed?
HC1 NEG NEG None N/A Lentivirus screen (Ch. 4) 4.1 and 4.2 N
HC2 NEG NEG None N/A Lentivirus screen (Ch. 4) 4.1 and 4.2 N
HC3 NEG NEG None N/A Lentivirus screen (Ch. 4) 4.1 and 4.2 N
C122 NEG POS None N/A Lentivirus screen (Ch. 4) 2.6; 4.1; and 4.2 N
D403 NEG POS None N/A Lentivirus screen (Ch. 4) 2.6; 4.1; and 4.2 N
D919 NEG POS None N/A Lentivirus screen (Ch. 4) 2.6; 4.1; and 4.2 N
S810 NEG POS None N/A Lentivirus screen (Ch. 4) 2.6; 4.1; and 4.2 N
S346 POS NEG KS Active Lentivirus screen (Ch. 4) 4.1 and 4.2 N
W946 POS NEG KS Active Lentivirus screen (Ch. 4) 4.1 and 4.2 N
H419 POS
(Asymptomatic)
POS None N/A Lentivirus screen (Ch. 4) 2.6; 4.1; 4.2; 4.3; and 5.2 Y
A556 POS POS KS Remission Lentivirus screen (Ch. 4) 2.6; 4.1; 4.2; 4.3; and 5.2 Y
B196 POS POS KS Remission Lentivirus screen (Ch. 4) 2.6; 4.1; 4.2; 4.3; and 5.2 Y*
B625 POS POS KS Remission Lentivirus screen (Ch. 4) 2.6; 4.1; 4.2; and 4.3 N
D208 POS POS KS Remission Lentivirus screen (Ch. 4) 2.6; 4.1; 4.2; and 4.3 N
K058 POS POS PEL Remission Lentivirus screen (Ch. 4) 2.6; 4.1; 4.2; and 4.3 N
M620 POS POS KS Remission Lentivirus screen (Ch. 4) 2.6; 4.1; 4.2; 4.3; and 5.2 Y
P940 POS POS KS and MCD Remission Lentivirus screen (Ch. 4)
Peptide screen (Section 5.2)
2.6; 4.1; 4.2; 4.3; and 5.2
2.9
Y
S079 POS POS KS Remission Lentivirus screen (Ch. 4) 2.6; 4.1; 4.2; and 4.3 N
T328 POS POS KS Remission Lentivirus screen (Ch. 4) 2.6; 4.1; 4.2; and 4.3 N
T541 POS POS KS Remission Lentivirus screen (Ch. 4)
Peptide screen (Section 5.2)
2.6; 4.1; 4.2; 4.3; and 5.2
2.9
Y
V689 POS POS KS and MCD Remission Lentivirus screen (Ch. 4) 2.6; 4.1; 4.2; 4.3; and 5.2 Y
TABLE S1: Summary of all study participants; cross-referenced with assays and tables in main body of thesis. POS = positive; NEG = negative; N =
no; Y = yes; N/A = not applicable; * = HLA-A and HLA-B subtypes not determined due to insufficient DNA available.
3
0
0301
Code KSHV
serostatus
HIV
serostatus
KSHV-related
Disease History
KSHV-related
Disease Status
Assays Table(s) HLA-
Typed?
HC-A NEG NEG None N/A Peptide screen (Section 5.2)
T-cell phenotyping (Section 5.3)
5.7
5.9
N
HC-B NEG NEG None N/A Peptide screen (Section 5.2) 5.7 N
HC-C NEG NEG None N/A Peptide screen (Section 5.2) 5.7 N
HC-D NEG NEG None N/A Peptide screen (Section 5.2) 5.7 N
B042 NEG** POS KS Remission Peptide screen (Section 5.2) 2.9 and 5.7 Y
B066 POS POS KS Remission Peptide screen (Section 5.2) 2.9 and 5.7 Y
C448 POS POS KS Remission Peptide screen (Section 5.2)
T-cell phenotyping (Section 5.3 & 5.4)
2.9 and 5.7
2.13 and 5.9
Y
D592 POS POS MCD Remission Peptide screen (Section 5.2) 2.9 and 5.7 Y
D850 POS POS MCD Remission Peptide screen (Section 5.2)
T-cell phenotyping (Section 5.4)
2.9 and 5.7
2.13
Y
G386 POS POS MCD Remission Peptide screen (Section 5.2) 2.9 and 5.7 Y
H501 POS POS KS and MCD Remission Peptide screen (Section 5.2)
T-cell phenotyping (Section 5.4)
2.9 and 5.7
2.13
Y
H980 POS POS KS Remission Peptide screen (Section 5.2) 2.9 and 5.7 Y
J228 POS POS MCD Remission Peptide screen (Section 5.2)
T-cell phenotyping (Section 5.3 & 5.4)
2.9 and 5.7
2.13 and 5.9
Y
K331 POS POS KS Remission Peptide screen (Section 5.2)
T-cell phenotyping (Section 5.3 & 5.4)
2.9 and 5.7
2.13 and 5.9
Y
M907 POS POS KS Remission Peptide screen (Section 5.2)
T-cell phenotyping (Section 5.3)
2.9 and 5.7
5.9
Y
P869 POS POS KS and MCD Remission Peptide screen (Section 5.2)
T-cell phenotyping (Section 5.3)
2.9 and 5.7
5.9
Y
S929 POS POS KS Remission Peptide screen (Section 5.2) 2.9 and 5.7 Y
TABLE S1 continued: Summary of all study participants; cross-referenced with assays and tables in main body of thesis. POS = positive; NEG = negative;
N = no; Y = yes; N/A = not applicable; ** indicates KSHV-seronegative, although borderline with cut-off for positive (section 5.2.b).
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Code KSHV
serostatus
HIV
serostatus
KSHV-related
Disease History
KSHV-related
Disease Status
Assays Table(s) HLA-
Typed?
B257 POS POS KS Active Peptide screen (Section 5.2)
T-cell phenotyping (Section 5.3 & 5.4)
2.9 and 5.7
2.13 and 5.9
Y
B792 POS POS KS Active Peptide screen (Section 5.2) 2.9 and 5.7 Y
S314 POS POS KS Active Peptide screen (Section 5.2) 2.9 and 5.7 Y
B862 POS POS MCD Remission T-cell phenotyping (Section 5.4) 2.13 and 5.10 Y
C473 POS POS KS Remission T-cell phenotyping (Section 5.4) 2.13 and 5.10 Y
C991 POS POS KS Remission T-cell phenotyping (Section 5.4) 2.13 and 5.10 Y
E043 POS POS KS Remission T-cell phenotyping (Section 5.4) 2.13 and 5.10 Y
F667 POS POS KS Remission T-cell phenotyping (Section 5.4) 2.13 and 5.10 Y
N047 POS POS MCD Remission T-cell phenotyping (Section 5.4) 2.13 and 5.10 Y
S343 POS POS KS Remission T-cell phenotyping (Section 5.4) 2.13 and 5.10 Y
S433 POS POS MCD Remission T-cell phenotyping (Section 5.4) 2.13 and 5.10 Y
S583 POS POS MCD Remission T-cell phenotyping (Section 5.4) 2.13 and 5.10 Y
V685 POS POS KS Remission T-cell phenotyping (Section 5.4) 2.13 and 5.10 Y
E881 POS POS KS Active T-cell phenotyping (Section 5.4) 2.13 and 5.10 Y
N484 POS POS KS Active T-cell phenotyping (Section 5.4) 2.13 and 5.10 Y
N494 POS POS KS Active T-cell phenotyping (Section 5.4) 2.13 and 5.10 Y
R632 POS POS KS Active T-cell phenotyping (Section 5.4) 2.13 and 5.10 Y
V313 POS POS KS Active T-cell phenotyping (Section 5.4) 2.13 and 5.10 Y
W375 POS POS KS Active T-cell phenotyping (Section 5.4) 2.13 and 5.10 Y
W481 POS POS KS Active T-cell phenotyping (Section 5.4) 2.13 and 5.10 Y
O629 POS POS KS Remission Peptide screen (S2) None Y
T107 POS POS KS Remission Peptide screen & T-cell phenotype (S2) None Y
TABLE S1 continued: Summary of all study participants; cross-referenced with assays and tables in main body of thesis. POS = positive; NEG =
negative; N = no; Y = yes; N/A = not applicable.
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S2: A Novel Late Lytic KSHV Epitope
Two further peripheral blood samples were obtained from two KSHV-positive,
HIV-positive, HLA-A*0201 study participants (O629 and T107). PBMCs were
isolated and tested for recognition of the 11 putative epitopes derived from
ORF28 and the nine previously identified epitopes, as described in section 5.2.
Participants ages were: O629 = 45 years; T107 = 35 years. Their CD4 counts
were: O629 = 96 cells/mm
3; T107 = 484 cells/mm
3. Both participants were male
and receiving HAART and had an undetectable HIV viral load (<50
copies/mm
3). Both participants had a history of KS but were currently in
remission having completed a course of systemic chemotherapy approximately
six months prior to venesection. Results from ELISpots to test peptide
recognition by the two participants are shown in Figure S1.
Both O629 and T107 responded to PHA, FEC and CMV-NLVPMATV. T107
also responded to HIV-SLYNTVATL (289.2 SFC per million PBMCs). O629
did not respond to any of the KSHV-derived peptides. T107, however,
responded to both K8.1-LVLILYLCV (91.7 SFC per million PBMCs) and one
of the novel late lytic KSHV epitopes derived from ORF28 (ORF28-P29; 40.0
SFC per million PBMCs). Thus the frequency of recognition of peptide ORF28-
P29 was 7.1% in the whole cohort of 20 HIV-positive, KSHV-positive, HLA-
A*0201-positive individuals tested (O629, T107 and the 18 participants
discussed in section 5.2). Interestingly, although ORF28-P29 was identified as a
candidate epitope in the HLA-A*0201-peptide binding and off-rate assays
(section 5.1), it did not score particularly well compared to the other candidate304
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FIGURE S1: CD8 T-cell responses to A*0201-restricted peptides by two HIV-positive, KSHV-positive, HLA-A*0201-positive study participants.
PHA and control peptides (FEC, SLY, NLV) were used at 5μg/ml, KSHV peptides were used at 20μg/ml. Responses shown as SFC per million PBMCs
with background response to T-cell media alone (Tcm) subtracted. Responses below 1.0 were set to 1.0 to enable plotting of data on a logarithmic scale.
Dashed line indicates positive response cut-off value of 20SFC per million PBMCs.
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epitopes identified, ranking 9
th out of 13 in the binding assay and 13
th out of 13
in the off-rate assay (Table 5.5).
Despite its low frequency of recognition, this epitope represents a novel KSHV
epitope derived from the late lytic glycoprotein ORF28, aa29-37 (IGLITVLFL).
Furthermore, as eight of the nine previously identified KSHV epitopes were not
recognised by any of the 20 KSHV-positive individuals, the new ORF28-P29
epitope may represent an epitope of equal, if not greater, biological importance
than many of the current known epitopes.
A pentamer containing the KSHV peptide IGLITVLFL from ORF28 aa29-37
(ORF28-P29) was synthesised and used in an experiment to determine the
memory phenotypes of CD8 T cells specific for this KSHV epitope from
participant T107. Results are shown in Figure S2.
In this individual, the proportion of NLVPMVATV-specific T cells was
unusually high (4.8% of total CD8 T cells). KSHV-specific T cells against
ORF28-P29 were much lower in frequency (0.01%), in line with the data from
the ELISpots (Section 5.2.c and Figure 5.5.b). The KSHV-specific T cells were
skewed towards a TEM phenotype (85.2% TEM cells and 9.3% TEMRA cells).
Unfortunately, it would not be rational to attempt to draw conclusions from this
single experiment, and it is worth noting that in this individual, CMV-
NLVPMVATV-specific T cells were unusually highly skewed towards a TEM
phenotype (95.5%). Nonetheless, the pentamer containing the ORF28-P29
peptide may prove to be a useful tool for future investigations of this nature, if306
more responders to the peptide can be identified. This would enable a more
thorough exploration of the memory phenotypes of KSHV-specific CD8 T-cells
during chronic infection and disease, as was originally proposed as an aim of
this thesis.
FIGURE S2: Comparison of memory phenotypes of CD8 T cells specific for CMV
or for KSHV. Results shown are from one individual, T107.
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